

CYCLOALKYL-FUSED TETRAHYDROQUINOLINES AS CRTH₂ RECEPTOR MODULATORS

FIELD OF THE INVENTION

[0001] The present invention relates to certain cycloalkyl-fused tetrahydroquinolines of the Formula (I) (also referred to herein as the “compounds of the Formula (I)”), compositions comprising such compounds, and methods of using such compounds for treating an inflammatory disease, or other disorder mediated by the the chemoattractant receptor-homologous molecule expressed on T-helper-type-2 cells (CRTH₂).

BACKGROUND OF THE INVENTION

[0002] Prostaglandin D₂ (PGD₂) belongs to a class of chemical mediators which cells synthesize in response to stimuli, such as local tissue damage or hormonal stimuli, or by cellular activation pathways. Cells synthesize PGD₂ from arachidonic acid by cyclooxygenase and other specific synthases in the pathway.

[0003] Upon stimulation, mast cells release PGD₂ in major amounts and this release plays a major role in the etiology of respiratory disease, such as asthma and congestion. PGD₂ achieves this effect by binding with either of two G-protein coupled receptors, which are the D-prostanoid (DP) receptor and the CRTH₂ receptor. TH-2 cells, eosinophils, and basophils express the CRTH₂ receptor, which mediates the chemoattractant effect of PGD₂.

[0004] Scientific studies support a clear role for PGD₂ in an allergic inflammatory response. PGD₂ is found at high levels in the bronchoalveolar lavage of asthmatics. Inhalation of PGD₂ enhances eosinophilic and lymphocytic airway inflammation in allergic animal models. Evidence obtained by studying CRTH₂ knockout mice demonstrates that PGD₂ achieves this enhancement by binding to the CRTH₂ receptor. Hence, CRTH₂ receptor antagonists would be expected to reduce the allergic inflammatory response caused by PGD₂, and these compounds would be useful in the treatment or prevention of allergic/immune disorders.

[0005] Current drugs of choice for the treatment of chronic inflammatory airway disease, such as asthma or COPD, are synthetic glucocorticoids; examples of these compounds currently indicated for treating these disorders include fluticasone and mometasone. The difficulty with treating patients with this class of compounds is that the compounds possess a number of systemic side-effects; these include adrenal suppression, altered bone metabolism and growth suppression in children. These side effects limit the dose that can be administered on a daily basis to the patient. While a non-steroidal class of therapeutics that inhibit bronchoconstriction

exists (CysLT₁ antagonists), this class of compounds has limited efficacy in achieving the endpoints of reducing inflammatory and improving in lung function when compared to the glucocorticoids. Therefore, a therapeutic that combines the efficacy of inhaled glucocorticoids without the side effects would be advantageous.

SUMMARY OF THE INVENTION

[0006] The present invention provides novel compounds of the Formula (I) as described below and pharmaceutically acceptable salts or esters thereof as well as pharmaceutical compositions containing them. The compounds of Formula (I) are useful in the treatment and prevention of diseases and disorders associated with uncontrolled or inappropriate stimulation of CRTH₂ function such as asthma.

BRIEF DESCRIPTION OF THE FIGURE

[0007] FIG. 1 shows a perspective view calculated from the crystallographic coordinates of a single crystal X-ray of a monotoluene solvate of 4-(cyclopropyl((3aS,9R,9aR)-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid, compound 17.

DETAILED DESCRIPTION OF THE INVENTION

Definitions

[0008] The terms used herein have their ordinary meaning and the meaning of such terms is independent at each occurrence thereof. That notwithstanding and except where stated otherwise, the following definitions apply throughout the specification and claims. Chemical names, common names, and chemical structures may be used interchangeably to describe the same structure. If a chemical compound is referred to using both a chemical structure and a chemical name, and an ambiguity exists between the structure and the name, the structure predominates. These definitions apply regardless of whether a term is used by itself or in combination with other terms, unless otherwise indicated. Hence, the definition of "alkyl" applies to "alkyl" as well as the "alkyl" portions of "fluoroalkyl," "-O-alkyl," etc.

[0009] As used herein, and throughout this disclosure, the following terms, unless otherwise indicated, shall be understood to have the following meanings:

[0010] A "patient" is a human or non-human mammal. In one embodiment, a patient is a human. In another embodiment, a patient is a chimpanzee.

[0011] The term "therapeutically effective amount" as used herein, refers to an amount of the compound of Formula (I) and/or an additional therapeutic agent, or a composition thereof that is effective in producing the desired therapeutic, ameliorative, inhibitory or preventative effect when administered to a patient suffering from a disease or disorder associated with uncontrolled or inappropriate stimulation of CRTH₂ function. In the combination therapies of the present invention, a therapeutically effective amount can refer to each individual agent or to the combination as a whole, wherein the amounts of all agents administered are together effective, but wherein the component agent of the combination may not be present individually in an effective amount.

[0012] The term "preventing," as used herein with respect to disease or disorder associated with uncontrolled or inappropriate stimulation of CRTH₂ function, refers to reducing the likelihood of disease or disorder associated with uncontrolled or inappropriate stimulation of CRTH₂ function.

[0013] The term "alkyl," as used herein, refers to an aliphatic hydrocarbon group having one of its hydrogen atoms replaced with a bond. An alkyl group may be straight or branched and contain from about 1 to about 20 carbon atoms. In one embodiment, an alkyl group contains from about 1 to about 12 carbon atoms. In different embodiments, an alkyl group contains from 1 to 6 carbon atoms (C₁-C₆ alkyl), 1 to 4 carbon atoms (C₁-C₄ alkyl), or from 1 to 3 carbon atoms (C₁-C₃ alkyl). Non-limiting examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, neopentyl, isopentyl, n-hexyl, isohexyl and neohexyl. In one embodiment, an alkyl group is linear. In another embodiment, an alkyl group is branched. Unless otherwise indicated, an alkyl group is unsubstituted.

[0014] The term "alkylene," as used herein, refers to an alkyl group, as defined above, wherein one of the alkyl group's hydrogen atoms has been replaced with a bond. Non-limiting examples of alkylene groups include -CH₂-, -CH₂CH₂-, -CH₂CH₂CH₂-, -CH₂CH₂CH₂CH₂-, -CH(CH₃)CH₂CH₂-, -CH(CH₃)- and -CH₂CH(CH₃)CH₂-. In one embodiment, an alkylene group has from 1 to about 6 carbon atoms (C₁-C₆ alkylene). In another embodiment, an alkylene group has from 1 to 3 carbon atoms (C₁-C₃ alkylene). In another embodiment, an alkylene group is branched. In another embodiment, an alkylene group is linear. In one embodiment, an alkylene group is -CH₂-. The term "C₁-C₃ alkylene" refers to an alkylene group having from 1 to 3 carbon atoms. Unless otherwise indicated, an alkylene group is unsubstituted.

[0015] The term "alkenyl," as used herein, refers to an aliphatic hydrocarbon group containing at least one carbon-carbon double bond and having one of its hydrogen atoms replaced with a bond. An alkenyl group may be straight or branched and contain from about 2 to

about 15 carbon atoms. In one embodiment, an alkenyl group contains from about 2 to 4 carbon atoms. Non-limiting examples of alkenyl groups include ethenyl, propenyl, n-butenyl, 3-methylbut-2-enyl, n-pentenyl, octenyl and decenyl. The term "C₂-C₆ alkenyl" refers to an alkenyl group having from 2 to 6 carbon atoms. The term "C₂-C₄ alkenyl" refers to an alkenyl group having from 2 to 4 carbon atoms. Unless otherwise indicated, an alkenyl group is unsubstituted.

[0016] The term "alkoxy" as used herein, refers to an -O-alkyl group, wherein an alkyl group is as defined above. Non-limiting examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and t-butoxy. An alkoxy group is bonded via its oxygen atom.

[0017] The term "aryl," as used herein, refers to an aromatic monocyclic or multicyclic ring system comprising from about 6 to about 14 carbon atoms. In one embodiment, an aryl group contains from about 6 to 10 carbon atoms (C₆-C₁₀ aryl). In another embodiment an aryl group is phenyl. Non-limiting examples of aryl groups include phenyl and naphthyl. Unless otherwise indicated, an aryl group is unsubstituted.

[0018] The term "cycloalkyl," as used herein, refers to a non-aromatic mono- or multicyclic ring system comprising from about 3 to about 10 ring carbon atoms. In one embodiment, a cycloalkyl contains from about 5 to 10 ring carbon atoms. In another embodiment, a cycloalkyl contains from 3 to 7 ring atoms (C₃-C₇ cycloalkyl). . In another embodiment, a cycloalkyl contains from 3 to 6 ring atoms (C₃-C₇ cycloalkyl). In another embodiment, a cycloalkyl contains from about 5 to about 6 ring atoms. Non-limiting examples of monocyclic cycloalkyls include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Non-limiting examples of multicyclic cycloalkyls include 1-decalinyl, norbornyl and adamantyl. Unless otherwise indicated, a cycloalkyl group is unsubstituted.

[0019] The term "halo," as used herein, means -F, -Cl, -Br or -I. In one embodiment, a halo group is -F or -Cl. In another embodiment, a halo group is -F.

[0020] The term "fluoroalkyl," as used herein, refers to an alkyl group as defined above, wherein one or more of the alkyl group's hydrogen atoms has been replaced with a fluorine. In one embodiment, a fluoroalkyl group has from 1 to 6 carbon atoms. In another embodiment, a fluoroalkyl group is substituted with from 1 to 3 F atoms. Non-limiting examples of fluoroalkyl groups include -CH₂F, -CHF₂, and -CF₃. The term "C₁-C₃ fluoroalkyl" refers to a fluoroalkyl group having from 1 to 3 carbon atoms.

[0021] The term "heteroaryl," as used herein, refers to an aromatic monocyclic or multicyclic ring system comprising about 5 to about 14 ring atoms, wherein from 1 to 4 of the ring atoms is independently O, N or S and the remaining ring atoms are carbon atoms. In one

embodiment, a heteroaryl group has 5 to 10 ring atoms. In another embodiment, a heteroaryl group is monocyclic and has 5 or 6 ring atoms. In another embodiment, a heteroaryl group is bicyclic. A heteroaryl group is joined via a ring carbon atom, and any nitrogen atom of a heteroaryl can be optionally oxidized to the corresponding N-oxide. The term "heteroaryl" also encompasses a heteroaryl group, as defined above, which is fused to a benzene ring. Non-limiting examples of heteroaryls include pyridyl, pyrazinyl, furanyl, thienyl, pyrimidinyl, pyridone (including N-substituted pyridones), isoxazolyl, isothiazolyl, oxazolyl, oxadiazolyl, thiazolyl, pyrazolyl, furazanyl, pyrrolyl, triazolyl, 1,2,4-thiadiazolyl, pyrazinyl, pyridazinyl, quinoxaliny, phthalazinyl, oxindolyl, imidazo[1,2-a]pyridinyl, imidazo[2,1-b]thiazolyl, benzofurazanyl, indolyl, azaindolyl, benzimidazolyl, benzothienyl, quinoliny, imidazolyl, benzimidazolyl, thienopyridyl, quinazolinyl, thienopyrimidyl, pyrrolopyridyl, imidazopyridyl, isoquinoliny, benzoazaindolyl, 1,2,4-triazinyl, benzothiazolyl and the like. In one embodiment, a heteroaryl group is a 5-membered heteroaryl. In another embodiment, a heteroaryl group is a 6-membered heteroaryl. In another embodiment, a heteroaryl group comprises a 5- to 6-membered heteroaryl group fused to a benzene ring. Unless otherwise indicated, a heteroaryl group is unsubstituted.

[0022] The term "heterocyclyl," as used herein, refers to a non-aromatic saturated monocyclic or multicyclic ring system comprising 3 to about 11 ring atoms, wherein from 1 to 4 of the ring atoms are independently O, S, or N, and the remainder of the ring atoms are carbon atoms. A heterocyclyl group can be joined via a ring carbon or ring nitrogen atom. In one embodiment, a heterocyclyl group is monocyclic and has from about 3 to about 7 ring atoms. In another embodiment, a heterocyclyl group is monocyclic has from about 4 to about 7 ring atoms. In another embodiment, a heterocyclyl group is bicyclic and has from about 7 to about 11 ring atoms. In still another embodiment, a heterocyclyl group is monocyclic and has 5 or 6 ring atoms. In one embodiment, a heterocyclyl group is monocyclic. In another embodiment, a heterocyclyl group is bicyclic. The term "heterocyclyl" also encompasses a heterocyclyl group, as defined above, which is fused to an aryl (*e.g.*, benzene) or heteroaryl ring. The nitrogen or sulfur atom of the heterocyclyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of monocyclic heterocyclyl rings include oxetanyl, piperidyl, pyrrolidinyl, piperazinyl, morpholinyl, thiomorpholinyl, thiazolidinyl, 1,4-dioxanyl, tetrahydrofuranyl, tetrahydrothiophenyl, delta-lactam, delta-lactone, and the like.

[0023] In one embodiment, a heterocyclyl group is a 5- to 6-membered monocyclic heterocyclyl. In another embodiment, a heterocyclyl group is a 5-membered monocyclic heterocyclyl. In another embodiment, a heterocyclyl group is a 6-membered monocyclic

heterocyclyl. The term “5- to 6-membered heterocyclyl” refers to a monocyclic heterocyclyl group having from 5 to 6 ring atoms. Unless otherwise indicated, a heterocyclyl group is unsubstituted.

[0024] “Heterocyclenyl” means a non-aromatic monocyclic or multicyclic ring system comprising about 3 to about 10 ring atoms, preferably about 5 to about 10 ring atoms, in which one or more of the atoms in the ring system is an element other than carbon, for example nitrogen, oxygen or sulfur atom, alone or in combination, and which contains at least one carbon-carbon double bond or carbon-nitrogen double bond. In specific embodiments of the ring system, from 1 to 4 of the ring atoms are independently O, S, or N, and the remainder of the ring atoms are carbon atoms. There are no adjacent oxygen and/or sulfur atoms present in the ring system. Preferred heterocyclenyl rings contain about 5 to about 6 ring atoms. The prefix aza, oxa or thia before the heterocyclenyl root name means that at least a nitrogen, oxygen or sulfur atom respectively is present as a ring atom. Unless otherwise indicated, a heterocyclenyl group is unsubstituted. The nitrogen or sulfur atom of the heterocyclenyl can be optionally oxidized to the corresponding N-oxide, S-oxide or S,S-dioxide. Non-limiting examples of suitable heterocyclenyl groups include 1,2,3,4- tetrahydropyridinyl, 1,2-dihydropyridinyl, 1,4-dihydropyridinyl, 1,2,3,6-tetrahydropyridinyl, 1,4,5,6-tetrahydropyrimidinyl, 2-pyrrolinyl, 3-pyrrolinyl, 2-imidazolynyl, 2-pyrazolynyl, dihydroimidazolyl, dihydrooxazolyl, dihydrooxadiazolyl, dihydrothiazolyl, 3,4-dihydro-2H-pyranyl, dihydrofuranyl, fluorodihydrofuranyl, 7-oxabicyclo[2.2.1]heptenyl, dihydrothiophenyl, dihydrothiopyranyl, and the like. “

[0025] The term “substituted” means that one or more hydrogens on the atoms of the designated are replaced with a selection from the indicated group, provided that the atoms’ normal valencies under the existing circumstances are not exceeded, and that the substitution results in a stable compound. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. By “stable compound” or “stable structure” is meant a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.

[0026] Esters of the compounds of the invention are also contemplated herein. For example, if a compound of Formula (I) contains a carboxylic acid functional group, a prodrug can comprise an ester formed by the replacement of the hydrogen atom of the acid group with a group such as, for example, (C₁–C₈)alkyl, (C₁–C₆)alkoxymethyl, (C₂–C₁₂)alkanoyloxymethyl, 1-(alkanoyloxy)ethyl having from 4 to 9 carbon atoms, 1-methyl-1-(alkanoyloxy)-ethyl having from 5 to 10 carbon atoms, alkoxycarbonyloxymethyl having from 3 to 6 carbon atoms, 1-

(alkoxycarbonyloxy)ethyl having from 4 to 7 carbon atoms, 1-methyl-1-(alkoxycarbonyloxy)ethyl having from 5 to 8 carbon atoms, N-(alkoxycarbonyl)aminomethyl having from 3 to 9 carbon atoms, 1-(N-(alkoxycarbonyl)amino)ethyl having from 4 to 10 carbon atoms, 3-phthalidyl, 4-crotonolactonyl, gamma-butyrolacton-4-yl, di-N,N-(C₁-C₂)alkylamino(C₂-C₃)alkyl (such as β-dimethylaminoethyl), carbamoyl-(C₁-C₂)alkyl, N,N-di (C₁-C₂)alkylcarbamoyl-(C₁-C₂)alkyl and piperidino-, pyrrolidino- or morpholino(C₂-C₃)alkyl, and the like.. Such esters may antagonize CRTH₂ themselves and/or can function as prodrugs of the corresponding carboxylic acids. In one embodiment, the esters are C₁-C₆ alkyl esters (*e.g.*, C₁-C₃ alkyl esters). In another embodiment, the esters are C₁-C₃ alkoxymethyl esters (*e.g.*, methoxymethyl esters).

[0027] When any substituent or variable occurs more than one time in any constituent or the compound of Formula (I), its definition on each occurrence is independent of its definition at every other occurrence, unless otherwise indicated.

[0028] The term "in purified form," as used herein, refers to the physical state of a compound after the compound is isolated from a synthetic process (*e.g.*, from a reaction mixture), a natural source, or a combination thereof. The term "in purified form," also refers to the physical state of a compound after the compound is obtained from a purification process or processes described herein or well-known to the skilled artisan (*e.g.*, chromatography, recrystallization and the like), in sufficient purity to be characterizable by standard analytical techniques described herein or well-known to the skilled artisan.

[0029] It should also be noted that any carbon as well as heteroatom with unsatisfied valences in the text, schemes, examples and tables herein is assumed to have the sufficient number of hydrogen atom(s) to satisfy the valences.

[0030] One or more compounds of the invention may exist in unsolvated as well as solvated forms with pharmaceutically acceptable solvents such as water, ethanol, and the like, and it is intended that the invention embrace both solvated and unsolvated forms. "Solvate" means a physical association of a compound of this invention with one or more solvent molecules. This physical association involves varying degrees of ionic and covalent bonding, including hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. "Solvate" encompasses both solution-phase and isolatable solvates. Non-limiting examples of suitable solvates include ethanlates, methanlates, and the like. "Hydrate" is a solvate wherein the solvent molecule is H₂O.

[0031] The compounds of Formula (I) may contain contain one or more stereogenic centers and can thus occur as racemates, racemic mixtures, single enantiomers, diastereomeric mixtures and individual diastereomers. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers and it is intended that all of the possible optical isomers and diastereomers in mixtures and as pure or partially purified compounds are included within the ambit of this invention. Any formulas, structures or names of compounds described in this specification that do not specify a particular stereochemistry are meant to encompass any and all existing isomers as described above and mixtures thereof in any proportion. When stereochemistry is specified, the invention is meant to encompass that particular isomer in pure form or as part of a mixture with other isomers in any proportion.

[0032] The independent syntheses of these diastereomers or their chromatographic separations may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates which are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration. If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography. The coupling reaction is often the formation of salts using an enantiomerically pure acid or base. The diastereomeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue. The racemic mixture of the compounds can also be separated directly by chromatographic methods utilizing chiral stationary phases, e.g., such as the supercritical fluid chromatography, which methods are well known in the art. Alternatively, any enantiomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.

[0033] It is also possible that the compounds of Formula (I) may exist in different tautomeric forms, and all such forms are embraced within the scope of the invention.

[0034] All stereoisomers (for example, geometric isomers, optical isomers and the like) of the present compounds (including those of the salts and solvates of the compounds as well as the salts, solvates and esters of the prodrugs), such as those which may exist due to asymmetric carbons on various substituents, including enantiomeric forms (which may exist even in the

absence of asymmetric carbons), rotameric forms, atropisomers, and diastereomeric forms, are contemplated within the scope of this invention. Individual stereoisomers of the compounds of the invention may, for example, be substantially free of other isomers, or may be admixed, for example, as racemates or with all other, or other selected, stereoisomers. The chiral centers of the present invention can have the S or R configuration as defined by the *IUPAC* 1974 Recommendations.

[0035] The compounds of Formula (I) can form salts which are also within the scope of this invention. Reference to a compound of Formula (I) herein is understood to include reference to salts thereof, unless otherwise indicated. The term "salt(s)", as employed herein, denotes acidic salts formed with inorganic and/or organic acids, as well as basic salts formed with inorganic and/or organic bases. In addition, when a compound of Formula (I) contains both a basic moiety, such as, but not limited to a pyridine or imidazole, and an acidic moiety, such as, but not limited to a carboxylic acid, zwitterions ("inner salts") may be formed and are included within the term "salt(s)" as used herein. Such acidic and basic salts used within the scope of the invention are pharmaceutically acceptable (*i.e.*, non-toxic, physiologically acceptable) salts. Salts of the compounds of Formula (I) may be formed, for example, by reacting a compound of Formula (I) with an amount of acid or base, such as an equivalent amount, in a medium such as one in which the salt precipitates or in an aqueous medium followed by lyophilization.

[0036] Exemplary acid addition salts include acetates, ascorbates, benzoates, benzenesulfonates, bisulfates, borates, butyrates, citrates, camphorates, camphorsulfonates, fumarates, hydrochlorides, hydrobromides, hydroiodides, lactates, maleates, methanesulfonates, naphthalenesulfonates, nitrates, oxalates, phosphates, propionates, salicylates, succinates, sulfates, tartarates, thiocyanates, toluenesulfonates (also known as tosylates,) and the like. Additionally, acids which are generally considered suitable for the formation of pharmaceutically useful salts from basic pharmaceutical compounds are discussed, for example, by P. Stahl *et al*, Camille G. (eds.) *Handbook of Pharmaceutical Salts. Properties, Selection and Use*. (2002) Zurich: Wiley-VCH; S. Berge *et al*, *Journal of Pharmaceutical Sciences* (1977) 66(1) 1-19; P. Gould, *International J. of Pharmaceutics* (1986) 33 201-217; Anderson *et al*, *The Practice of Medicinal Chemistry* (1996), Academic Press, New York; and in *The Orange Book* (Food & Drug Administration, Washington, D.C. on their website). These disclosures are incorporated herein by reference.

[0037] Exemplary basic salts include ammonium salts, alkali metal salts such as sodium, lithium, and potassium salts, alkaline earth metal salts such as calcium and magnesium salts, salts with organic bases (for example, organic amines) such as dicyclohexylamines, t-butyl

amines, and salts with amino acids such as arginine, lysine and the like. Basic nitrogen-containing groups may be quarternized with agents such as lower alkyl halides (*e.g.*, methyl, ethyl, and butyl chlorides, bromides and iodides), dialkyl sulfates (*e.g.*, dimethyl, diethyl, and dibutyl sulfates), long chain halides (*e.g.*, decyl, lauryl, and stearyl chlorides, bromides and iodides), aralkyl halides (*e.g.*, benzyl and phenethyl bromides), and others.


[0038] The present invention further includes the compounds of Formula (I) in all their isolated forms. For example, the above-identified compounds are intended to encompass all forms of the compounds such as, any solvates, hydrates, stereoisomers, and tautomers thereof.

[0039] As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts.

[0040] In the compounds of generic Formula (I), the atoms may exhibit their natural isotopic abundances, or one or more of the atoms may be artificially enriched in a particular isotope having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number predominantly found in nature. The present invention is meant to include all suitable isotopic variations of the compounds of generic Formula (I). For example, different isotopic forms of hydrogen (H) include protium (¹H) and deuterium (²H). Protium is the predominant hydrogen isotope found in nature. Enriching for deuterium may afford certain therapeutic advantages, such as increasing *in vivo* half-life or reducing dosage requirements, or may provide a compound useful as a standard for characterization of biological samples. Isotopically-enriched compounds within generic Formula (I) can be prepared without undue experimentation by conventional techniques well known to those skilled in the art or by processes analogous to those described in the Schemes and Examples herein using appropriate isotopically-enriched reagents and/or intermediates.

Compounds of the Invention


[0041] In embodiment no. 1, the present invention provides a compound of the Formula (I):



or a pharmaceutically acceptable salt or ester thereof, wherein

R^1 is

- (i) H,
- (ii) C_1 - C_4 alkyl,
- (iii) C_2 - C_4 alkenyl,
- (iv) C_3 - C_7 cycloalkyl,
- (v) $-(C_1$ - C_3 alkylene)- R^9 wherein R^9 is C_3 - C_7 cycloalkyl, phenyl or a 5- to 6-membered heteroaryl containing 1 to 2 heteroatoms selected from the group consisting of N, O, and S,
- (vi) phenyl,
- (vii) $-C(O)-R^5$, wherein R^5 is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, phenyl,

- (viii) or a group of the formula , wherein v is 1, 2, or 3;


R^2 is

- (i) $-Q-W-V$, wherein

Q is $-C(O)-$, $-C(O)O-$, $-C(O)N(H)-$, $-C(O)N(C_1-C_6 \text{ alkyl})-$, $-CH_2-$, or $-S(O)_2-$;


W is

- (a) C_1 - C_8 alkylene, wherein said alkylene of W is unsubstituted or substituted by 1 to 2 fluoro;
- (b) $-CH=CH-$, or


- (c) a phenylene of the formula ; wherein said phenylene is unsubstituted or substituted by 1 to 2 halo;

V is

- (a) $-CO_2H$, or
- (b) tetrazolyl, or

- (c) a group of the formula , wherein R^{VI} is selected from the group consisting of C₁-C₆ alkyl, C₃-C₆ cycloalkyl, and phenyl;


(ii) -M-CO₂H, wherein



X^A is S or O;

X^B is N or C(H);

with the proviso that when R¹ is -C(O)-R⁵, then R² is -CH₂-W-V;


Y is -C(O)-, -S(O)₂-, or a group of the formula ,

wherein X^{A1} is S or O; and

X^{B1} is N or C(H);

Z is

- (i) absent,
- (ii) -(C₁-C₆) alkylene-,
- (iii) -O-,
- (iv) -O-(C₁-C₆ alkylene)-, wherein said -O-(C₁-C₆ alkylene)- of Z is unsubstituted or substituted by 1 to 3 fluoro,
- (v) -N(H)-, or

- (vi) a group of the formula , wherein r is 1, 2, 3, or 4;

E is

- (i) phenyl,
- (ii) naphthyl,
- (iii) tetrahydronaphthyl,
- (iv) indanyl,
- (v) 5- to 10-membered mono- or bicyclic heteroaryl containing one to three heteroatoms selected from the group consisting of N, O, and S,

(vi) 5- to 10-membered mono- or bicyclic heterocyclenyl containing one to three heteroatoms selected from the group consisting of N, O, and S, wherein said phenyl, naphthyl, tetrahydronaphthyl, indanyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heterocyclenyl of E is unsubstituted or substituted by one to three R⁴ moieties, wherein

each R⁴ is selected from the group consisting of C₁-C₆ alkyl, C₁-C₃ alkoxy, -CN, halo, hydroxyl, C₁-C₃ fluoroalkyl, -O-(C₁-C₃ fluoroalkyl), -S-(C₁-C₃ alkyl), -S-(C₁-C₃ fluoroalkyl), C₃-C₇ cycloalkyl, R^{4a}, -O-R^{4a}, or 5- to 6-membered heterocyclenyl containing 1 or 2 heteroatom selected from the group consisting of N, O, and S;

R^{4a} is phenyl or a 5 to 6-membered heteroaryl ring containing one to two heteroatoms selected from the group consisting of N, O, and S;

wherein R^{4a} is unsubstituted or substituted by one to two moieties

independently selected from the group consisting of C₁-C₆ alkyl, C₁-C₃ alkoxy, halo, -CN, C₁-C₃ fluoroalkyl, -O-(C₁-C₃ fluoroalkyl), -S-(C₁-C₃ fluoroalkyl), and -SO₂-(C₁-C₃ alkyl),

or, wherein two R⁴ moieties are substituted on vicinal carbon atoms of E, the two R⁴ moieties together with the carbon atoms to which they are attached form a dioxolane ring;

(vii) C₃-C₇ cycloalkyl, or

(viii) C₁-C₆ alkyl;

n is 0, 1, or 2;

each occurrence of R⁷ is independently halo, C₁-C₃ fluoroalkyl, hydroxy(C₁-C₃ alkyl), -CN, phenyl, or a 5- to 6-membered heteroaryl containing 1 to 2 heteroatoms selected from the group consisting of N, O, and S, wherein said phenyl or heteroaryl of R⁷ is independently unsubstituted or substituted with 1 to 2 halo;

t is 0, 1, 2, or 3;

each occurrence of R⁸ is independently C₁-C₃ alkyl, C₂-C₃ alkenyl, or fluoro;

u is 0, 1, or 2; and

R^{8a} is H or C₁-C₆ alkyl.

[0042] The compounds of Formulae (IA'), (IA''), (IB), (IB'), (IB''), (IC), (IC'), and (IC'') as are described in detail below, are embodiments of the compound of Formula (I).


[0043] Described below are further embodiments of the compound of Formula (I).

[0044] In embodiment no. 2, R^1 is C_1 - C_4 alkyl, C_3 - C_7 cycloalkyl, or $-(C_1$ - C_3 alkylene)- R^9 , wherein R^9 is C_3 - C_7 cycloalkyl, and the remaining variables are as set forth in embodiment no. 1.

[0045] In embodiment no. 3, R^1 is methyl, ethyl, cyclopropyl, cyclobutyl, $-CH_2$ -cyclopropyl, or phenyl, and the remaining variables are as set forth in embodiment no. 1.


[0046] In embodiment no 4,
 R^2 is $-Q-W-V$;
 Q is $-C(O)-$, $-C(O)O-$, $-C(O)N(CH_3)-$ or $-CH_2-$;
 W is C_1 - C_4 alkylene; and
 V is $-CO_2H$; and the remaining variables are as set forth in any one of embodiment nos. 1-3.

[0047] In embodiment no. 5, the group $-Q-W-V$ is selected from the group consisting of:




and the remaining variables are as set forth in any one of embodiment nos. 1-3.


[0048] In embodiment no. 6,
 R^2 is $-Q-W-V$;
 Q is $-C(O)-$;
 W is C_1 - C_4 alkylene; and



V is a group of the formula $\text{---} \text{C}(=\text{O}) \text{N}(\text{H}) \text{SO}_2 \text{R}^{\text{V1}}$, wherein R^{V1} is selected from the group consisting of C_1 - C_6 alkyl and C_3 - C_6 cycloalkyl; and the remaining variables are as set forth in any one of embodiment nos. 1-3.


[0049] In embodiment no 7,
 W is $-CH_2CH_2-$; and
 R^{V1} is selected from the group consisting of methyl and cyclopropyl; and the remaining variables are as set forth in embodiment no. 6.





[0050] In embodiment no. 8, Y is -C(O)- or , and the remaining variables are as set forth in any one of embodiment nos. 1-7.



[0051] In embodiment no. 9, Y is -C(O)-, and the remaining variables are as described are as set forth in any one of embodiment nos. 1-7.

[0052] In embodiment no. 10, Y is -Y-Z is selected from the group consisting of -C(O)-,



-C(O)O-CH₂-, -C(O)O-C(H)(CH₃)-, and , and the remaining variables are as set forth in any one of embodiment nos. 1-7.



[0053] In embodiment no. 11, E is phenyl, thienyl, , or , wherein E is unsubstituted or substituted by one to two moieties independently selected from the group consisting of methyl, fluoro, trifluoromethoxy, -O-phenyl, and thiazolyl, and the remaining variables are as set forth in any one of embodiment nos. 1-10.

[0054] In embodiment no. 12, said ester is a C₁-C₆ alkyl carboxylic acid ester, and the remaining variables are as described in any one of embodiment nos. 1-11. For example, when V is -CO₂H, said ester can be a methyl carboxylic acid ester, *i.e.*, -CO₂CH₃, or ethyl carboxylic acid ester, *i.e.*, -CO₂CH₂CH₃.

[0055] In embodiment no. 13, each occurrence of R⁷ is independently chloro or fluoro; and t is 0, 1, or 2, and the remaining variables are as set forth in any one of embodiment nos. 1-12.

[0056] In embodiment no. 14, n is 0 (such that a cyclobutyl ring is formed) or 1, and the remaining variables are as set forth in any one of embodiment nos. 1-11.


[0057] In embodiment no. 15, n is 0 or 1, R⁸ is methyl, and the remaining variables are as set forth in any one of embodiment nos. 1-14.

[0058] In embodiment no. 16, R^{8a} is H or methyl, and the remaining variables are as set forth in any one of embodiment nos. 1-15.

[0059] In embodiment no. 17, R^{8a} is H, and the remaining variables are as set forth in any one of embodiment nos. 1-15.

[0060] In embodiment no. 18, the bond joining the substituent $N(R^1)(R^2)$ to the tetrahydroquinoline in the tricyclic core of Formula (I) and the bond on the vicinal carbon atom which joins the cycloalkyl ring to the tetrahydroquinoline are on the same side of the plane of the tetrahydroquinoline, or are cis to each other. In addition, the bonds joining the cycloalkyl ring to the tetrahydroquinoline are on the same side of the plane of the tetrahydroquinoline, or are cis to each other. Such a configuration in the central tricyclic core of the compound of the Formula (I) is referred to hereinafter as a "cis, cis" configuration. The variables are as set forth in any one of embodiment nos. 1-17.


[0061] In one embodiment of a compound having a cis,cis configuration, *i.e.*, embodiment no. 19, the compound of the Formula (I) has the Formula (IA')



(IA'), and the variables R^1 , R^2 , R^7 , R^8 , R^{8a} , Y, Z, E, n, u, and t

are as set forth in any one of embodiment nos. 1-17.

[0062] In embodiment no. 20, the compound of the Formula (I) has the Formula (IA'')




(IA''), and the variables R^1 , R^2 , R^7 , R^8 , R^{8a} , Y, Z, E, n, u, and t

are as set forth in any one of embodiment nos. 1-17.

[0063] In embodiment no. 21, the present invention provides a compound of the Formula (I) as described in any one of embodiment nos. 1-11 and 13-20, or a pharmaceutically acceptable salt thereof.

[0064] In embodiment no. 22, the compound of the Formula (I) has the Formula (IB)





wherein



R^1 is H, C_1 - C_4 alkyl, cyclopropyl, cyclobutyl, $-\text{CH}_2$ -cyclopropyl, $-\text{CH}_2$ -cyclobutyl, or phenyl;

Q is $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$, $-\text{C}(\text{O})\text{N}(\text{CH}_3)-$, or $-\text{CH}_2-$;

m is 1 or 2;



Z is absent, $-(C_1-C_3)$ alkylene-, $-\text{OCH}_2-$, $-\text{OCH}(\text{CH}_3)-$, or a group of the formula  ;

E is phenyl, thienyl,  , or  , wherein E is unsubstituted or substituted by one to two R^4 moieties independently selected from the group consisting of C_1 - C_3 alkyl, fluoro, trifluoromethoxy, $-\text{S}-\text{CF}_3$, $-\text{O}$ -phenyl, and thiazolyl;


n is 0 or 1;


each occurrence of R^7 is independently chloro or fluoro; and

t is 0, 1, or 2.

[0065] In embodiment no. 23, R^1 is H, C_1 - C_2 alkyl, cyclopropyl, cyclobutyl, $-\text{CH}_2$ -cyclopropyl, or $-\text{CH}_2$ -cyclobutyl, and the remaining variables are as set forth in embodiment no. 22.

[0066] In embodiment no. 24, R^1 is cyclopropyl and the remaining variables are as set forth in embodiment no. 22.

[0067] In embodiment no. 25, the group  (wherein the truncated bond joins with the nitrogen atom bearing R^1) is selected from the group consisting of




and the remaining variables are as set forth in any one of embodiment nos. 22-24.


[0068] In embodiment no. 26, n is 1, and the remaining variables are as set forth in any one of embodiment nos. 22-25.


[0069] In embodiment no. 27, n is 0, and the remaining variables are as set forth in any one of embodiment nos. 22-25.

[0070] In embodiment no. 28, Y is -C(O)-, Z is absent, and the remaining variables are as set forth in any one of embodiment nos. 22-27.


[0071] In embodiment no. 29, Y is -C(O)-, Z is -(C₁-C₃) alkylene-, and the remaining variables are as set forth in any one of embodiment nos. 22-27.

[0072] In embodiment no. 30, Y is , Z is absent, and the remaining variables are as set forth in any one of embodiment nos. 22-27.


[0073] In embodiment no. 31, the bond joining the group  to the central piperidine ring and the bonds joining the cycloalkane ring to the piperidine ring in the compound of Formula (IB) are disposed in a cis, cis configuration, and the variables R¹, R⁷, Q, Y, Z, E, m, n, and t are as set forth in any one of embodiment nos. 22-30. For instance, in one alternative, the compound of the Formula (IB) has the Formula (IB')



In another alternative, the compound of the Formula (IB) has the Formula (IB'')



[0074] In embodiment no. 32, the compound of the Formula (I) has the Formula (IC)



wherein

Q is $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$, or $-\text{CH}_2-$;

m is 1 or 2;

Z is absent or $-\text{OCH}_2-$;


each occurrence of R^4 is independently C_1 - C_3 alkyl, fluoro, trifluoromethoxy, or $-\text{S}-\text{CF}_3$;


v is 0, 1, or 2;

n is 0 or 1;

each occurrence of R^7 is independently chloro or fluoro; and

t is 0, 1, or 2.

[0075] In embodiment no. 33, the group  is selected from the group consisting of:





set forth for embodiment no. 32.


[0076] In embodiment no. 34, Z is absent and the remaining variables are as set forth for any one of embodiment nos. 32 and 33.

[0077] In embodiment no. 35, Z is -OCH₂- and the remaining variables are as set forth for any one of embodiment nos. 32 and 33.


[0078] In embodiment no. 36, n is 1 and the remaining variables are as set forth for any one of embodiment nos. 32-35.



[0079] In embodiment, no. 37, the bond joining the group  to the central piperidine ring and the bonds joining the cycloalkane ring to the piperidine ring in the compound of Formula (IC) are disposed in a cis, cis configuration, and the variables R⁴, R⁷, Q, m, n, t, and v are as described in any one of embodiment nos. 32-36. For instance, in one alternative, the compound of the Formula (IC) has the Formula (IC')



In another alternative, the compound of the Formula (IC) has the Formula (IC'')



[0080] In embodiment no. 38, the compound has the Formula (IC'), wherein

Q is -C(O)- or -CH₂-;

m is 2;

R⁷ is F;

t is 0 or 1


R⁴ is -OCF₃ or halo;

v is 0 or 1; and

Z is absent (such that the carbonyl of Y is directly bonded to the phenyl of E).

[0081] In embodiment no. 39, the compound has the Formula (I), wherein Z is

- (i) absent,
- (ii) $-(C_1-C_6)$ alkylene-,
- (iii) $-O-$,
- (iv) $-O-(C_1-C_6)$ alkylene-,
- (v) $-N(H)-$, or

- (vi) a group of the formula , wherein r is 1, 2, 3, or 4;

E is

- (i) phenyl,
- (ii) naphthyl,
- (iii) tetrahydronaphthyl,
- (iv) indanyl,
- (v) 5- to 10-membered mono- or bicyclic heteroaryl containing one to three heteroatoms selected from the group consisting of N, O, and S,
- (vi) 5- to 10-membered mono- or bicyclic heterocyclenyl containing one to three heteroatoms selected from the group consisting of N, O, and S,

wherein said phenyl, naphthyl, tetrahydronaphthyl, indanyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heterocyclenyl of E is unsubstituted or substituted by one to three R^4 moieties, wherein

each R^4 is selected from the group consisting of C_1-C_6 alkyl, C_1-C_3 alkoxy, $-CN$, halo, C_1-C_3 fluoroalkyl, $-O-(C_1-C_3)$ fluoroalkyl, $-S-(C_1-C_3)$ fluoroalkyl, C_3-C_7 cycloalkyl, R^{4a} , $-O-R^{4a}$, or 5- to 6-membered heterocyclenyl containing 1 or 2 heteroatom selected from the group consisting of N, O, and S;

R^{4a} is phenyl or a 5 to 6-membered heteroaryl ring containing one to two heteroatoms selected from the group consisting of N, O, and S;

wherein R^{4a} is unsubstituted or substituted by one to two moieties

independently selected from the group consisting of C_1-C_6 alkyl, C_1-C_3 alkoxy, halo, $-CN$, C_1-C_3 fluoroalkyl, $-O-(C_1-C_3)$ fluoroalkyl, $-S-(C_1-C_3)$ fluoroalkyl, and $-SO_2-(C_1-C_3)$ alkyl,

or, wherein two R⁴ moieties are substituted on vicinal carbon atoms of E, the two R⁴ moieties together with the carbon atoms to which they are attached form a dioxolane ring;

(vii) C₃-C₇ cycloalkyl, or

(viii) C₁-C₆ alkyl;

each occurrence of R⁷ is independently halo, C₁-C₃ fluoroalkyl, -CN, phenyl, or a 5- to 6-membered heteroaryl containing 1 to 2 heteroatoms selected from the group consisting of N, O, and S, wherein said phenyl or heteroaryl of R⁷ is independently unsubstituted or substituted with 1 to 2 halo; and

the remaining variables are as described in embodiment no. 1.

[0082] In embodiment no. 40, the invention also provides any one of the compounds specified in **Tables A** and **B** in the Examples section below, which tables include compounds 7, 9, 9A, 9B, 10, 11, 11A, 11B, 11C, 12, 12B, 12C, 12D, 12E, 13, 13C, 13D, 13E, 14, 14C, 14D, 14E, 14F, 14G, 14H, 14i, 14K, 14L, 14N, 14o, 14P, 15, 16, 16A, 16B, 16C, 16D, 16E, 17, 17G, 17H, 17i, 17J, 17K, 17L, 17M, 17N, 17o, 17P, 17Q, 17R, 17S, 17T, 17U, 17V, 17W, 17X, 17Y, 17Z, 17AA, 17AB, 17AC, 17AD, 17AE, 17AF, 17AG, 17AH, 17Ai, 17AJ, 17AK, 17AL, 17AM, 17AN, 17Ao, 17AP, 17AQ, 17AR, 17AS, 17AT, 17AU, 17AV, 17AW, 17AX, 17AY, 17AZ, 17BA, 17BB, 17BC, 17BD, 17BE, 17BF, 17BG, 17BH, 17Bi, 17BJ, 17BK, 17BL, 17BM, 17BN, 17Bo, 17BP, 17BQ, 17BR, 17BS, 17BT, 17BU, 17BV, 17BW, 17BX, 17BY, 17BZ, 17CA, 17CB, 17CC, 17CD, 17CE, 17CF, 17CG, 17CH, 17Ci, 17CJ, 17CK, 17CL, 17CM, 17CN, 17Co, 17CP, 17CQ, 17CR, 17CS, 17CT, 17CU, 17CV, 17CW, 17CX, 17CY, 17CZ, 17DA, 17DB, 17DC, 17DD, 17DE, 17DF, 17DG, 17DH, 17Di, 17DJ, 17DK, 17DL, 17DN, 17Do, 18, 18C, 18D, 18E, 18F, 18G, 18H, 18i, 18J, 18K, 18L, 18M, 18N, 18o, 18P, 18Q, 18R, 18S, 18T, 19, 20, 21, 21A, 21B, 21C, 21D, 21E, 21F, 21G, 21H, 21i, 21J, 21K, 21L, 22, 22A, 22D, 22E, 22F, 22G, 22H, 22i, 22J, 22K, 22L, 22M, 22N, 22o, 22P, 22Q, 22R, 22S, 22T, 22U, 22V, 22W, 22X, 22Y, 23, 23B, 23C, 23D, 23E, 23F, 23G, 23H, 23i, 24, 24B, 24C, 24D, 25, 26, 27, 27A, 27B, 27C, 27D, 27E, 27F, 27G, 27H, 27i, 27J, 27K, 27L, 27M, 27N, 27o, 27P, 27Q, 27R, 27S, 28, 29, 30, 31, 32, 32C, 32D, 32E, 32F, 32G, 32H, 32i, 32J, 32K, 32L, 32M, 32N, 32o, 32P, 32Q, 32R, 32S, 32T, 32U, 33, 34, 35, 35D, 35E, 35F, 35G, 35H, 35i, 35J, 35K, 36, 36A, 36B, 36C, 37, 38, 38D, 38E, 38F, 38G, 39, 40, 41, 42, 43, 43B, 43C, 44, 44B, 44C, 44D, 44E, 44F, 45, 46, 47, 47D, 47E, 47F, 47G, 48, 48C, 49, 49B, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123,

124, 125, 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172, 173, and 174, or a pharmaceutically acceptable salt thereof. The structures of these compounds are set forth in the Examples section below.

[0083] In embodiment no. 41, the invention provides a compound selected from the group consisting of:

4-[{cis, cis-4-[(benzyloxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}(cyclopropyl)amino]-4-oxobutanoic acid;

4-[{cis, cis-4-[(benzyloxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}(phenyl)amino]-4-oxobutanoic acid;

4-{ethyl [cis, cis-4-{[4-(trifluoromethoxy)phenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid;

4-{cyclopropyl[cis, cis-4-{[4-(trifluoromethoxy)phenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid;

4-[{cis, cis-4-[(benzyloxy)carbonyl]-6-fluoro-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}(cyclopropyl)amino]-4-oxobutanoic acid;

4-{cyclopropyl[cis, cis-6-fluoro-4-{[4-phenoxyphenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid;

4-{cyclopropyl[cis, cis-3-{[4-(trifluoromethoxy)phenyl]carbonyl}-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino}-4-oxobutanoic acid;

({cyclopropyl[cis, cis-4-{[4-(trifluoromethoxy)phenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]carbonyl}oxy)acetic acid;

3-(phenylmethyl) cis,cis-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5-fluoro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

4-(phenylmethyl) cis, cis-9-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

4-(phenylmethyl) cis, cis-9-[(3-carboxy-1-oxopropyl)cyclopropylamino]-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

4-[cyclopropyl[(cis, cis)-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

4-[[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]methylamino]-4-oxobutanoic acid;

4-[(cyclobutylmethyl)[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-(3-phenoxybenzoyl)-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxo-butanoic acid;

4-(cyclopropyl(cis, cis-4-(thiophene-2-carbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid;

[[[[(cis,cis-6-chloro-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]carbonyl]oxy]acetic acid;

4-[cyclopropyl[cis,cis-5-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

deuterated-4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9(R)-yl-(d)]amino]-4-oxobutanoic acid;

4-[[[(cis, cis)-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclobutylamino]-4-oxobutanoic acid;

4-[[[(cis, cis)-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[[[(cis, cis)-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[(trans-2-phenylcyclopropyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[cyclobutyl[(cis, cis)-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

4-[[[(cis, cis)-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[[[(cis, cis)-6-chloro-4-[(2,3-dihydro-1H-inden-2-yl)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[[[(cis, cis)-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[3-(5-thiazolyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

4-[(2,4-difluorophenyl)methyl] (cis, cis)-9-[[[(carboxymethoxy)carbonyl]cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

4-[1-(4-fluorophenyl)ethyl] (cis,cis)-9-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

4-(1,2,3,4-tetrahydro-2-naphthalenyl) (cis, cis)-9-[(3-carboxy-1-oxopropyl)cyclopropylamino]-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

4-[cyclopropyl[(cis, cis)-6-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

3-(phenylmethyl) (cis,cis)-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5-chloro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

4-[[[(cis,cis)-5-chloro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]cyclopropylamino]-4-oxobutanoic acid ;

3-(phenylmethyl) (cis,cis)-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

4-[cyclopropyl[(cis,cis)-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid ;

4-(phenylmethyl) (cis,cis)-9-[[[(carboxymethoxy)carbonyl]cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

4-(phenylmethyl) (cis,cis)-9-[[[(carboxymethoxy)carbonyl]cyclopropylamino]-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

[[[cyclopropyl[(cis,cis)-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]carbonyl]oxy]acetic acid;

[[[cyclopropyl[(cis,cis)-3-(3,4-difluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino]carbonyl]oxy]acetic acid;

[[[cyclopropyl[(cis,cis)-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]oxy]acetic acid ;

4-(phenylmethyl) (cis,cis)-9-[[[(2S)-carboxy-1-azetidiny]carbonyl]cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

N-[[cyclopropyl[(cis,cis)-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]-N-methylglycine;

[[[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[5-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,4-oxadiazol-2-yl]-1H-cyclopenta[b]quinoline-9-yl]amino]carbonyl]oxy]acetic acid;

2-[ethyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxazolecarboxylic acid;

3-(phenylmethyl) cis,cis-8-[(3-carboxypropyl)cyclopropylamino]-5-fluoro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]butanoic acid;

4-[cyclopropyl[cis,cis-5-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]butanoic acid;

4-[cyclopropyl[(cis,cis)-2,3,3a,4,9,9a-hexahydro-4-[4-[(trifluoromethyl)thio]benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

4-(ethyl((cis,cis)-3-(4-(trifluoromethylthio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid;

4-(ethyl((cis,cis)-3-(4-ethylbenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid;

3-(phenylmethyl) 8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5,6-difluoro-2,2a,8,8a-tetrahydro-cyclobuta[b]quinoline-3(1H)-carboxylate;

4-[cyclopropyl[(cis,cis)-5,6-dichloro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

4-(cyclopropyl((cis,cis)-5,6-difluoro-3-(4-(trifluoromethoxy)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid;

4-[cyclopropyl[(cis,cis)-6-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxo-butanoic acid; and

(R)-1-(((cis,cis)-3-(benzyloxycarbonyl)-5,6-difluoro-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)carbamoyl)azetidine-2-carboxylic acid;

4-(cyclopropyl(cis, cis-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid ;

4-(ethyl(cis, cis-6-fluoro-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid ;

4-(ethyl(cis, cis-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ;

4-(cyclopropyl(cis, cis-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ; and

4-(cyclopropyl(cis, cis-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)butanoic acid;

or a pharmaceutically acceptable salt thereof.

[0084] In embodiment no. 42, the invention provides a compound selected from the group consisting of:

4-{cyclopropyl[cis, cis-4-{[4-(trifluoromethoxy)phenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid;

4-[cyclopropyl[cis,cis-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

4-[[cis,cis-6-chloro-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[cyclopropyl[cis,cis-5-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[cis,cis-6-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

3-(phenylmethyl) (cis,cis)-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5-chloro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

3-(phenylmethyl) (cis,cis)-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

4-[cyclopropyl[cis,cis-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid ;

[[[cyclopropyl[cis,cis-3-(3,4-difluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino]carbonyl]oxy]acetic acid;

3-(phenylmethyl) cis,cis-8-[(3-carboxypropyl)cyclopropylamino]-5-fluoro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]butanoic acid;

4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-[(trifluoromethyl)thio]benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

(R)-1-((cis,cis-3-(benzyloxycarbonyl)-5,6-difluoro-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)carbamoyl)azetidine-2-carboxylic acid;

4-(cyclopropyl(cis, cis-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid ;

4-(ethyl(cis, cis-6-fluoro-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid ;

4-(ethyl(cis, cis-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ;

4-(cyclopropyl(cis, cis-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ; and

4-(cyclopropyl(cis, cis-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)butanoic acid;

or a pharmaceutically acceptable salt thereof.

[0085] In embodiment no. 43, the invention provides a compound selected from the group consisting of:

4-{cyclopropyl[cis, cis-4-{[4-(trifluoromethoxy)phenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid;

4-{cyclopropyl[(3aS,9aR)-4-{[4-(trifluoromethoxy)phenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9(R)-yl]amino}-4-oxobutanoic acid;

4-{cyclopropyl[(3aR,9aS)-4-{[4-(trifluoromethoxy)phenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9(S)-yl]amino}-4-oxobutanoic acid;

4-[cyclopropyl[cis,cis-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[(3aS,9aR)-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9(R)-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[(3aR,9aS)-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9(S)-yl]amino]-4-oxobutanoic acid;

4-[[cis,cis-6-chloro-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[[[(3aS,9aR)-6-chloro-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9(R)-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[[[(3aR,9aS)-6-chloro-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9(S)-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[cyclopropyl[cis,cis-5-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[(2aS,8aR)-5-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8(R)-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[(2aR,8aS)-5-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8(S)-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[cis,cis-6-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[(2aS,8aR)-6-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8(R)-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[(2aR,8aS)-6-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8(S)-yl]amino]-4-oxobutanoic acid;

3-(phenylmethyl) (cis,cis)-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5-chloro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

3-(phenylmethyl) (2aS,8aR)-8(R)-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5-chloro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

3-(phenylmethyl) (2aR,8aS)-8(S)-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5-chloro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

3-(phenylmethyl) (cis,cis)-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

3-(phenylmethyl) (2aS,8aR)-8(R)-[(3-carboxy-1-oxopropyl)cyclopropylamino]-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

3-(phenylmethyl) (2aR,8aS)-8(S)-[(3-carboxy-1-oxopropyl)cyclopropylamino]-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

4-[cyclopropyl[cis,cis-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[(2aS,8aR)-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8(R)-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[(2aR,8aS)-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8(S)-yl]amino]-4-oxobutanoic acid;

[[[cyclopropyl[cis,cis-3-(3,4-difluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino]carbonyl]oxy]acetic acid;

[[[cyclopropyl[(2aS,8aR)-3-(3,4-difluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8(R)-yl]amino]carbonyl]oxy]acetic acid;

[[[cyclopropyl[(2aR,8aS)-3-(3,4-difluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8(S)-yl]amino]carbonyl]oxy]acetic acid;

3-(phenylmethyl) cis,cis-8-[(3-carboxypropyl)cyclopropylamino]-5-fluoro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

3-(phenylmethyl) (2aS,8aR)-8(R)-[(3-carboxypropyl)cyclopropylamino]-5-fluoro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

3-(phenylmethyl) (2aR,8aS)-8(S)-[(3-carboxypropyl)cyclopropylamino]-5-fluoro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]butanoic acid;

4-[cyclopropyl[(3aS,9aR)-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9(R)-yl]amino]butanoic acid;

4-[cyclopropyl[(3aR,9aS)-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9(S)-yl]amino]butanoic acid;

4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-[(trifluoromethyl)thio]benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[(3aS,9aR)-2,3,3a,4,9,9a-hexahydro-4-[4-[(trifluoromethyl)thio]benzoyl]-1H-cyclopenta[b]quinolin-9(R)-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[(3aR,9aS)-2,3,3a,4,9,9a-hexahydro-4-[4-[(trifluoromethyl)thio]benzoyl]-1H-cyclopenta[b]quinolin-9(S)-yl]amino]-4-oxobutanoic acid;

(R)-1-((cis,cis-3-(benzyloxycarbonyl)-5,6-difluoro-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)carbamoyl)azetidine-2-carboxylic acid;

(R)-1-(((2aS,8aR)-3-(benzyloxycarbonyl)-5,6-difluoro-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8(R)-yl)(cyclopropyl)carbamoyl)azetidine-2-carboxylic acid;

(R)-1-(((2aR,8aS)-3-(benzyloxycarbonyl)-5,6-difluoro-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8(S)-yl)(cyclopropyl)carbamoyl)azetidine-2-carboxylic acid;

4-(cyclopropyl(cis, cis-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid ;

4-(cyclopropyl((2aS,8aR)-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid ;

4-(cyclopropyl((2aR,8aS)-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid ;

4-(ethyl(cis, cis-6-fluoro-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid ;

4-(ethyl((2aS,8aR)-6-fluoro-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid ;

4-(ethyl((2aR,8aS)-6-fluoro-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid ;

4-(ethyl(cis, cis-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ;

4-(ethyl((3aS,9aR)-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ;

4-(ethyl((3aR,9aS)-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ;

4-(cyclopropyl(cis, cis-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ;

4-(cyclopropyl((3aS,9aR)-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ;

4-(cyclopropyl((3aR,9aS)-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ; and

4-(cyclopropyl((3aS,9R,9aR)-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)butanoic acid;

or a pharmaceutically acceptable salt thereof.

[0086] In embodiment no. 44, the invention provides a compound selected from the group consisting of:

4-{cyclopropyl[[[(3aS,9aR)-4-{[4-(trifluoromethoxy)phenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9(R)-yl]amino}-4-oxobutanoic acid;

4-[cyclopropyl[(3aS,9aR)-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9(R)-yl]amino]-4-oxobutanoic acid;

4-[[[(3aS,9aR)-6-chloro-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9(R)-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[cyclopropyl[(2aS,8aR)-6-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8(R)-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[(2aR,8aS)-6-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8(S)-yl]amino]-4-oxobutanoic acid;

4-(ethyl((3aS,9aR)-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ;

4-[cyclopropyl[(3aS,9aR)-2,3,3a,4,9,9a-hexahydro-4-[4-[(trifluoromethyl)thio]benzoyl]-1H-cyclopenta[b]quinolin-9(R)-yl]amino]-4-oxobutanoic acid; and

4-(cyclopropyl((3aS,9R,9aR)-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)butanoic acid;

or a pharmaceutically acceptable salt thereof.

[0087] The invention also provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof in purified form.

Compositions and Administration

[0088] This invention is also directed to pharmaceutical compositions which comprise a therapeutically effective amount of the compound of Formula (I), or a pharmaceutically acceptable salt of said compound and a pharmaceutically acceptable carrier.

[0089] A preferred dosage is about 0.001 to 100 mg/kg of body weight/day of the compound of Formula (I). An especially preferred dosage is about 0.01 to 10 mg/kg of body weight/day of a compound of Formula (I), or a pharmaceutically acceptable salt of said compound.

[0090] The term "pharmaceutical composition" is also intended to encompass both the bulk composition and individual dosage units comprised of more than one (*e.g.*, two) pharmaceutically active agents such as, for example, a compound of the present invention and an additional therapeutic agent selected from the lists of the additional agents described herein below, along with any pharmaceutically inactive excipients. The bulk composition and each individual dosage unit can contain fixed amounts of the aforesaid "more than one pharmaceutically active agents". The bulk composition is material that has not yet been formed into individual dosage units. An illustrative dosage unit is an oral dosage unit such as tablets, pills and the like. Similarly, the herein-described method of treating a patient by administering a pharmaceutical composition of the present invention is also intended to encompass the administration of the afore-said bulk composition and individual dosage units.

[0091] For preparing pharmaceutical compositions from the compounds described by this invention, inert, pharmaceutically acceptable carriers can be either solid or liquid. Solid form preparations include powders, tablets, dispersible granules, capsules, cachets and suppositories. The powders and tablets may be comprised of from about 5 to about 95 percent active ingredient. Suitable solid carriers are known in the art, *e.g.*, magnesium carbonate, magnesium stearate, talc, sugar or lactose. Tablets, powders, cachets and capsules can be used as solid dosage forms suitable for oral administration. Examples of pharmaceutically acceptable carriers and methods of manufacture for various compositions may be found in A. Gennaro (ed.), *Remington's Pharmaceutical Sciences*, 18th Edition, (1990), Mack Publishing Co., Easton, Pennsylvania.

[0092] Liquid form preparations include solutions, suspensions and emulsions. Examples of materials useful for forming such liquid form preparations include water or water-propylene glycol solutions for parenteral injection, or sweeteners and opacifiers for oral solutions, suspensions and emulsions. Liquid form preparations may also include solutions or suspensions for intranasal administration.

[0093] Aerosol preparations suitable for inhalation may include solutions and solids in powder form, which may be in combination with a pharmaceutically acceptable carrier, such as an inert compressed gas, *e.g.*, nitrogen.

[0094] Also included are solid form preparations that are intended to be converted, shortly before use, to liquid form preparations for either oral or parenteral administration. Such liquid forms include solutions, suspensions and emulsions.

[0095] The compounds of the invention can also be deliverable transdermally. The transdermal compositions can take the form of creams, lotions, aerosols and/or emulsions and can be included in a transdermal patch of the matrix or reservoir type as are conventional in the art for this purpose.

[0096] The compounds of this invention may also be delivered subcutaneously.

[0097] Preferably the compound is administered orally.

[0098] Preferably, the pharmaceutical preparation is in a unit dosage form. In such form, the preparation is subdivided into suitably sized unit doses containing appropriate quantities of the active component, *e.g.*, an effective amount to achieve the desired purpose.

[0099] The quantity of active compound in a unit dose of preparation may be varied or adjusted from about 0.001 mg to about 100 mg per kg body weight of a mammal, preferably from about 0.01 mg to about 10 mg per kg. The actual dosage employed may be varied depending upon the requirements of the patient and the severity of the condition being treated. Determination of the proper dosage regimen for a particular situation is within the skill of the art. For convenience, the total daily dosage may be divided and administered in portions during the day as required.

[00100] The compositions of the invention can further comprise one or more additional therapeutic agents, as discussed in further detail below. Accordingly, in one embodiment, the present invention provides compositions comprising: (i) a compound of Formula (I) or a pharmaceutically acceptable salt thereof; (ii) one or more additional therapeutic agents, that are not compounds of Formula (I); and (iii) a pharmaceutically acceptable carrier, wherein the amounts in the composition are together effective to treat one of the disease or conditions discussed above.

Uses of the Compounds

[00101] The compounds of Formula (I) bind to CRTH₂ and, therefore, are useful in characterizing tissues containing CRTH₂, and in identifying further compounds which bind to CRTH₂. The general value of the compounds of the invention in binding the CRTH₂ receptor

can be determined, for example, using the radioligand binding assay described below in the Examples section.

[00102] The compounds of Formula (I) can also be useful as modulators of CRTH₂ receptor function. In some embodiments, compounds of Formula (I) are antagonists of the CRTH₂ receptor. The general value of the compounds of the invention in antagonizing CRTH₂ receptor function can be determined, for example, using the chemiluminescent-based cAMP assay, the β -Arrestin assay, or the eosinophil shape change assay described below in the Examples section.

[00103] While not being bound by any specific theory, Applicants believe that the compounds of Formula (I) are useful in treating the symptoms of diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH₂ function because of their ability to antagonize the CRTH₂ receptor. Accordingly, in one embodiment, the invention provides a method for treating a disease or conditions associated with uncontrolled or inappropriate stimulation of CRTH₂ function, comprising administering a therapeutically effective amount of a compound of Formula (I) to a patient in need of such treatment.

[00104] Diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH₂ function include (but are not limited to) asthma, congestion, allergic rhinitis, atopic dermatitis, chronic obstructive pulmonary disease ("COPD"), dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, bronchial asthma, food allergy, systemic mast cell disorder, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis, and basophile-related diseases, such as basophilic leukemia and basophilic leukocytosis, in humans and other mammals. Examples of cerebrovascular disorders include stroke.

[00105] In certain embodiments, the present invention provides a method for treating asthma, congestion, allergic rhinitis or COPD which comprises administering a therapeutically effective dose of a compound of Formula (I) or a pharmaceutically acceptable salt thereof to a patient in need of such treatment. In a specific embodiment, the disease or condition being treated is asthma. In another embodiment, the disease or condition being treated is COPD.

[00106] In addition, compounds of the Formula (I) which act as CRTH₂ receptor antagonists can inhibit prostanoind-induced smooth muscle contraction by antagonizing contractile prostanoids or mimicking relaxing prostanoids and hence may be used in the treatment of dysmenorrhea, premature labor and eosinophil related disorders.

[00107] In another embodiment, the present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for treating a disease or condition selected from the group consisting of asthma, congestion, allergic rhinitis, atopic dermatitis, COPD, dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, bronchial asthma, food allergy, systemic mast cell disorder, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis, and basophile-related diseases, such as basophilic leukemia and basophilic leukocytosis.

[00108] In another embodiment, the present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof for use in treating a disease or condition from the group consisting of asthma, congestion, allergic rhinitis, atopic dermatitis, COPD, dermatitis, inflammatory bowel disease, rheumatoid arthritis, allergic nephritis, conjunctivitis, bronchial asthma, food allergy, systemic mast cell disorder, anaphylactic shock, urticaria, eczema, itching, inflammation, ischemia-reperfusion injury, cerebrovascular disorders, pleuritis, ulcerative colitis, eosinophil-related diseases, such as Churg-Strauss syndrome and sinusitis, and basophile-related diseases, such as basophilic leukemia and basophilic leukocytosis.

Combination Therapy

[00109] The compounds of Formula (I) or their pharmaceutically acceptable salts may be used in combination, either in a single formulation or co-administered as separate formulations with at least one additional therapeutic agent to treat or prevent the diseases and conditions described herein. These additional therapeutic agents include, but are not limited to: (1) a DP receptor antagonist, such as S-5751 and laropiprant; (2) a corticosteroid, such as triamcinolone acetonide, budesonide, beclomethasone, fluticasone and mometasone; (3) a β 2-adrenergic agonist, such as salmeterol, formoterol, arformoterol, terbutaline, metaproterenol, albuterol and the like; (4) a leukotriene modifier, including a leukotriene receptor antagonist, such as montelukast, zafirlukast, pranlukast, or a lipooxygenase inhibitor including 5-lipooxygenase inhibitors and FLAP (5-lipooxygenase activating protein) inhibitors, such as zileuton; (5) an antihistamine such as bromopheniramine, chlorpheniramine, dexchlorpheniramine, triprolidine, clemastine, diphenhydramine, diphenylpyraline, tripeleminamine, hydroxyzine, methdilazine, promethazine, trimeprazine, azatadine, cyproheptadine, antazoline, pheniramine pyrilamine, astemizole, terfenadine, loratadine, cetirizine, fexofenadine, descarboethoxyloratadine, and the like; (6) a decongestant, including phenylephrine, phenylpropanolamine, pseudophedrine,

oxymetazoline, ephinephrine, naphazoline, xylometazoline, propylhexedrine, or levo-desoxyephedrine; (7) an antiitussive, including codeine, hydrocodone, caramiphen, carbetapentane, or dexamethorphan; (8) another prostaglandin ligand, including prostaglandin F agonist such as latanoprost; misoprostol, enprostil, rioprostil, ornoprostol or rosaprostol; (9) a diuretic; (10) non-steroidal antiinflammatory agents (NSAIDs), such as propionic acid derivatives (alminoprofen, benoxaprofen, bucloxic acid, carprofen, fenbufen, fenoprofen, fluprofen, flurbiprofen, ibuprofen, indoprofen, ketoprofen, miroprofen, naproxen, oxaprozin, pirprofen, pranoprofen, suprofen, tiaprofenic acid, and tioxaprofen), acetic acid derivatives (indomethacin, acemetacin, alclofenac, clidanac, diclofenac, fenclofenac, fenclozic acid, fentiazac, furofenac, ibufenac, isoxepac, oxpinac, sulindac, tiopinac, tolmetin, zidometacin, and zomepirac), fenamic acid derivatives (flufenamic acid, meclofenamic acid, mefenamic acid, niflumic acid and tolfenamic acid), biphenylcarboxylic acid derivatives (diflunisal and flufenisal), oxicams (isoxicam, piroxicam, sudoxicam and tenoxicam), salicylates (acetyl salicylic acid, sulfasalazine) and the pyrazolones (apazone, bezpiperylon, feprazone, mofebutazone, oxyphenbutazone, phenylbutazone); (11) cyclooxygenase-2 (COX-2) inhibitors, such as celecoxib and rofecoxib; (12) inhibitors of phosphodiesterase type IV (PDE-IV) *e.g.*, Ariflo, roflumilast; (13) antagonists of the chemokine receptors, especially CCR-1, CCR-2, and CCR-3; (14) cholesterol lowering agents such as HMG-CoA reductase inhibitors (lovastatin, simvastatin and pravastatin, fluvastatin, atorvastatin, and other statins), sequestrants (cholestyramine and colestipol), nicotinic acid, fenofibric acid derivatives (gemfibrozil, clofibrat, fenofibrate and benzaifibrate), and probucol; (15) anti-diabetic agents such as insulin, sulfonylureas, biguanides (metformin), α -glucosidase inhibitors (acarbose) and glitazones (troglitazone, pioglitazone, englitazone, rosiglitazone and the like); (16) preparations of interferon beta (interferon beta-1a, interferon beta-1b); (17) anticholinergic agents, such as muscarinic antagonists (ipratropium bromide and tiotropium bromide), as well as selective muscarinic M3 antagonists; (18) steroids such as beclomethasone, methylprednisolone, betamethasone, prednisone, dexamethasone, and hydrocortisone; (19) triptans commonly used for the treatment of migraine such as sumatriptan and rizatriptan; (20) alendronate and other treatments for osteoporosis; (21) other compounds such as 5-aminosalicylic acid and prodrugs thereof, antimetabolites such as azathioprine and 6-mercaptopurine, cytotoxic cancer chemotherapeutic agents, bradykinin (BK2) antagonists such as FK-3657, TP receptor antagonists such as seratrovast, neurokinin antagonists (NK1/NK2), VLA-4 antagonists, such as those described in US 5,510,332, WO97/03094, WO97/02289, WO96/40781, WO96/22966, WO96/20216, WO96/01644, WO96/06108, WO95/15973 and WO96/31206. In addition, the invention encompasses a method of treating prostaglandin D2

mediated diseases comprising: administration to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound of Formula (I), optionally co-administered with one or more of such ingredients as listed immediately above.

[00110] When administering a combination therapy to a patient in need of such administration, the therapeutic agents in the combination, or a pharmaceutical composition or compositions comprising the therapeutic agents, may be administered in any order such as, for example, sequentially, concurrently, together, simultaneously and the like.

[00111] In one embodiment, the compound of Formula (I) is administered during a time when the additional therapeutic agent(s) exert their prophylactic or therapeutic effect, or *vice versa*.

[00112] In another embodiment, the compound of Formula (I) and the additional therapeutic agent(s) are administered in doses commonly employed when such agents are used as monotherapy for treating the disorder.

[00113] In another embodiment, the compound of Formula (I) and the additional therapeutic agent(s) are administered in doses lower than the doses commonly employed when such agents are used as monotherapy for treating the disorder.

[00114] In one embodiment, the compound of Formula (I) and the additional therapeutic agent(s) are present in the same composition, which is suitable for oral administration.

[00115] The compound of Formula (I) and the additional therapeutic agent(s) can act additively or synergistically. A synergistic combination may allow the use of lower dosages of one or more agents and/or less frequent administration of one or more agents of a combination therapy. A lower dosage or less frequent administration of one or more agents may lower toxicity of the therapy without reducing the efficacy of the therapy.

[00116] The doses and dosage regimen of the additional therapeutic agent(s) used in the combination therapies of the present invention for the treatment or prevention of a disease or disorder can be determined by the attending clinician, taking into consideration the approved doses and dosage regimen in the package insert; the age, sex and general health of the patient; and the type and severity of the viral infection or related disease or disorder.

[00117] Another aspect of this invention is a kit comprising a therapeutically effective amount of the compound of Formula (I) or a pharmaceutically acceptable salt of said compound, optionally at least one additional therapeutic agent listed above and a pharmaceutically acceptable carrier, vehicle or diluent.

Methods of Preparing the Compounds of Formula (I)

[00118] In general, the compounds in the invention may be produced by a variety of processes known to those skilled in the art and by know, processes analogous thereto. The invention disclosed herein is exemplified by the following preparations and examples which should not be construed to limit the scope of the disclosure. Alternative mechanistic pathways and analogous structures will be apparent to those skilled in the art. The practitioner is not limited to these methods. Illustrative general synthetic methods are set out below and then specific compounds of the the Formula (I) are prepared in the Examples.

[00119] One skilled in the art will recognize that one route will be optimized depending on the choice of appendage substituents. Additionally, one skilled in the art will recognize that in some cases the order of steps has to be controlled to avoid functional group incompatibility.

[00120] The prepared compounds may be analyzed for their composition and purity as well as characterized by standard analytical techniques such as, for example, elemental analysis, NMR, mass spectroscopy and IR spectra.

[00121] One skilled in the art will recognize that reagents and solvents actually used may be selected from several reagents and solvents well known in the art to be effective equivalents. Hence, when a specific solvent or reagent is mentioned, it is meant to be an illustrative example of the conditions desirable for that particular reaction scheme or for the preparation described below.

[00122] Where NMR data are presented, ¹H spectra were obtained on either a Varian VXR-400 (400 MHz, 1H), Varian Gemini-300 (300 MHz), Varian Mercury VX-400 (400 MHz), Bruker-Biospin AV-500 (500 MHz) or Bruker Avance DRX-500 (500 MHz), and chemical shifts are reported as ppm with number of protons and multiplicities indicated parenthetically. Where LC/MS data are presented, analyses was performed using a 1200 series Agilent 6140 Quadrupole LCMS with a 1.8 μM Zorbax SB-C18 column (10-95% of MeCN-H₂O with 0.1% TFA over 2.7 min, 1 mL/min) or with an Applied Biosystems API-150 mass spectrometer and Gemini C18 column (50 x 4.6 mm, 10-95% CH₃CN-H₂O with 0.05% TFA over 5 min, 1 mL/min).

[00123] Preparative chiral HPLC separations were generally carried out using supercritical fluid chromatography by eluting a chiral column such as OJ-H, (4.6 x 250mm, Chiral Technologies, Inc., West Chester, Pennsylvania) with a mobile phase of isopropanol and supercritical CO₂.

[00124] The following solvents, reagents, protecting groups, moieties, and other designations may be referred to by their abbreviations in parenthesis:

[00125] Me = methyl; Et = ethyl; Pr = propyl; iPr – isopropyl; Bu = butyl; t-Bu = tert-butyl; Ph = phenyl, and Ac = acetyl

[00126] μl = microliters

[00127] AcOEt or EtOAc = ethyl acetate

[00128] AcOH or HOAc = acetic acid

[00129] aq = aqueous

[00130] Ar = aryl

[00131] atm = atmosphere

[00132] 9-BBN = 9-borabicyclo[3.3.1]nonane

[00133] Bn = benzyl

[00134] Boc or BOC = tert-butoxycarbonyl

[00135] Bz = benzoyl

[00136] Boc = tert-butoxycarbonyl

[00137] cat = catalyst or catalytic

[00138] Cbz or CBZ = benzyloxycarbonyl

[00139] DBU = 1,8-Diaza-7-bicyclo[5.4.0]undecene

[00140] DCM = dichloromethane

[00141] DCE = dichloroethane

[00142] DMAP = 4-Dimethylaminopyridine

[00143] DIBAL = diisobutylaluminum hydride

[00144] DIPEA or Hünig's Base = N,N-diisopropylethylamine

[00145] DME = 1,2-dimethoxyethane

[00146] DMF = dimethylformamide

[00147] DMS = dimethylsulfide

[00148] DMSO = dimethyl sulfoxide

[00149] EDCI or DEC = 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide

[00150] ee = enantiomeric excess

[00151] EDTA = ethylenediaminetetraacetic acid

[00152] Et₂O = diethyl ether

[00153] g = grams


[00154] h = hour

[00155] HMDS = 1,1,1,3,3,3-hexamethyldisilazane

- [00156] HATU = N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)uranium hexafluorophosphate
- [00157] HOBt = 1-hydroxybenzotriazole
- [00158] Im = imidazole
- [00159] LAH = lithium aluminum hydride
- [00160] LDA = lithium diisopropylamide
- [00161] LCMS = liquid chromatography mass spectrometry
- [00162] LG = leaving group
- [00163] min = minute
- [00164] mg = milligrams
- [00165] mL = milliliters
- [00166] mmol = millimoles
- [00167] MeOH: methanol
- [00168] MS = mass spectrometry
- [00169] NBS = N-bromosuccimide
- [00170] NMR = nuclear magnetic resonance spectroscopy
- [00171] PG = protecting group
- [00172] Pyr = pyridine
- [00173] RT or rt = room temperature (ambient, about 25 °C)
- [00174] sat = saturated
- [00175] SFC = supercritical fluid chromatography
- [00176] SM = starting material
- [00177] TBSCl = t-butyldimethylsilyl chloride
- [00178] TBS = t-butyldimethyl silyl
- [00179] TFA = trifluoroacetic acid
- [00180] TFAA = trifluoroacetic anhydride
- [00181] THF = tetrahydrofuran
- [00182] TLC = thin layer chromatography
- [00183] TMS = trimethylsilyl
- [00184] Tos or Ts = p-toluenesulfonyl (tosyl)
- [00185] Tol = toluene
- [00186] IBMX = 3-Isobutyl-1-methylxanthine
- [00187] HBSS = Hank's balanced salt solution
- [00188] HEPES = 1-[4-(2-Hydroxyethyl)-1-piperazinyl]ethane-2-sulfonic acid


[00189] The compounds of this invention can be prepared through the general approach outlined in the following schemes. These schemes are being provided to illustrate the present invention. To assist one in this endeavor, the ordinary practitioner would have full knowledge of literature sources such as *Chemical Abstracts*; *Beilstein*, *Protective Groups in Organic Synthesis* 2nd Edition T.W. Greene, P.G.M. Wuts 1991, Wiley and Sons; *Comprehensive Organic Transformations*, *Advanced Organic Chemistry* etc.

Scheme 1




[00190] As shown in Scheme 1 above, compounds of the Formula (I) can be prepared from substituted 4-methoxyquinolines **a1**. Compounds **b1** are prepared from **a1** in the presence of allylmagnesium bromide and Cbz-Cl. The alkene in **b1** is used as a key functional group to provide primary alcohol **c1** with 2-4 carbon length linkers. The primary alcohols are then converted to iodides **d1** before they are cyclized under basic conditions to provide ketones **e1**. Compounds **h1** are obtained from **e1** by reductive amination, acylation and hydrolysis. Analogs based on **g1** can be synthesized by hydrogenation followed by acylation, carbamate, or urea formation before hydrolysis to give final acids **k1**.

Scheme 2



[00191] For cyclopentyl fused ring compounds, a second route can also be employed as shown Scheme 2 above and Scheme 3 below. Starting from substituted anilines, ethyl 2-oxocyclopentanecarboxylate is condensed with substituted anilines to give the esters (**a2**). The esters (**a2**) are hydrolyzed to acids (**b2**) which undergo Friedel-Crafts reaction to give cyclized products **c2**. Cbz intermediate **d2** and acylated product **e2** can be synthesized from **c2**. Following a similar process as described above for **e1-h1** and **g1** to **kl**, further analogs such as **h2** and **j2** can be prepared from **e2**. Tertiary amine analogs **j2** can be prepared from **f2** by reductive amination followed by hydrolysis.


Scheme 3




[00192] The starting materials and reagents used in preparing compounds described below are either available from commercial suppliers such as Aldrich Chemical Co. (Wisconsin, USA) and Acros Organics Co. (New Jersey, USA) or were prepared by literature methods known to those skilled in the art.

[00193] Where the stereodesignations of the specifically exemplified compounds in the tables below specify "racemic, cis, cis", this description means that the compound is racemic and has a structure wherein the bonds joining the tetrahydroquinoline ring in the core to the

cycloalkyl ring have a cis configuration, and that the bond joining the $-N(R^1)(R^2)$ group to the tetrahydroquinoline ring and the adjacent bond also has a cis configuration. By way of example, where an example indicates that the isolated compound has the structure:




and has a stereodesignation indicated as "racemic, cis, cis", this designation means that the isolated compound is a racemic mixture of the following enantiomers:




and

[00194] Where the stereodesignations of the specifically exemplified compounds in the tables below specify "cis, cis, single enantiomer" or "cis, cis, enantiopure," this designation means that the isolated compound is a single enantiomer or is enriched in a single enantiomer as compared to the other enantiomer. Furthermore, this description means that the compound has a structure wherein the bonds joining the tetrahydroquinoline ring in the core to the cycloalkyl ring have a cis configuration, and that the bond joining the $-N(R^1)(R^2)$ group to the tetrahydroquinoline ring and the adjacent bond also has a cis configuration.

[00195] These examples are being provided to further illustrate the present invention. They are for illustrative purposes only; the scope of the invention is not to be considered limited in any way thereby.

EXAMPLES**Example 1: Preparation of Racemic Benzyl cis,cis-9-(cyclopropylamino)-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (1E)****Step 1: Benzyl 2-allyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate**


[00196] A solution of allylmagnesium bromide (1.00 M in tetrahydrofuran, 101 mL, 101 mmol, 2.00 equiv) was added to a solution of 4-methoxy quinoline (8.00 g, 50.3 mmol, 1 equiv) in tetrahydrofuran (335 mL) at -78°C . The reaction mixture was stirred at -78°C for 1 h, then benzyl chloroformate (14.35 mL, 101.0 mmol, 2.00 equiv) was added via syringe over 5 min. The reaction mixture was stirred for an additional 15 minutes at -78°C , then the cooling bath was removed and the reaction mixture was allowed to warm to 23°C . After 1 h, added methanol (40 mL). After stirring for 5 min, aqueous hydrochloric acid solution (2 N, 20 mL) was added and the mixture was stirred for 10 min. The mixture was then concentrated by rotary evaporation to remove most of the tetrahydrofuran and methanol, and the residue was partitioned between ethyl acetate and water. The organic phase was washed with brine, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography (5% ethyl acetate-hexanes, grading to 20% ethyl acetate-hexanes) to afford **1A** as a colorless oil. $[\text{M}+\text{H}]^{+}$: 322.2.

Step 2: Benzyl 2-(3-hydroxypropyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate

[00197] A solution of 9-borabicyclo[3.3.1]nonane (0.4 M in hexanes, 224 mL, 90 mmol, 2 equiv) was added to a solution of benzyl 2-allyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (13.7 g, 42.6 mmol, 1 equiv) in tetrahydrofuran (213 mL) at 0°C . After the addition was complete, the cooling bath was removed and the reaction mixture was stirred for 15 h. The reaction mixture was then cooled to 0°C , and aqueous sodium hydroxide solution (5 M, 85 mL, 10 equiv) was added by addition funnel over 10 minutes. After the addition was complete,


aqueous hydrogen peroxide solution (30% by weight, 174 mL, 40 equiv) was added by addition funnel over 10 minutes. After the addition was complete, the cooling bath was removed and the biphasic reaction mixture was stirred for 45 minutes. The mixture was then partitioned between ethyl acetate and saturated aqueous sodium chloride solution. The layers were separated, and the organic phase was washed with an additional portion of saturated aqueous sodium chloride solution. The washed solution was dried over sodium sulfate, and the dried solution was then filtered. The filtrate was concentrated, and the residue was dissolved in 1,2-dichloroethane (213 mL). Manganese dioxide (18.5 g, 213 mmol, 5.00 equiv) was added, and the reaction mixture was heated to 80 °C. After stirring for 2 h at 80 °C, the reaction mixture was cooled to 23 °C and filtered through Celite®. The filtrate was concentrated, and the residue was purified by flash-column chromatography (50% ethyl acetate-hexanes, grading to ethyl acetate) to afford **1B** as a colorless oil. $[M+H]^+$: 340.2.

Step 3: Benzyl 2-(3-iodopropyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate




[00198] Iodine (12.5 g, 49.4 mmol, 1.30 equiv) was added to a solution of benzyl 2-(3-hydroxypropyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (12.9 g, 38.0 mmol, 1 equiv), triphenylphosphine (13.0 g, 49.4 mmol, 1.30 equiv), and imidazole (6.47 g, 95.0 mmol, 1 equiv) in dichloromethane (380 mL) at 23 °C. After stirring for 15 minutes, the reaction mixture was partitioned between dichloromethane and water. The organic phase was dried over sodium sulfate, and the dried solution was filtered. The filtrate was concentrated, and the residue was purified by flash-column chromatography (hexanes, grading to 30% ethyl acetate-hexanes) to afford **1C** as a colorless oil. $[M+H]^+$: 450.1.

Step 4: Racemic Benzyl cis-9-oxo-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate




[00199] A solution of sodium bis(trimethylsilyl)amide in tetrahydrofuran (1.0 M, 39.4 mL, 39.4 mmol, 1.10 equiv) was added to a solution of benzyl 2-(3-iodopropyl)-4-oxo-3,4-dihydroquinoline-1(2*H*)-carboxylate (16.1 g, 35.8 mmol, 1 equiv) in tetrahydrofuran (716 mL) at -78°C . The reaction mixture was stirred at -78°C for 1 h, then the cooling bath was removed and the reaction mixture was allowed to warm. After stirring for 40 min, water was added (300 mL), and the reaction mixture was concentrated by rotary evaporation to remove most of the tetrahydrofuran. The residue was partitioned between ethyl acetate and water. The organic phase was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography (hexanes, grading to 40% ethyl acetate-hexanes) to afford **1D** as a colorless oil. $[\text{M}+\text{H}]^{+}$: 322.2.

Step 5: Racemic Benzyl cis, cis-9-(cyclopropylamino)-1,2,3,3a,9,9a-hexahydro-4*H*-cyclopenta[*b*]quinoline-4-carboxylate




[00200] Titanium (IV) ethoxide (4.84 mL, 23.3 mmol, 2.50 equiv) was added to a solution of benzyl cis-9-oxo-1,2,3,3a,9,9a-hexahydro-4*H*-cyclopenta[*b*]quinoline-4-carboxylate (3.00 g, 9.34 mmol, 1 equiv) and cyclopropylamine (1.83 mL, 23.3 mmol, 2.50 equiv) in tetrahydrofuran. The reaction vessel was sealed and heated to 60°C . After stirring for 16 h, the reaction mixture was cooled to 23°C and poured over saturated aqueous sodium chloride solution (50 mL). The biphasic mixture was stirred for 5 min, then filtered through Celite® with the aid of ethyl acetate. The filtrate was partitioned between ethyl acetate and brine, and the organic phase was then dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was dissolved in methanol (30 mL) and tetrahydrofuran (60 mL), and the solution was cooled to 0°C . Sodium borohydride (855 mg, 22.6 mmol, 2.50 equiv) was added to the cooled solution. After stirring for 15 min at 0°C , the cooling bath was removed, and the reaction mixture was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to afford **1E**. $[\text{M}+\text{H}]^{+}$: 363.3.

Example 2: Preparation of Racemic Benzyl cis, cis-9-amino-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[*b*]quinoline-4-carboxylate (2)



[00201] Sodium cyanoborohydride (78 mg, 1.2 mmol, 2.0 equiv) was added to a mixture of benzyl cis-9-oxo-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[*b*]quinoline-4-carboxylate (200 mg, 0.622 mmol, 1 equiv) and ammonium acetate (480 mg, 6.22 mmol, 10 equiv) in methanol (6.2 mL). The reaction vessel was sealed and heated to 70 °C. After stirring at 70 °C for 90 min, the reaction mixture was cooled to 23 °C and partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography (50% ethyl acetate-hexanes, grading to ethyl acetate, then flushing with 10% methanol-dichloromethane) to afford **2**.


Example 3: Preparation of Racemic Benzyl cis, cis-9-(acetylamino)-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[*b*]quinoline-4-carboxylate (3)



Acetic anhydride (0.250 mL, 2.65 mmol, 5.00 equiv) was added to a solution of benzyl cis, cis-9-amino-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[*b*]quinoline-4-carboxylate **2** (171 mg, 0.530 mmol, 1 equiv) and *N,N*-diisopropylethylamine (0.278 mL, 1.59 mmol, 3.00 equiv) in dioxane (5.3 mL) at 23 °C. The reaction mixture was stirred for 10 min, and then was partitioned between ethyl acetate and aqueous hydrochloric acid solution (1 N). The organic


layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to afford **3**. $[M+H]^+$: 365.2.

Example 4: Preparation of Racemic Benzyl cis, cis-9-(cyclobutylamino)-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (4A)



[00202] Benzyl cis, cis-9-(cyclobutylamino)-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate **4A** was prepared from benzyl cis-9-oxo-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate using a procedure similar to that used for Example 1, Step 5, substituting cyclobutylamine and acetic acid for ammonium acetate. $[M+H]^+$: 377.3.


Example 5: Preparation of Racemic Benzyl cis, cis-9-(isopropylamino)-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate



[00203] Benzyl cis, cis-9-(isopropylamino)-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate **5A** was prepared from racemic benzyl cis-9-oxo-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate using a procedure similar to that used in Example 1, Step 5. $[M+H]^+$: 365.3.


Example 6: Preparation of Racemic Benzyl cis, cis-9-(cyclopropylamino)-6-fluoro-1,2,3,3a,9,9a-hexahydro-4*H*-cyclopenta[*b*]quinoline-4-carboxylate (6D)

Step 1: 2-[(3-Fluorophenyl)amino]cyclopentanecarboxylic acid (6A)




[00204] Sodium hydroxide (96 mL, 478 mmol, 5 M in water, 5 equiv.) was added to a mixture of ethyl 2-[(3-fluorophenyl)amino]cyclopentanecarboxylate (reported by Micovic *et al.*, *Synthesis*, **1991**, 1043-1045) (24.0 g, 96 mmol, 1 equiv) in dioxane (95 mL). The reaction was heated to 100 °C and stirred for one hour. The reaction mixture was then cooled to 23 °C and acidified to pH = 3 with 2N HCl. The reaction mixture was then partitioned between ethyl acetate and water. The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to afford **6A** as a mixture of *cis* and *trans* isomers. $[M+H]^+$: 224.1.

Step 2: Racemic cis-6-Fluoro-1,2,3,3a,4,9a-hexahydro-9*H*-cyclopenta[*b*]quinolin-9-one (6B)




[00205] Eaton's reagent (100 mL, 630 mmol, 6.6 equiv.) was added to 2-[(3-fluorophenyl)amino]cyclopentanecarboxylic acid **6A** (21.3 g, 95 mmol, 1 equiv). The mixture was heated to 70 °C and stirred for one hour. The reaction mixture was then cooled to 23 °C and quenched with the addition of wet ice. The mixture was then neutralized to pH = 10 with the portionwise addition of solid sodium hydroxide pellets. The reaction mixture was then partitioned between ethyl acetate and water. The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The filtrate was purified by flash-column chromatography (hexanes, grading to 50% ethyl acetate-hexanes) to afford **6B**. $[M+H]^+$: 206.2.

Step 3: Racemic Benzyl cis-6-fluoro-9-oxo-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[*b*]quinoline-4-carboxylate (6C)



[00206] Phosgene (20% in toluene, 1.0 g, 2.2 mmol, 1.5 equiv) was added to a solution of cis-6-fluoro-1,2,3,3a,4,9a-hexahydro-9H-cyclopenta[*b*]quinolin-9-one **6B** (300 mg, 1.5 mmol, 1 equiv) and diisopropyl ethylamine (380 μ L, 2.2 mmol, 1.5 equiv) in THF (14.6 mL). After stirring at 23 °C for two hours the solution was treated with benzyl alcohol (450 μ L, 4.4 mmol, 3 equiv) and sodium hydride (60% in mineral oil, 230 mg, 5.9 mmol, 4 equiv). After stirring at 23 °C for 12 hours the reaction was neutralized to pH = 7 with 1N HCl. The reaction mixture was then partitioned between ethyl acetate and water. The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The filtrate was purified by flash-column chromatography (hexanes, grading to 50% ethyl acetate-hexanes) to afford **6C**. $[M+H]^+$: 340.2.


Step 4: Racemic Benzyl cis, cis-9-(cyclopropylamino)-6-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[*b*]quinoline-4-carboxylate (6D)



[00207] Benzyl cis, cis-9-(cyclopropylamino)-6-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[*b*]quinoline-4-carboxylate **6D** was prepared from benzyl cis-6-fluoro-9-oxo-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[*b*]quinoline-4-carboxylate using a procedure similar to that used in Example 1, Step 5. $[M+H]^+$: 381.2.


Example 7: Preparation of Racemic 4-[(cis, cis-4-[(Benzyloxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)(cyclopropyl)amino]-4-oxobutanoic acid (7)

Step 1: Racemic Benzyl cis, cis-9-[cyclopropyl(4-methoxy-4-oxobutanoyl)amino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (7A)



[00208] Methyl 4-chloro-4-oxobutanoate (1.54 mL, 12.3 mmol, 2.50 equiv) was added to a solution of benzyl cis, cis-9-(cyclopropylamino)-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (**1E**) (1.78 g, 4.91 mmol, 1 equiv) and *N,N*-diisopropylethylamine (2.57 mL, 14.7 mmol, 3.00 equiv) in dioxane (33 mL) at 23 °C (used a 23 °C water bath to control the exotherm that was observed during the addition). The reaction mixture was stirred for 1 h, and then it was partitioned between ethyl acetate and aqueous hydrochloric acid solution (1 N). The organic layer was washed sequentially with aqueous sodium hydroxide solution (1 N) and saturated aqueous sodium chloride solution, and the washed organic layer was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography (20% ethyl acetate-hexanes, grading to ethyl acetate) to afford **7A**. $[M+H]^+$: 477.2.


Step 2: Racemic 4-[(cis, cis-4-[(Benzyloxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)(cyclopropyl)amino]-4-oxobutanoic acid (7)



[00209] Aqueous sodium hydroxide solution (1 N, 0.168 mL, 0.168 mmol, 4.0 equiv) was added to a solution of benzyl cis, cis-9-[cyclopropyl(4-methoxy-4-oxobutanoyl)amino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate **7A** (20 mg, 0.42 mmol, 1 equiv) in dioxane (0.42 mL). The reaction vessel was sealed and heated to 80 °C. After stirring for 1 h at 80 °C, the reaction mixture was cooled to 23 °C and partitioned between ethyl acetate

and aqueous hydrochloric acid solution. The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to afford **7** as a white solid. $[M+H]^+$: 463.3.

Example 8: Preparation of Enantiomerically Pure 1,2,3,3a,4,9a-hexahydro-9H-cyclopenta[*b*]quinolin-9-one (8**)**



Step 1

[00210] Isobutyl chloroformate (1.5 mL, 11.5 mmol) was added to a solution of *i*-Pr₂NEt (2.3 mL, 13 mmol) and (1*S*, 2*R*)-2-(benzyloxycarbonyl)-cyclopentane-carboxylic acid **8A**, (Small Molecules, Inc., Hoboken, New Jersey) (2.15 g, 8.70 mmol) in acetone (35 mL) at 0 °C. The resulting solution was stirred at 0 °C for 1 h. A solution of NaN₃ (1.40 g, 21.0 mmol) in 14 mL of water was added. The resulting mixture was stirred at room temperature for another hour. DCM was added to the reaction mixture. The aqueous layer was separated and extracted with DCM. The organic extracts were combined and washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was dissolved in toluene (50 mL), and benzyl alcohol (1.5 mL, 14.5 mmol) and Et₃N (2.4 mL, 17.1 mmol) were added. The resulting mixture was heated at 130°C for 1 h. The reaction mixture was cooled to room temperature, diluted with EtOAc, and washed with 1 N HCl. The aqueous layer was separated, and extracted with EtOAc. The organic extracts were combined and washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified over a silica gel column (80 g), eluting with 10% EtOAc in hexanes, followed by 15% EtOAc in hexanes to give 3.14 g of product **8B** as a white solid (95%).

Step 2

[00211] 10% Pd on carbon (3 g) was added to a solution of compound **8B** (3.14 g, 10.2 mmol) in MeOH (45 mL). The resulting mixture was placed under 1 atm of hydrogen and stirred at room temperature overnight. The mixture was filtered through a pad of Celite®, and the filtrate was concentrated *in vacuo* to give 1.4 g of the desired product **8C** as a white solid (100%).

Step 3

[00212] Compound **8C** (1.0 g, 7.8 mmol), iodobenzene (1.76 g, 8.7 mmol), CuI (148 mg, 0.78 mmol), Cs₂CO₃ (7.64 g, 23.4 mmol) were mixed in DMF (12 mL) in a sealed tube. The content was evacuated and refilled with nitrogen three times. 2-Isobutyrylcyclohexanone (0.26 mL, 1.6 mmol) was added to the mixture with a syringe via a septum. The septum was replaced with a screwed cap, and the sealed tube was heated at 50°C overnight. The reaction mixture was cooled to room temperature and checked with TLC. EtOAc and water were added to the mixture. The aqueous layer was separated and washed with EtOAc. The EtOAc layers were combined and extracted with 1 N NaOH three times to make sure that the desired product is retained in the basic water layer. The aqueous layer was treated with 1 N HCl carefully to adjust the pH to between 4 and 5. The resulting aqueous layer was then extracted with EtOAc. The combined organic extracts were washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo* to give 1.24 g (77%) desired product **8D** as a brown oil.

Step 4

[00213] Thionyl chloride (0.56 mL, 3.0 mmol) was added dropwise to compound **8D** (0.85 g, 2.57 mmol) in MeOH (12 mL) at 0°C. The resulting solution was stirred at 0°C for 30 min and then at room temperature for 4 h. The mixture was concentrated under vacuum. The residue was dissolved in DCM and washed with 1 N NaOH. The organic layer was washed with brine, dried (MgSO₄) and concentrated *in vacuo*. The residue was purified over a 40 g silica gel column, eluting with 5% EtOAc in hexanes, followed by 10% EtOAc in hexanes to give 0.68 g desired product **8E** as an off-white solid (78%).

Step 5

[00214] LHMDs (0.4 mL, 1 M in THF, 0.40 mmol) was added to compound **8E**; (35 mg, 0.16 mmol) in THF (2 mL) at 0°C. The mixture was stirred at room temperature overnight. The reaction was monitored by TLC and LCMS. EtOAc and water were added to the mixture. The aqueous layer was separated and extracted with EtOAc. The organic extracts were combined, washed with brine, dried (MgSO₄), filtered and concentrated. The residue was purified by silica



gel thin-layer-chromatography, eluting with 1:5 EtOAc-hexanes, to give 20 mg of desired product **8F**.

Step 6


[00215] Triflic acid (20 μ L, 0.23 mmol) was added to a solution of compound **8F** (20 mg, 0.11 mmol) in DCE (1 mL) at 0°C. The reaction was followed by LCMS until done. The reaction mixture was diluted with EtOAc and washed with 1 N NaOH. The aqueous layer was separated and extracted with EtOAc. The combined organic extracts was washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified by thin-layer-chromatography, eluting with EtOAc-hexanes, to give 15 mg desired compound **8** (75%). The enantiomeric purity of compound **8**, predominantly in (3aS, 9aR) configuration, was determined by HPLC analysis to be 92%.

Example 9: Preparation of Compounds 9, 9A, and 9B

[00216] The compounds in the following table were prepared from corresponding unsubstituted tricyclic ketone or N-Cbz substituted tricyclic ketone in a similar manner to the process shown in Example 1, step 5, and Example 7, steps 1 and 2. The corresponding unsubstituted ketone or N-Cbz substituted ketones were resolved with chiral HPLC to provide enantiomerically pure ketone intermediates which were converted to final products.


#	Structure	Stereo designation	Name	[M+H] ⁺
9		cis, cis, single enantiomer	3-(phenylmethyl) cis,cis-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5-fluoro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate	489 [M+Na] ⁺
9A		cis, cis, single enantiomer	4-(phenylmethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	519.0 [M+Na] ⁺

9B

3aS,9R,9aR,
single
enantiomer4-(((3aS,9R,9aR)-4-
((benzyloxy)carbonyl)-7-
fluoro-2,3,3a,4,9,9a-hexahydro-
1H-cyclopenta[b]quinolin-9-
yl)(cyclopropyl)amino)-4-
oxobutanoic acid


481.2

Example 10: Preparation of Racemic 4-[(*cis*, *cis*-4-[(Benzyloxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)(cyclopropyl)amino]-2-methyl-4-oxobutanoic acid (**10**)

**10**

[00217] A solution of racemic benzyl *cis*, *cis*-9-(cyclopropylamino)-1,2,3,3a,9,9a-hexahydro-4*H*-cyclopenta[b]quinoline-4-carboxylate (**1E**) (25 mg, 0.069 mmol, 1 equiv) and 3-methyldihydrofuran-2,5-dione (0.15 mL, 1.6 mmol, 23 equiv) in dioxane (0.35 mL) was heated to 110 °C in a sealed tube. After heating for 1 h, the oil bath temperature was increased to 130 °C for 1 h. The reaction mixture was then cooled to 23 °C and partitioned between ethyl acetate and aqueous hydrochloric acid solution. The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography (dichloromethane, grading to 10% methanol-dichloromethane). The residue was then dissolved in DMSO (1 mL), and purified by reverse-phase HPLC (40% acetonitrile-water, grading to 80% acetonitrile-water, with 0.1% trifluoroacetic acid in both the acetonitrile and water) to afford **10**. $[M+H]^+$: 477.2.

Example 11: Preparation of N1-cyclopropyl-N1-((3a*S*,9*R*,9a*R*)-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl)-N4-(methylsulfonyl)succinamide




[00218] Carbonyldiimidazole (13.65 mg, 0.084 mmol) was added to a stirred mixture of compound **17** (30 mg, 0.056 mmol) (see Example 17 below) in tetrahydrofuran (2 mL) at room temperature. The mixture was stirred at 70 °C for 2 h before it was cooled to room temperature and DBU (0.017 mL, 0.112 mmol) and methanesulfonamide (8.01 mg, 0.084 mmol) were added. The reaction mixture was stirred at room temperature for overnight before it was concentrated under reduced pressure. The residue was purified via preparative TLC, eluting with CH₂Cl₂/MeOH = 10:1 to give enantiopure **11** (26.3 mg, 0.043 mmol, 77 % yield) as a white solid. [M+H]⁺: 611.8.

[00219] Compound **11A**, **11B**, and **11C** were prepared using a similar procedure as is described above. Compound **11A** was prepared from compound **17**. Compounds **11B** and **11C** were prepared from compound **83** (see below).

#	Structure	Stereo designation	Name	[M+H] ⁺
11A		3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i> , single enantiomer	N1-cyclopropyl-N4-(cyclopropylsulfonyl)-N1-((3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i>)-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[<i>b</i>]quinolin-9-yl)succinamide	637.7
11B		cis, cis, single enantiomer	N1-(cyclopropylsulfonyl)-N4-ethyl-N4-(cis, cis-3-(4-(trifluoromethylthio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[<i>b</i>]quinolin-8-yl)succinamide	610.1


11C

cis, cis, single
enantiomerN1-ethyl-N4-
(methylsulfonyl)-N1-(cis, cis-
3-(4-
(trifluoromethylthio)benzoyl)-
1,2,2a,3,8,8a-
hexahydrocyclobuta[b]quinoli
n-8-yl)succinamide

584.1


Example 12: Preparation of Racemic Benzyl cis, cis-9-[(4-methoxy-4-oxobutanoyl)(phenyl)amino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (12)

Step 1: Racemic Benzyl cis, cis-9-anilino-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (12A)



[00220] Tris(dibenzylideneacetone)dipalladium (89 mg, 0.098 mmol, 0.15 equiv), 2-dicyclohexylphosphino-2'-(*N,N*-dimethylamino)biphenyl (115 mg, 0.293 mmol, 0.45 equiv), and benzyl cis, cis-9-amino-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate **2** (210 mg, 0.651 mmol, 1 equiv) were charged in a reaction vial and tetrahydrofuran (6.5 mL) was added. Nitrogen gas was bubbled through the solution for 5 min to remove excess oxygen, and then iodobenzene (0.145 mL, 1.30 mmol, 2.0 equiv) and lithium bis(trimethylsilyl)amide in tetrahydrofuran (1.0 M, 0.977 mL, 0.977 mmol, 1.50 equiv) were added sequentially. The reaction vial was sealed and heated to 55 °C for 16 h. After cooling to 23 °C, the reaction mixture was partitioned between ethyl acetate and water, and the organic layer was washed with saturated aqueous sodium chloride solution. The washed solution was dried over sodium sulfate, and the dried solution was filtered. The filtrate was purified by flash-column chromatography (hexanes, grading to 30% ethyl acetate-hexanes) to afford **12A**. $[M+Na]^+$: 421.2.




Step 2: Racemic Benzyl cis, cis-9-[(4-methoxy-4-oxobutanoyl)(phenyl)amino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (12)



[00221] Sodium hydride (60% dispersion in oil, 58.2 mg, 1.46 mmol, 4.0 equiv) was added to a solution of methyl 4-chloro-4-oxobutanoate (0.183 mL, 1.46 mmol, 4.0 equiv) and **12A** (145 mg, 0.364 mmol, 1 equiv) in dioxane (2.4 mL) at 23 °C. The reaction vessel was sealed, and the reaction mixture was heated to 75 °C. After stirring for 2.5 h, the temperature was increased to 85 °C. After stirring at 85 °C for 2.5 h, the reaction mixture was cooled to 23 °C, and saturated aqueous ammonium chloride solution was added slowly (vigorous gas evolution). The quenched reaction mixture was partitioned between ethyl acetate and water, and the organic layer was washed with saturated aqueous sodium chloride solution. The washed solution was dried over sodium sulfate, and the dried solution was filtered. The filtrate was purified by flash-column chromatography (hexanes, grading to 60% ethyl acetate-hexanes) to afford compound **17**. $[M+H]^+$: 513.3.


[00222] The following compounds were prepared from racemic benzyl cis, cis-9-[(4-methoxy-4-oxobutanoyl)(phenyl)amino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate **12A**, using procedures similar to those described in Example 14 below.

#	Structure	Stereo designation	Name	$[M+H]^+$
12B		racemic, cis, cis	methyl 4-oxo-4-{phenyl[cis, cis-4-(pyridin-3-ylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}butanoate	484.2

12C		racemic, cis, cis	4-[{cis, cis-4-[(benzyloxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}(phenyl)amino]-4-oxobutanoic acid	499.2
12D		racemic, cis, cis	4-oxo-4-{phenyl[<i>cis</i> , <i>cis</i> -4-(pyridin-3-ylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}butanoic acid	470.2
12E		racemic, <i>cis</i> , <i>cis</i>	4-oxo-4-{phenyl[<i>cis</i> , <i>cis</i> -4-(phenylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}butanoic acid	469.2


Example 13: Preparation of Racemic 4-[{*cis*, *cis*-4-[(Benzyloxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}(ethyl)amino]-4-oxobutanoic acid (13)

Step 1: Racemic benzyl *cis*, *cis*-9-(ethylamino)-1,2,3,3a,9,9a-hexahydro-4*H*-cyclopenta[b]quinoline-4-carboxylate (13)



[00223] **13A** was prepared from benzyl *cis*-9-oxo-1,2,3,3a,9,9a-hexahydro-4*H*-cyclopenta[b]quinoline-4-carboxylate **1D** using a procedure similar to that used in Example 1, Step 5. $[M+H]^+$: 351.2.

Step 2: Racemic 4-[(cis, cis-4-[(Benzyloxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)(ethyl)amino]-4-oxobutanoic acid (13)




[00224] 4-[(Cis, cis-4-[(Benzyloxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)(ethyl)amino]-4-oxobutanoic acid ($[M+H]^+$: 451.2) was prepared from **13B** using a sequence similar to that used for Example 7, step 2. Compound **13B** was prepared from **13A** following a similar procedure as Example 7, step 1.

[00225] The following examples were prepared from racemic benzyl cis, cis-9-[ethyl(4-methoxy-4-oxobutanoyl)amino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (**13B**) using procedures similar to those used in Example 14.

#	Structure	Stereo designation	Name	$[M+H]^+$
13C		racemic, cis, cis	4-{ethyl [cis, cis-4-{[4-(trifluoromethoxy)phenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid	505.1
13D		racemic, cis, cis	4-{ethyl[cis, cis-4-(phenylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid	421.2

13E


racemic, cis,
cis

4-{ethyl[cis, cis-4-(pyridin-3-ylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid

422.2


Example 14: Preparation of Racemic 4-{Cyclopropyl[cis, cis-4-(phenylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid (14)

Step 1: Methyl 4-{cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoate (14A)




[00226] Palladium (10% on carbon, 103 mg, 0.050 equiv) was added to a solution of benzyl cis, cis-9-[cyclopropyl(4-methoxy-4-oxobutanoyl)amino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate **7A** (922 mg, 1.93 mmol, 1 equiv) in ethanol (14.5 mL) and ethyl acetate (4.84 mL). A three-way stopcock connected to a hydrogen balloon and a vacuum line was fitted to the top of the flask, and the flask was subjected to alternating vacuum purging and hydrogen filling cycles (4 x). The reaction mixture was then stirred under hydrogen for 90 min at 23 °C, and then was filtered through cotton. The filtrate was concentrated to afford **14A**, which was used without further purification. $[M+H]^+$: 343.2.

Step 2: Methyl 4-[[cis, cis-4-benzoyl-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl](cyclopropyl)amino]-4-oxobutanoate (14B)




[00227] Benzoyl chloride (0.028 mL, 0.24 mmol, 1.5 equiv) was added to a solution of methyl 4-{cyclopropyl[*cis*, *cis*-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl]amino}-4-oxobutanoate **14A** (55 mg, 0.16 mmol, 1 equiv) and *N,N*-diisopropylethylamine (0.084 mL, 0.48 mmol, 3.0 equiv) in dichloromethane (1.60 mL) at 23 °C. The reaction mixture was stirred at 23 °C for 30 min, and then was partitioned between ethyl acetate and aqueous hydrochloric acid solution (1 N). The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography (40% ethyl acetate-hexanes, grading to ethyl acetate) to afford **14B**. $[M+H]^+$: 447.2.

Step 3: 4-[[*cis*, *cis*-4-Benzoyl-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl](cyclopropyl)amino]-4-oxobutanoic acid (14**)**








[00228] Compound **14** was prepared from methyl 4-[[*cis*, *cis*-4-benzoyl-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl](cyclopropyl)amino]-4-oxobutanoate **14B** using a procedure similar to that used in Example 2, Step 2. $[M+H]^+$: 433.2


[00229] The following compounds were made from racemic methyl 4-{cyclopropyl[*cis*, *cis*-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl]amino}-4-oxobutanoate (**14A**) using procedures similar to those used in Example 14, Steps 2 and 3:

#	Structure	Stereo designation	Name	$[M+H]^+$
14C		racemic, <i>cis</i> , <i>cis</i>	4-{cyclopropyl[<i>cis</i> , <i>cis</i> -4-{4-(trifluoromethoxy)phenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[<i>b</i>]quinolin-9-yl]amino}-4-oxobutanoic acid	517.2

14D		racemic, cis, cis	4-(cyclopropyl{ cis, cis-4-[(1-methyl-1H-indol-2-yl)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}amino)-4-oxobutanoic acid	486.2
14E		racemic, cis, cis	4-{cyclopropyl[cis, cis-4-(thiophen-3-ylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid	439.0
14F		racemic, cis, cis	4-[{cis, cis-4-[(4-bromophenyl)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}(cyclopropyl)amino]-4-oxobutanoic acid	511.1
14G		racemic, cis, cis	4-{cyclopropyl[cis, cis-4-(cyclopropylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid	397.0
14H		racemic, cis, cis	4-(cyclopropyl{cis, cis-4-[(3-morpholin-4-ylphenyl)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}amino)-4-oxobutanoic acid	518.2


14i		racemic, cis, cis	4-{cyclopropyl[2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid	434.2
14K		racemic, cis, cis	4-[(4-chlorophenyl)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl(cyclopropyl)amino-4-oxobutanoic acid	467.1
14L		racemic, cis, cis	4-(cyclopropyl{2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}amino)-4-oxobutanoic acid	463.2
14N		racemic, cis, cis	methyl 4-(cyclopropyl{2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}amino)-4-oxobutanoate	500.2
14o		racemic, cis, cis	methyl 4-(cyclopropyl[2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino)-4-oxobutanoate	453.2

14P

racemic, cis,
cismethyl 4-[(4-chlorophenyl)carbonyl]-
2,3,3a,4,9,9a-hexahydro-1H-
cyclopenta[b]quinolin-9-
yl(cyclopropyl)amino]-4-
oxobutanoate

481.2


Example 15: Preparation of Racemic Benzyl cis, cis-9-[cyclopropyl(4-methoxy-4-oxobutanoyl)amino]-6-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (15)



15

[00230] 15 was prepared from benzyl cis, cis-9-(cyclopropylamino)-6-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (**6D**) using a procedure similar to that used for Example 7, Step 1. $[M+H]^+$: 495.2.

Example 16: 4-[(cis, cis-4-[(Benzyloxy)carbonyl]-6-fluoro-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl(cyclopropyl)amino]-4-oxobutanoic acid (16)



15


16

[00231] **16** was prepared from benzyl cis, cis-9-[cyclopropyl(4-methoxy-4-oxobutanoyl)amino]-6-fluoro-1,2,3,3a,9,9a-hexahydro-4*H*-cyclopenta[*b*]quinoline-4-carboxylate (**15**) using a procedure similar to that used in Example 7, Step 2. $[M+H]^+$: 481.2.

[00232] The following examples were prepared from racemic benzyl cis, cis-9-[cyclopropyl(4-methoxy-4-oxobutanoyl)amino]-6-fluoro-1,2,3,3a,9,9a-hexahydro-4*H*-cyclopenta[*b*]quinoline-4-carboxylate (**15**) using procedures similar to that used in Example 14, Steps 1 and 2 (for the esters in the table) and Example 14, Steps 1–3 (for the carboxylic acids in the table).

#	Structure	Stereo Designation	Name	$[M+H]^+$
16A		racemic, cis, cis	Methyl 4-{cyclopropyl[cis, cis-6-fluoro-4-(pyridin-3-ylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[<i>b</i>]quinolin-9-yl]amino}-4-oxobutanoate	466.2
16B		racemic, cis, cis	Methyl 4-{cyclopropyl[cis, cis-6-fluoro-4-[(4-phenoxyphenyl)carbonyl]-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[<i>b</i>]quinolin-9-yl]amino}-4-oxobutanoate	557.2
16C		racemic, cis, cis	Methyl 4-{cyclopropyl[cis, cis-6-fluoro-4-(phenylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[<i>b</i>]quinolin-9-yl]amino}-4-oxobutanoate	465.2
16D		racemic, cis, cis	4-{cyclopropyl[cis, cis-6-fluoro-4-(phenylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[<i>b</i>]quinolin-9-yl]amino}-4-oxobutanoic acid	461.1

16E


racemic, cis,
cis4-{cyclopropyl[trans, trans-6-fluoro-4-
[(4-phenoxyphenyl)carbonyl]-2,3,
3a,4,9,9a-hexahydro-1H-
cyclopenta[b]quinolin-9-yl]amino)-
4-oxobutanoic acid

543.2

Example 17: Preparation of Enantiopure 4-(Cyclopropyl((3aS,9R,9aR)-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid


(17)

Step 1



[00233] In a 500 mL round bottom flask was added acetic acid (81 mL), water (8.05 mL, 447 mmol), 4-fluoroaniline (10 mL, 97 mmol), ethyl 2-oxocyclopentanecarboxylate (13.13 mL, 97 mmol) followed by zinc (25.4 g, 388 mmol). The reaction was warmed to 80 °C, during which time gas evolution was noted. After 2 h, the bubbling had stopped and the reaction was cooled to rt. The slurry was then diluted with MeOH and the zinc solids were removed by filtering through a fritted funnel. The collected filtrate was then concentrated on the rotovap and then diluted with DCM and wet ice. The solution was neutralized with NH_4OH to pH=10. The mixture was then poured into a separation funnel containing DCM and water. The mixture was extracted 3x with DCM. The combined fractions were washed with brine, dried over Na_2SO_4 and concentrated *in vacuo*. The resulting oil **17A** was used without further purification.


Step 2



[00234] The above obtained ester **17A** (24.0 g, 96 mmol) was dissolved in Dioxane (95 mL) and treated with NaOH (96 mL, 478 mmol). The reaction stirred at 100 C for one hour. The reaction was then cooled to rt and acidified with 2 N HCl to pH=3. The reaction mixture


was then poured into a separation funnel containing EtOAc and water. The mixture was extracted 3x with EtOAc. The combined fractions were washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The resulting oil was used without further purification.

Step 3




[00235] Acid **17B** (21.3 g, 95 mmol) was treated with Eaton's reagent (100 mL, 630 mmol) and warmed to 70 °C. The reaction stirred for one hour. As the reaction stirred it turned deep red/brown. LCMS shows that the SM has been consumed. The reaction is cooled to rt and then quenched by the portionwise addition of wet ice. The mixture was then treated with solid NaOH pellets until the pH was 10. The reaction mixture was then poured into a separation funnel containing EtOAc and water. The mixture was extracted 3x with EtOAc. The combined fractions were washed with brine, dried over Na₂SO₄ and concentrated *in vacuo*. The residue was purified by column chromatography (Biotage, 340 g, 0-50% EtOAc/heptane) which afforded **17C** (10 g).


Step 4




[00236] Boc₂O (9.50 g, 41.7 mmol) was added to the solution of 7-fluoro-2,3,3a,4-tetrahydro-1H-cyclopenta[b]quinolin-9(9aH)-one **17C** (13.9 mmol), Et₃N (5.80 mL, 41.7 mmol) and DMAP (1.70 g, 13.9 mmol) in 1,4-dioxane (100 mL), the resultant mixture was kept stirring at rt overnight. The mixture was diluted with EtOAc (100 mL), washed with H₂O (100 mL), and brine (100 mL), the organic was dried over MgSO₄ and concentrated. The residue was purified via silica gel column chromatography (EtOAc/Hexane = 1:10), to obtain the racemic, Boc protected ketone amine **17D'** as a light yellow syrup, 4.0 g. The racemic ketone **17D'** was resolved with chiral HPLC to give enantiomerically pure **17D** using an OJ-H, 4.6 x 250mm column eluting with an isocratic system of 15% w/ IPA in supercritical CO₂ at a flow rate of 3 mL/min. The configuration of **17D** was determined to have the 3a*S*, 9a*R* configuration by inference from the configuration of the subsequently prepared product **17** below.

Step 5

[00237] The ketone **17D** was converted to the desired enantiopure amide **17E** following steps similar to those described in Example 1 and Example 7.

Step 6

[00238] TFA (1 mL) was added to the solution of Boc amide **17E** (0.723 mmol) in CH_2Cl_2 (2 mL), the resultant mixture was kept stirring at rt for 2 hrs. The solution was concentrated to dryness, the residue was taken up in CH_2Cl_2 (10 mL), washed with NaHCO_3 (1 N, 5 mL), the organic layer was dried over MgSO_4 and concentrated. The residue was purified via silica gel column chromatography ($\text{EtOAc/Hexane} = 1:3$), obtained enantiopure free amine **17F** as a light yellow solid 200 mg; $[\text{M}+\text{H}]^+ = 357$.

Step 7

[00239] The amine **17F** was converted the final enantiopure amide product **17** by following steps similar to those described in Example 14, steps 2 and 3. ^1H NMR (500 MHz, CDCl_3) δ ppm: 7.29 (d, 2H); 7.08 (d, 2H); 6.60 (m, 2H); 6.38 (m, 1H); 5.168 (m, 1H); 3.09 (m, 3H); 2.82 (m, 3H); 2.42 (m, 1H); 2.03 (m, 1H); 1.57 (m, 2H); 1.40 (m, 2H); 1.22~1.00 (m, 5H). $[\text{M}+\text{H}]^+ = 534.8$.

[00240] The structure of product **17**, C₂₇H₂₆F₄N₂O₅, C₇H₈, was determined by single-crystal X-ray crystallography on a crystal isolated from material crystallized from toluene (10 mg anhydrous compound dissolved in 200 μ L toluene and evaporated overnight). The crystal selected was representative of the bulk sample. Crystal data at 100 K:

$$\begin{array}{lll} a = 11.1083(13) \text{ \AA} & \alpha = 90.00^\circ & V = 1528.4(3) \text{ \AA}^3 \\ b = 8.7372(10) & \beta = 100.730(6) & \text{Space group} = P2_1, \#4 \\ c = 16.028(2) & \gamma = 90.00 & Z = 2 \end{array}$$






[00241] Data were collected on a Bruker CCD diffractometer using copper K α radiation and integrated to a resolution of 0.84 $\text{\AA}^{-1}$ which yielded 4840 unique reflections from 34030 measured reflections.

[00242] The structure was solved using direct methods. The refined model has all non-H atoms refined anisotropically, and H atoms at their calculated positions, with agreement statistics of: $R_1 = 3.4\%$, for 407 variables and 4629 reflections and $wR_2 = 9.4\%$ using all 4840 reflections. The compound crystallized as a monotoluene solvate. There were no unusual bond distances or angles. The absolute stereochemistry was determined unambiguously using resonant scattering effects as *R,S,R* at C1, C8 and C12, respectively. A perspective view of **17** calculated from the crystallographic coordinates is presented in FIG. 1.






[00243] The compounds in the following table were prepared by a similar synthetic process as illustrated in Examples 1, 14 and 17. The enantiomerically pure final products are either obtained through chiral resolution of final racemic compounds (**17BN**, **17BX**, **17BY**, **17BZ**, **17CA**, **17CJ**) or prepared from enantiomerically pure tetraquinoline amides (prepared from a Boc-protected, CBz-protected, or unprotected chiral tetrahydroquinolin-9(9aH)-one) (**17AE**, **17AF**, **17AG**, **17BM**, **17BO**, **17BP**, **17BQ**, **17BR**, **17BS**, **17BT**, **17BU**, **17BV**, **17BW**, **17CC**, **17CD**, **17CE**, **17CF**, **17CG**, **17CH**, **17CI**, **17CK**, and **17CL-17DL**). Chiral HPLC separation of racemic tetrahydroquinolin-9(9aH)-ones such as **17D'** (Boc-protected), **1D** (CBz-protected), and **17C** (unprotected) affords enantiomerically pure chiral tetrahydroquinolin-9(9aH)-ones.






#	structure	stereo designation	chemical name	[M+H] ⁺
17G		racemic, cis, cis	4-[[cis,cis-4-benzoyl-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl](cyclopropylmethyl)amino]-4-oxobutanoic acid	447.2
17H		racemic, E, cis, cis	(2E)-4-[[cis,cis-4-benzoyl-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl](cyclopropylmethyl)amino]-4-oxo-2-butenoic acid	445.2
17i		racemic, cis, cis	4-[[cis,cis-4-benzoyl-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl](1-methylcyclopropyl)amino]-4-oxobutanoic acid	447.2
17J		racemic, cis, cis	methyl 4-[[((cyclopropylmethyl)[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoate	545.3
17K		racemic, cis, cis	4-(phenylmethyl) cis,cis-9-[(3-carboxy-1-oxopropyl)(cyclopropylmethyl)amino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	477.3
17L		racemic, cis, cis	4-[[((cyclopropylmethyl)[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	531.3






17M		racemic, cis, cis	4-[[cis,cis-4-benzoyl- 2,3,3a,4,9,9a-hexahydro-1H- cyclopenta[b]quinolin-9- yl](1-methylethyl)amino]-4- oxobutanoic acid	435.2
17N		racemic, cis, cis	5-[[cis,cis-4-benzoyl- 2,3,3a,4,9,9a-hexahydro-1H- cyclopenta[b]quinolin-9- yl]methylamino]-5- oxopentanoic acid	421.2
17o		racemic, cis, cis	5-[[cis,cis-2,3,3a,4,9,9a- hexahydro-4-[4- (trifluoromethoxy)benzoyl]- 1H-cyclopenta[b]quinolin-9- yl]methylamino]-5- oxopentanoic acid	505.3
17P		racemic, cis, cis	(2E)-4-[[cis,cis-4-benzoyl- 2,3,3a,4,9,9a-hexahydro-1H- cyclopenta[b]quinolin-9- yl]methylamino]-4-oxo-2- butenoic acid	405.2
17Q		racemic, cis, cis	(2E)-4-[[cis,cis- 2,3,3a,4,9,9a-hexahydro-4- [4- (trifluoromethoxy)benzoyl]- 1H-cyclopenta[b]quinolin-9- yl]methylamino]-4-oxo-2- butenoic acid	489.3
17R		racemic, cis, cis	methyl 4-[[cis,cis- 2,3,3a,4,9,9a-hexahydro-4- [4- (trifluoromethoxy)benzoyl]- 1H-cyclopenta[b]quinolin-9- yl]methylamino]-4- oxobutanoate	505.3

17S		racemic, cis, cis	4-[[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]methylamino]-4-oxobutanoic acid	491.3
17T		racemic, cis, cis	4-[[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl](1-methylethyl)amino]-4-oxobutanoic acid	519.3
17U		racemic, cis, cis	4-(phenylmethyl) cis,cis-9-[(3-carboxy-1-oxopropyl)methylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	437.2
17V		racemic, cis, cis	4-[[cis,cis-2,3,3a,4,9,9a-hexahydro-4-(3-pyridinylcarbonyl)-1H-cyclopenta[b]quinolin-9-yl]methylamino]-4-oxobutanoic acid	408.2
17W		racemic, cis, cis	4-[[cis,cis-4-([1,1'-biphenyl]-4-ylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]methylamino]-4-oxobutanoic acid	483.3


17X		racemic, cis, cis	4-[[cis,cis-4-(4-chlorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]methylamino]-4-oxobutanoic acid	441.2
17Y		racemic, cis, cis	4-[[cis,cis-4-(4-ethylbenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]methylamino]-4-oxobutanoic acid	435.2
17Z		racemic, cis, cis	4-[[cis,cis-4-(3,4-dichlorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]methylamino]-4-oxobutanoic acid	475.3
17AA		racemic, cis, cis	4-[[cis,cis-4-(3-chlorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]methylamino]-4-oxobutanoic acid	441.2
17AB		racemic, cis, cis	4-[[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl](3,3,3-trifluoropropyl)amino]-4-oxobutanoic acid	573.3
17AC		racemic, cis, cis	4-[[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl](1-methylcyclopropyl)amino]-4-oxobutanoic acid	531.3

17AD		racemic, cis, cis	4- [(cyclobutylmethyl)[cis,cis- 2,3,3a,4,9,9a-hexahydro-4- [4- (trifluoromethoxy)benzoyl]- 1H-cyclopenta[b]quinolin-9- yl]amino]-4-oxobutanoic acid	545.3
17AE		cis, cis single enantiomer	4-[ethyl[cis, cis-4-(4- ethylbenzoyl)-2,3,3a,4,9,9a- hexahydro-1H- cyclopenta[b]quinolin-9- yl]amino]-4-oxobutanoic acid	449.2
17AF		(cis, cis); Cyclopropyl ring trans (racemic).	4-[ethyl[cis, cis- 2,3,3a,4,9,9a-hexahydro-4- [(2-phenyl-1- cyclopropyl)carbonyl]-1H- cyclopenta[b]quinolin-9- yl]amino]-4-oxobutanoic acid	461.3
17AG		cis, cis single enantiomer	4-[ethyl[cis, cis- 2,3,3a,4,9,9a-hexahydro-4- (3,4,5-trifluorobenzoyl)-1H- cyclopenta[b]quinolin-9- yl]amino]-4-oxobutanoic acid	475.3
17AH		racemic, cis,cis	4-[[cis,cis-4-(3- bromobenzoyl)- 2,3,3a,4,9,9a-hexahydro-1H- cyclopenta[b]quinolin-9- yl]cyclopropylamino]-4- oxobutanoic acid	511.3

17Ai		racemic, cis,cis	4-[cyclopropyl[<i>cis,cis</i> -2,3,3a,4,9,9a-hexahydro-4-[3-(trifluoromethoxy)benzoyl]-1H-cyclopenta[<i>b</i>]quinolin-9-yl]amino]-4-oxobutanoic acid	517.3
17AJ		racemic, cis,cis	4-[[<i>cis,cis</i> -4-(2-bromobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[<i>b</i>]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	511.3
17AK		racemic, cis,cis	4-[cyclopropyl[<i>cis,cis</i> -2,3,3a,4,9,9a-hexahydro-4-(3-phenoxybenzoyl)-1H-cyclopenta[<i>b</i>]quinolin-9-yl]amino]-4-oxo-butanoic acid	525.3
17AL		racemic, cis,cis	4-[cyclopropyl[<i>cis,cis</i> -2,3,3a,4,9,9a-hexahydro-4-(3-methoxybenzoyl)-1H-cyclopenta[<i>b</i>]quinolin-9-yl]amino]-4-oxobutanoic acid	463.3
17AM		racemic, cis,cis	4-[cyclopropyl[<i>cis,cis</i> -2,3,3a,4,9,9a-hexahydro-4-(2-methoxybenzoyl)-1H-cyclopenta[<i>b</i>]quinolin-9-yl]amino]-4-oxobutanoic acid	463.3

17AN		racemic, cis,cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-(2-quinolinylcarbonyl)-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	484.3
17Ao		racemic, cis,cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[2-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	517.3
17AP		racemic, cis,cis	4-[cyclopropyl[cis,cis-4-[4-(difluoromethoxy)benzoyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	499.3
17AQ		racemic, cis,cis	4-((cis, cis-4-(cyclohexanecarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)(cyclopropyl)amino)-4-oxobutanoic acid	439.2
17AR		racemic, cis, cis	4-(cyclopropyl(cis, cis-4-(thiophene-2-carbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid	439.2


17AS

racemic, cis,
cis

4-(cyclopropyl(cis, cis-4-(2-phenylacetyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid

447.2


17AT

racemic, cis,
cis

4-(cyclopropyl(cis, cis-4-(3-methylbenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid

447.2


17AU

racemic, cis,
cis

4-(cyclopropyl(cis, cis-4-(4-methylbenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid

447.2


17AV

racemic, cis,
cis

4-(cyclopropyl(cis, cis-4-(2-fluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid


451.2

17AW

racemic, cis,
cis4-(cyclopropyl(cis, cis-4-(3-
fluorobenzoyl)-
2,3,3a,4,9,9a-hexahydro-1H-
cyclopenta[b]quinolin-9-
yl)amino)-4-oxobutanoic
acid


451.2

17AX

racemic, cis,
cis4-(cyclopropyl(cis, cis-4-(4-
fluorobenzoyl)-
2,3,3a,4,9,9a-hexahydro-1H-
cyclopenta[b]quinolin-9-
yl)amino)-4-oxobutanoic
acid


451.2

17AY

racemic, cis,
cis4-(cyclopropyl(cis, cis-4-(3,5-dimethylisoxazole-4-
carbonyl)-2,3,3a,4,9,9a-
hexahydro-1H-
cyclopenta[b]quinolin-9-
yl)amino)-4-oxobutanoic
acid


452.2

17AZ

racemic, cis,
cis4-(cyclopropyl(cis, cis-4-(2-(
thiophen-2-yl)acetyl)-
2,3,3a,4,9,9a-hexahydro-1H-
cyclopenta[b]quinolin-9-
yl)amino)-4-oxobutanoic
acid

453.2


17BA

racemic, cis,
cis

4-(cyclopropyl(cis, cis-4-(3-phenylpropanoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid

461.3


17BB

racemic, cis,
cis

4-(cyclopropyl(cis, cis-4-(2-phenoxyacetyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid

463.3


17BC

racemic, cis,
cis

4-(cyclopropyl(cis, cis-4-(2,4-difluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid

469.3


17BD

racemic, cis,
cis

4-(cyclopropyl((cis, cis-4-(3,5-difluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid

469.3

17BE




racemic, cis,
cis,
(cyclopropyl
ring is trans
substituted)

4-(cyclopropyl(cis, cis-4-
trans-2-
phenylcyclopropanecarbonyl
)-2,3,3a,4,9,9a-hexahydro-
1H-cyclopenta[b]quinolin-9-
yl)amino)-4-oxobutanoic
acid

473.3

17BF




racemic, cis,
cis

4-(cyclopropyl(cis, cis-4-(2-
(4-methoxyphenyl)acetyl)-
2,3,3a,4,9,9a-hexahydro-1H-
cyclopenta[b]quinolin-9-
yl)amino)-4-oxobutanoic
acid

477.3

17BG




racemic, cis,
cis

4-((cis, cis-4-(1-naphthoyl)-
2,3,3a,4,9,9a-hexahydro-1H-
cyclopenta[b]quinolin-9-
yl)(cyclopropyl)amino)-4-
oxobutanoic acid

483.3

17BH




racemic, cis,
cis

4-(cyclopropyl(cis, cis-4-
(2,4-dichlorobenzoyl)-
2,3,3a,4,9,9a-hexahydro-1H-
cyclopenta[b]quinolin-9-
yl)amino)-4-oxobutanoic
acid


501.3

17Bi

racemic, cis,
cis4-((cis, cis-4-(2-naphthoyl)-
2,3,3a,4,9,9a-hexahydro-1H-
cyclopenta[b]quinolin-9-
yl)(cyclopropyl)amino)-4-
oxobutanoic acid


483.3

17BJ

racemic, cis,
cis4-(cyclopropyl(cis, cis-4-(2-
(3,4-
dimethoxyphenyl)acetyl)-
2,3,3a,4,9,9a-hexahydro-1H-
cyclopenta[b]quinolin-9-
yl)amino)-4-oxobutanoic
acid


507.3

17BK





racemic, cis,
cis4-(((cis, cis)-4-
(benzo[d][1,3]dioxole-5-
carbonyl)-2,3,3a,4,9,9a-
hexahydro-1H-
cyclopenta[b]quinolin-9-
yl)(cyclopropyl)amino)-4-
oxobutanoic acid






477.3






17BL






racemic, cis,
cis4-(cyclopropyl(cis, cis-4-
(furan-2-carbonyl)-
2,3,3a,4,9,9a-hexahydro-1H-
cyclopenta[b]quinolin-9-
yl)amino)-4-oxobutanoic
acid






423.2

17BM		cis, cis at fused ring enantiopure; (racemic cyclopropyl ring is trans substituted)	4-[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[(trans-2-phenylcyclopropyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	473.3
17BN		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-(2-thienylcarbonyl)-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	439.2
17Bo		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-(1-naphthalenylcarbonyl)-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	483.3
17BP		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis-4-[4-(difluoromethoxy)benzoyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	499.3


17BQ		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-(2-quinolinylcarbonyl)-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	484.3
17BR		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis-4-(2-fluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	451.2
17BS		cis, cis at fused ring (enantiopure), trans-substitution at cyclopropyl, single diastereomer 1	4-[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[(trans-2-phenylcyclopropyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	473.3
17BT		cis, cis fused ring (enantiopure), trans-substitution at cyclopropyl,, single diastereomer 2	4-[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[(trans-2-phenylcyclopropyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	473.3
17BU		cis, cis,, single enantiomer	4-[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-(2-naphthalenylcarbonyl)-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	483.3

17BV		cis, cis, single enantiomer	4-[cyclopropyl[<i>cis, cis</i> -4-(2,4-difluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[<i>b</i>]quinolin-9-yl]amino]-4-oxobutanoic acid	469.3
17BW		cis, cis, single enantiomer	4-[cyclopropyl[<i>cis, cis</i> -4-(3-fluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[<i>b</i>]quinolin-9-yl]amino]-4-oxobutanoic acid	451.2
17BX		cis, cis, single enantiomer, peak 1	4-[[<i>cis, cis</i> -6-chloro-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[<i>b</i>]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	568.8
17BY		cis, cis, single enantiomer, peak 2	4-[[<i>cis, cis</i> -6-chloro-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[<i>b</i>]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	590.8 [M+Na] ⁺
17BZ		cis, cis, single enantiomer, peak 1	[[[<i>cis, cis</i> -6-chloro-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[<i>b</i>]quinolin-9-yl]cyclopropylamino]carbonyl]oxy]acetic acid	571

17CA		cis, cis, single enantiomer, peak 2	[[[cis,cis-6-chloro-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]carbon yl]oxy]acetic acid	571
17CB		racemic, cis, cis	4-[[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl](2-propenyl)amino]-4-oxobutanoic acid	517
17CC		cis, cis, single enantiomer	4-[cyclopropyl[cis,cis-5-fluoro-3-(4-fluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid	455
17CD		cis, cis, single enantiomer	4-[cyclopropyl[cis,cis-3-(4-ethylbenzoyl)-5-fluoro-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid	465
17CE		cis, cis, single enantiomer	4-[cyclopropyl[cis,cis-5-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid	543 [M+Na]+


17CF		cis, cis, single enantiomer	deuterated-4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9(R)-yl-(d)]amino]-4-oxobutanoic acid	518.2
17CG		racemic, cis, cis	4-[[cis-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	550.5
17CH		racemic, cis, cis	4-[[cis, cis-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclobutylamino]-4-oxobutanoic acid	564.5
17Ci		racemic, cis, cis	2-[[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]benzoic acid	564.6
17CJ		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	516.7

17CK

cis, cis, single
enantiomer4-[[[cis, cis-6-chloro-
2,3,3a,4,9,9a-hexahydro-4-
[4-
(trifluoromethoxy)benzoyl]-
1H-cyclopenta[b]quinolin-9-
yl]cyclobutylamino]-4-
oxobutanoic acid


565.3

17CL

cis, cis, single
enantiomer4-[[[cis, cis-6-chloro-
2,3,3a,4,9,9a-hexahydro-4-
[3-
(trifluoromethoxy)benzoyl]-
1H-cyclopenta[b]quinolin-9-
yl]cyclobutylamino]-4-
oxobutanoic acid


565.3

17CM

cis, cis, single
enantiomer4-[[[cis, cis-6-chloro-4-(4-
fluorobenzoyl)-
2,3,3a,4,9,9a-hexahydro-1H-
cyclopenta[b]quinolin-9-
yl]cyclobutylamino]-4-
oxobutanoic acid


499.3

17CN

cis, cis, single
enantiomer4-[[[cis, cis-6-chloro-4-(3-
fluorobenzoyl)-
2,3,3a,4,9,9a-hexahydro-1H-
cyclopenta[b]quinolin-9-
yl]cyclobutylamino]-4-
oxobutanoic acid






499.3






17Co






cis, cis, single
enantiomer4-[[[cis, cis-6-chloro-4-(3,4-
difluorobenzoyl)-
2,3,3a,4,9,9a-hexahydro-1H-
cyclopenta[b]quinolin-9-
yl]cyclobutylamino]-4-
oxobutanoic acid






517.3

17CP		cis, cis, single enantiomer	4-[[cis, cis-6-chloro-4-(3,5-difluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]cyclobutylamino]-4-oxobutanoic acid	538.5 [M+Na] ⁺
17CQ		cis, cis, single enantiomer	4-[[cis, cis-6-chloro-4-(4-ethylbenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]cyclobutylamino]-4-oxobutanoic acid	509.3
17CR		cis, cis, single enantiomer	4-[[cis, cis-6-chloro-2,3,3a,4,9,9a-hexahydro-4-(2-naphthalenylcarbonyl)-1H-cyclopenta[b]quinolin-9-yl]cyclobutylamino]-4-oxobutanoic acid	531.3
17CS		cis, cis, single enantiomer	4-[[cis, cis-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclobutylamino]-4-oxobutanoic acid	549.3
17CT		cis, cis, single enantiomer	4-[[cis, cis-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	551


17CU		cis, cis, single enantiomer	4-[[cis, cis-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[3-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	551
17CV		cis, cis, single enantiomer	4-[[cis, cis-6-chloro-4-(4-fluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	485.6
17CW		cis, cis, single enantiomer	4-[[cis, cis-6-chloro-4-(3,5-difluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	503.6
17CX		cis, cis at fused ring (enantiopure) trans substitution at cyclopropyl ring (enantiopure), single diastereomer, (less polar one)	4-[[cis, cis-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[(trans-2-phenylcyclopropyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	506.7
17CY		cis, cis at fused ring (enantiopure), trans substitution at the cyclopropyl ring (enantiopure) single diastereomer, (more polar one)	4-[[cis, cis-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[(trans-2-phenylcyclopropyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	506.6

17CZ		cis, cis, single enantiomer	4-[cyclobutyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	552.5 [M+Na] ⁺
17DA		cis, cis, single enantiomer	4-[cyclobutyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[3-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	552.5 [M+Na] ⁺
17DB		cis, cis, single enantiomer	4-[cyclobutyl[cis, cis-4-(4-fluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	486.7 [M+Na] ⁺
17DC		cis, cis, single enantiomer	4-[cyclobutyl[cis, cis-4-(3,5-difluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	504.6 [M+Na] ⁺
17DD		cis, cis at fused ring (enantiopure), trans substitution at cyclopropyl ring (enantiopure), single diastereomer, (less polar one)	4-[cyclobutyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[(trans-2-phenylcyclopropyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	508.6 [M+Na] ⁺

17DE		cis, cis at fused ring (enantiopure), trans substitution at cyclopropyl ring (enantiopure), single diastereomer, (more polar one)	4-[cyclobutyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[(trans-2-phenylcyclopropyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	486.7
17DF		3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i> single enantiomer	4-[cyclopropyl[(3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i>)-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[3-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	534.6
17DG		3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i> single enantiomer	4-[cyclopropyl[(3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i>)-7-fluoro-4-(3-fluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	468.7
17DH		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[[4-(trifluoromethoxy)phenyl]acetyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	530.7
17Di		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[1-oxo-3-[4-(trifluoromethoxy)phenyl]propyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	544.7

17DJ		Cis, cis at fused ring (enantiopure); R and S diastereomers at 1 naphthalenyl atom	4-[[cis, cis-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	520.6
17DK		cis, cis, single enantiomer	4-[[cis, cis-6-chloro-4-[(2,3-dihydro-1H-inden-2-yl)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	506.6
17DL		cis, cis (enantiopure), R and S diastereomers at 1 naphthalenyl atom	4-[[cis, cis-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	521.2
17DN		racemic, cis, cis	4-[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[(1-methyl-1H-benzimidazol-2-yl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	487.3
17Do		racemic, cis, cis	[[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]sulfonyl]acetic acid	539

Alternative Preparation of the Intermediate (3a*S*,9a*R*)-tert-butyl 7-fluoro-9-oxo-3,3a,9,9a-tetrahydro-1*H*-cyclopenta[*b*]quinoline-4(2*H*)-carboxylate (17*D*)



Step 1

[00244] Cis-methyl 2-((4-fluorophenyl)amino)cyclopentanecarboxylate (racemic cis-17*A'*): A 1-L, three-necked, round-bottomed flask was charged with 4-fluoroaniline (50 mL, 528 mmol), methyl 2-oxocyclopentane-1-carboxylate (78.0 g, 528 mmol), 600 mL of AcOH, and 60 mL of water. Zn dust (<10 micron, 103.6 g, 1584 mmol) was added portionwise over 10 minutes and then, the mixture was stirred at 70 °C for 3 h. The reaction mixture was cooled to room temperature, filtered through Celite® with the aid of MeOH, and concentrated. Dichloromethane (500 mL) was added in one portion and the pH was carefully adjusted with ammonium hydroxide to 10. The resulting organic layer was separated, washed with brine, and concentrated to give 130 g of an orange solid. Recrystallization from hexanes afforded 80 g (64%) of cis-methyl 2-((4-fluorophenyl)amino)cyclopentanecarboxylate (racemic cis-17*A'*) as off-white crystals.

Step 2

[00245] Cis-6-(4-fluorophenyl)-6-azabicyclo[3.2.0]heptan-7-one (racemic 17*DP*): A 500-mL, three-necked, round-bottomed flask was charged with cis-methyl 2-((4-fluorophenyl)amino)cyclopentanecarboxylate (racemic cis-17*A'*) (15.77 g, 66.5 mmol) and 75 mL of THF. The reaction mixture was cooled at 5 °C while a 1 M solution of LiHMDS (73.1 mL, 73.1 mmol) was added dropwise via syringe over 10 min. The resulting reaction mixture

was stirred at 5 °C to 15 °C for 1.5 h. The reaction mixture was then quenched into 200 mL of aqueous ammonium chloride and 250 mL of ethyl acetate. The organic layer was separated, washed with brine, dried over magnesium sulfate, filtered, and concentrated to give 14 g of cis-6-(4-fluorophenyl)-6-azabicyclo[3.2.0]heptan-7-one (racemic 17DP) as an orange oil.

Step 3

[00246] **7-Fluoro-2,3,3a,4-tetrahydro-1H-cyclopenta[b]quinolin-9(9aH)-one:** A 500-mL, three-necked, round-bottomed flask was charged with cis-6-(4-fluorophenyl)-6-azabicyclo[3.2.0]heptan-7-one (racemic 17DP) (26.5 g, 129 mmol) and 250 mL of dichloroethane. The reaction mixture was cooled at 5 °C while triflic acid was added via syringe over 10 min. The reaction mixture was stirred at 50 °C for 4 h. The reaction mixture was cooled to room temperature with an ice-water bath and then quenched with saturated sodium bicarbonate to adjust the pH to 10. The organic layer was separated, washed with brine, dried over MgSO₄, filtered, and concentrated to give 26.5 g of a 90:10 mixture of the title compound as a brown semi-solid.

Step 4

[00247] **Cis-tert-butyl 7-fluoro-9-oxo-3,3a,9,9a-tetrahydro-1H-cyclopenta[b]quinoline-4(2H)-carboxylate (racemic cis-17D'):** A 500-mL, three-necked, round-bottomed flask was charged with the tricyclic aniline (90:10) (26.5 g, 129 mmol), triethylamine (45.0 mL, 323 mmol), DMAP (1.57 g, 12.9 mmol), and 200 mL of dioxane. Boc₂O (59.2 g, 271 mmol) was added in one portion and the reaction mixture was stirred at room temperature for 17 h. The reaction mixture was then diluted with EtOAc and water. The organic layer was separated, washed with a 0.5 M solution of HCl, washed with saturated sodium bicarbonate, washed with brine, dried over MgSO₄, filtered, and concentrated to give a brown oil. This material was diluted with 200 mL of MeOH and charged with potassium carbonate. The reaction mixture was stirred at room temperature for 2 h. Purification by column chromatography afforded 30 g (76% 3-step yield from the starting tricyclic aniline) of cis-tert-butyl 7-fluoro-9-oxo-3,3a,9,9a-tetrahydro-1H-cyclopenta[b]quinoline-4(2H)-carboxylate (racemic cis-17D') as a thick, yellow oil.

Step 5

[00248] **(3aS,9aR)-tert-butyl 7-fluoro-9-oxo-3,3a,9,9a-tetrahydro-1H-cyclopenta[b]quinoline-4(2H)-carboxylate (17D):** Racemic cis-17D' (30 g) was separated by supercritical fluid chromatography using the conditions described below to give 13.5 g of (3aS,9aR)-tert-butyl 7-fluoro-9-oxo-3,3a,9,9a-tetrahydro-1H-cyclopenta[b]quinoline-4(2H)-

carboxylate (**17D**) (45% yield, >99% ee). **17D** was the first eluting enantiomer under these conditions.

SFC separation conditions:

Flow rate: 260 g/min

Modifier percentage: 5%

Back Pressure: 150 bar

Column: AD-H, 50 x 250 mm


Inj: 0.7 mL

Modifier: IPA

UV: 227 nm




Concentration: 50 mg/mL in MeOH

Example 18: Preparation of Racemic 4-[Cyclopropyl[*cis,cis*-2,3,3a,4,9,9a-hexahydro-4-[4-(2-pyrimidinyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid







[00249] Bromide (**18A**, 60 mg, 0.11 mmol.) which was prepared from **14A** following a similar procedure as described in Example 14, step 2 with 4-bromobenzoylchloride, 2-(tributylstannyl)pyrimidine (126 mg, 0.34 mmol) and tetrakis(triphenylphosphine)palladium(0) (26 mg, 0.023 mmol) were mixed in DMF (1 mL). The reaction mixture was degassed and heated in a sealed vial at 80 °C overnight. The reaction mixture was cooled to room temperature, filtered through Celite®. The filtrate was diluted with ethyl acetate and washed with water. The organic extracts were combined, washed with brine, dried (MgSO₄), filtered and concentrated. The residue was purified by preparative TLC (eluted with 50% ethyl acetate-hexane) to afford the desired compound (20 mg, 0.038 mmol). Ester **18B** was hydrolyzed to give compound **18** following the same procedure as described in Example 14, step 3. $[M+H]^+ = 511.3$.

[00250] The compounds in the following table were prepared in a similar fashion to the process illustrated in Example 18, starting from the appropriate bromides using coupling reactions.


#	Structure	Stereo Designation	Name	[M+H] ⁺
18C		racemic, cis, cis	4-[[cis,cis-4-([1,1'-biphenyl]-4-ylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	509.3
18D		racemic, cis, cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(1H-pyrazol-1-yl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	499.3
18E		racemic, cis, cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[3-(2-pyrimidinyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	511.3

18F		racemic, cis, cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[3-(5-pyrimidinyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	511.3
18G		racemic, cis, cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[3-(5-thiazolyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	516.3
18H		racemic, cis, cis	4-[cyclopropyl[cis,cis-4-[3-(2-ethoxy-5-pyrimidinyl)benzoyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	555.3
18i		racemic, cis, cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[3-(4-pyridazinyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	511.3
18J		racemic, cis, cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[3-(2-methoxy-4-thiazolyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	546.3

18K		racemic, cis, cis	4-[cyclopropyl[<i>cis,cis</i> -2,3,3a,4,9,9a-hexahydro-4-[3-(2-methoxy-5-thiazolyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	546.3
18L		<i>cis, cis</i> , single enantiomer	4-[[<i>cis, cis</i> -4-([1,1'-biphenyl]-4-ylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	509.3
18M		<i>cis, cis</i> , single enantiomer	4-[cyclopropyl[<i>cis, cis</i> -2,3,3a,4,9,9a-hexahydro-4-(3-phenoxybenzoyl)-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	525.3
18N		racemic, <i>cis, cis</i>	4-[cyclopropyl[<i>cis,cis</i> -2,3,3a,4,9,9a-hexahydro-4-[4-(5-pyrimidinyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	511.3
18o		racemic, <i>cis, cis</i>	4-[cyclopropyl[<i>cis,cis</i> -2,3,3a,4,9,9a-hexahydro-4-[4-(5-thiazolyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	516.3

18P		racemic, cis, cis	4-[cyclopropyl[<i>cis,cis</i> -4-[4-(5-ethoxy-2-pyrimidinyl)benzoyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	555.3
18Q		racemic, <i>cis</i> , <i>cis</i>	4-[cyclopropyl[<i>cis,cis</i> -2,3,3a,4,9,9a-hexahydro-4-[4-(4-pyridazinyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	511.3
18R		racemic, <i>cis</i> , <i>cis</i>	4-[cyclopropyl[<i>cis,cis</i> -2,3,3a,4,9,9a-hexahydro-4-[4-(2-methoxy-5-thiazolyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	546.3
18S		<i>Cis, cis</i> , single enantiomer	4-[cyclopropyl[<i>cis, cis</i> -2,3,3a,4,9,9a-hexahydro-4-[3-(5-thiazolyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	516.3

18T




cis, cis,, single enantiomer

4-[cyclopropyl][cis, cis-2,3,3a,4,9,9a-hexahydro-4-[3-(4-pyridazinyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid

511.3


Example 19: Preparation of Racemic 4-(Phenylmethyl) cis,cis-9-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-2,2-dimethyl-4H-cyclopenta[b]quinoline-4-carboxylate (19)

Step 1



[00251] 4,4-Dimethylcyclohexanone (9.0 g, 71.31 mmol) and potassium permanganate (22.53 g, 142.63 mmol) were taken up in 450 mL of water. To this, an aqueous solution of NaOH (1.02 g, 25.67 mmol) in 9 mL water was added at room temperature. The mixture was stirred for 48 hours. Aqueous sodium bisulfite was then added until the purple color disappeared. A brown solid was filtered off, and the clear filtrate was brought to pH 1 with concentrated HCl. The solution was extracted with ether (100 mL) three times. The combined ether layers were then dried over anhydrous sodium sulfate. The filtrate was concentrated *in vacuo* to afford the product diacid **19A** (9.01 g) in 73% yield.


Step 2



[00252] The diacid **19A** (4.0 g, 22.96 mmol) was dissolved in 10 mL methanol, and to this solution, concentrated sulfuric acid (0.7 mL) was added dropwise. The solution was heated to 85 °C for 2 hours. The methanol was removed by concentration. Water was added and the pH of the


mixture was adjusted to pH 7 by slow addition of saturated sodium bicarbonate. The solution was extracted with ether three times. The combined ether layers were then dried over anhydrous sodium sulfate. The filtrate was concentrated *in vacuo* to afford the product diester **19B** (3.86 g) in 83% yield.

Step 3




[00253] Potassium *tert*-butoxide (5.3 g, 47.31 mmol) was taken up in 45 mL THF and cooled to 0 °C. To this, the diester **19B** (6.38 g, 31.54 mmol) was added, and the solution was stirred at room temperature for 24 hours. Glacial acetic acid (2.5 mL) was added resulting in an orange solution containing a white precipitate. A solution of Na₂HPO₄ (7.2 g) in 50 mL water was added causing the suspension to become homogeneous. The solution was extracted with dichloromethane (25 mL) three times. The combined organic layers were then washed with brine and dried over anhydrous sodium sulfate. The filtrate was concentrated *in vacuo* and the residue was purified by flash chromatography on silica gel eluting with 0 to 20% ethyl acetate in hexane to afford the product ketoester **19C** (5.36 g) in 100% yield.

Step 4




[00254] In a 1 L flask, was added glacial acetic acid (20 mL), water (2.5 mL), aniline (2.15 mL, 23.62 mmol), keto-ester **19C** (4.0 g, 23.62 mmol), and zinc (6.17 g, 94.48 mmol) and heated to 80 °C for 1 hour and 15 minutes. Zinc salts were filtered off, and the solution was diluted with methanol. The filtrate was concentrated followed by dilution with dichloromethane and ice water. The pH was adjusted to pH 10 with ammonium hydroxide, and the mixture was extracted with dichloromethane three times. The combined organic layers were then washed with brine and dried over anhydrous sodium sulfate. The filtrate was concentrated *in vacuo* to afford the product aniline ester **19D** (7.72 g) in >100% yield (crude).

Step 5




[00255] Aniline ester **19D** (5.84 g, 23.61 mmol) was dissolved in dioxane (25 mL) and 5M NaOH (23.61 mL, 118.05 mmol) added and heated to 100 °C for 1 hour. The reaction mixture was cooled to room temperature and brought to pH 3 with 2 N concentrated HCl. The solution was extracted with dichloromethane three times. The combined organic layers were then washed with brine and dried over anhydrous sodium sulfate. The filtrate was concentrated *in vacuo* to afford the product aniline acid **19E** (6.3 g) in >100% yield (crude).

Step 6




[00256] Aniline acid **19E** (5.5 g, 23.57 mmol) was taken up in Eaton's Reagent (24.69 mL, 155.58 mmol) and heated to 70 °C for 3 hours. The mixture was cooled to 0 °C and quenched portion-wise with ice water. NaOH pellets were added until pH 10 was reached. The mixture extracted with ethyl acetate three times. The combined organic layers were then washed with brine and dried over anhydrous sodium sulfate. The filtrate was concentrated *in vacuo* and the residue purified by flash chromatography on silica gel eluting with 0 to 50% ethyl acetate in hexane to afford the product cis-ketone amine **19F** (0.550 g) in 11% yield.

Step 7




[00257] Compound **19** (racemic, cis, cis) was obtained from the cis-ketone amine **19F** following steps similar to those described in Examples 6, step 3 and 4, and Example 7, steps 1 and 2. $[M+H]^+ = 491.3$.

Example 20: Preparation of 4-[Cyclopropyl[*cis,cis*-2,3,3a,4,9,9a-hexahydro-2,2-dimethyl-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[*b*]quinolin-9-yl]amino]-4-oxobutanoic acid (**20**)



[00258] Compound **20** was prepared from the ketone amine **19F** following similar procedures as those described in Examples 14, step 2 (to introduce 4-trifluoromethoxy benzoylamide), and Example 6, step 4, and then Example 7, steps 1 and 2. $[M+H]^+ = 545.3$.




Example 21: Preparation of Racemic 4-(Cyclopropyl[*cis, cis*-4-[(1-methylethoxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[*b*]quinolin-9-yl]amino)-4-oxobutanoic acid (**21**)




[00259] A solution of methyl 4-[[*cis, cis*-4-(chlorocarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[*b*]quinolin-9-yl](cyclopropyl)amino]-4-oxobutanoate (prepared as in Example 22, mixture A) (36 mg, 0.089 mmol) in tetrahydrofuran (356 μ l) was added to isopropanol (13.6 μ l, 0.178 mmol) in a Bohdan tube. Sodium bis(trimethylsilyl)amide (133 μ l, 0.133 mmol) was added to the reaction mixture. The tube was capped and left to shake at rt overnight. In the morning, the reaction mixture was transferred to a microwave vial and lithium hydroxide (1.0 M in water, 540 μ l, 0.54 mmol) was added. The vial was capped, and the reaction mixture was heated thermally at 65 $^{\circ}$ C for 1 h. The reaction mixture was allowed to cool to rt, dried *in vacuo*,

and diluted with DMSO (1 mL). Analytically pure material was obtained by purification by preparative HPLC reverse phase (C-18), eluting with acetonitrile/water + 0.05% formic acid. Lyophilizing afforded **21** as the formate salt. $[M+H]^+$: 415.1.

[00260] The following compounds were prepared from racemic methyl 4-[[cis, cis-4-(chlorocarbonyl)-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl](cyclopropyl)amino]-4-oxobutanoate with a procedure similar to that used for example 21, varying the alcohol used in the first step:

#	Structure	Stereo designation	Name	$[M+H]^+$
21A		racemic, cis, cis	4-{[cis, cis-4-{[(4-chlorobenzyl)oxy]carbonyl}-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[<i>b</i>]quinolin-9-yl](cyclopropyl)amino}-4-oxobutanoic acid	497.2
21B		racemic, cis, cis	4-(cyclopropyl{ cis, cis-4-[(4-fluorophenoxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[<i>b</i>]quinolin-9-yl}amino)-4-oxobutanoic acid	467.1
21C		racemic, cis, cis	4-(cyclopropyl{ cis, cis-4-[(naphthalen-2-ylmethoxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[<i>b</i>]quinolin-9-yl}amino)-4-oxobutanoic acid	513.2

21D




racemic, cis, cis

4-{cyclopropyl[*cis*, *cis*-4-
 {[(2-
 fluorobenzyl)oxy]carbonyl}
 -2,3,3a,4,9,9a-hexahydro-
 1H-cyclopenta[b]quinolin-
 9-yl]amino}-4-oxobutanoic
 acid

481.1

21E




racemic, cis, cis

4-{cyclopropyl[*cis*, *cis*-4-
 {[(4-
 methoxybenzyl)oxy]carbon
 yl}-2,3,3a,4,9,9a-
 hexahydro-1H-
 cyclopenta[b]quinolin-9-
 yl]amino}-4-oxobutanoic
 acid

493.2

21F




racemic, cis, cis

4-(cyclopropyl{ *cis*, *cis*-4-
 [(1-
 phenylethoxy)carbonyl]-
 2,3,3a,4,9,9a-hexahydro-
 1H-cyclopenta[b]quinolin-
 9-yl} amino)-4-oxobutanoic
 acid

477.1

21G




racemic, cis, cis

4-(cyclopropyl{cis, cis-4-[(pyridin-2-ylmethoxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}amino)-4-oxobutanoic acid

464.1

21H




racemic, cis, cis

4-(cyclopropyl{cis, cis-4-[(2,2-dimethylpropoxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}amino)-4-oxobutanoic acid

443.2

21i




racemic, cis, cis

4-(cyclopropyl{cis, cis-4-[(cyclopropylmethoxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}amino)-4-oxobutanoic acid

427.1

21J




racemic, cis, cis

4-(cyclopropyl{cis, cis-4-
[(pyridin-4-
ylmethoxy)carbonyl]-
2,3,3a,4,9,9a-hexahydro-
1H-cyclopenta[b]quinolin-
9-yl}amino)-4-oxobutanoic
acid

464.2

21K




racemic, cis, cis

4-{cyclopropyl[*cis, cis*-4-
(phenoxycarbonyl)-
2,3,3a,4,9,9a-hexahydro-
1H-cyclopenta[b]quinolin-
9-yl]amino}-4-oxobutanoic
acid

449.1

21L




racemic, cis, cis

4-{cyclopropyl[*cis, cis*-4-
{[(3,4-
dichlorobenzyl)oxy]carbon
yl}-2,3,3a,4,9,9a-
hexahydro-1H-
cyclopenta[b]quinolin-9-
yl]amino}-4-oxobutanoic
acid

531.1

Example 22: Preparation of Enantiopure 4-[(4-Fluorophenyl)methyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (22)






[00261] The solution of starting enantiopure ester **14A'** (50 mg, 0.146 mmol, prepared from enantiomer of **1D** after chiral HPLC separation following similar sequences in Example 1, step 5; Example 7, step 1 and Example 14, step 1.) and DIPEA (80 μ L, 0.438 mmol) in CH_2Cl_2 (1 mL) was cooled in an ice- H_2O bath, phosgene (20% solution in toluene) (170 μ L, 0.292 mmol) was added, the resultant mixture was kept stirring at 0 $^\circ\text{C}$ for 2 hrs, then rt for 15 mins. The mixture was concentrated to dryness; the residue was taken up in THF (1 mL) and cooled in an ice- H_2O bath as mixture **A**.







[00262] To the solution of the benzyl alcohol (0.876 mmol) in THF (1 mL) was added NaH (72 mg, 1.75 mmol). The resultant mixture was kept stirring at rt for 30 min, and then cooled in an ice- H_2O bath as mixture **B**.





[00263] The mixture **A** was added to the mixture **B** in an ice- H_2O bath via a syringe, the resultant mixture was kept stirring at 0 $^\circ\text{C}$ for 1 hrs, then rt for 16 h. The mass spectrum indicated the disappearance of the starting material ester and intermediate.





[00264] MeOH (2 mL) and H_2O (2 mL) were added, the mixture was kept stirring at rt for 1 h. The mass spectrum indicated completion of the hydrolysis of the ester. Et_2O (3 mL) and H_2O (1 mL) were added, the aqueous layer was separated, acidified with 1 N HCl to pH ~2, extracted with Et_2O (2 x 3 mL), the combined organic layer was dried over MgSO_4 and concentrated. The residue was purified by reverse phase HPLC, to obtain a white solid, 40 mg as the desired enantiopure product **22**. $[\text{M}+\text{H}]^+ = 480.8$. ^1H NMR (500 MHz, CDCl_3) δ ppm: 7.37 (m, 3H); 7.19 (t, 1H); 7.06 (m, 3H); 6.75 (m, 1H); 5.24 (d, $J = 11\text{Hz}$, 1H); 5.13 (d, $J = 11\text{Hz}$, 1H); 4.86 (m, 1H); 3.09 ~2.75 (m, 6H); 2.15 (m, 1H); 1.91 (m, 1H); 1.53 (m, 2H); 1.40 (m, 1H); 1.20 ~ 0.9 (m, 6H).






[00265] The compounds in the following table were prepared in a similar manner as described in Example 22 from the appropriate starting material tetraquinoline amide esters. The enantiomerically pure final products were either obtained through chiral resolution of final racemic product (**22J**, **22K**) or were prepared from enantiomerically pure tetraquinoline amides (prepared from chiral tetrahydroquinolin-9(9aH)-one) (**22A**, **22D-22I**, **22L-22Y**). Some final acids were obtained from hydrolysis of esters with NaOH (1 N).

#	Structure	stereo designation	Name	[M+H] ⁺
22A		cis, cis,, single enantiomer	4-[(3,5-difluorophenyl)methyl] cis, cis-[(3-carboxy-1-oxopropyl)ethylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	487.3
22D		cis, cis, single enantiomer	4-[(2,4-difluorophenyl)methyl] cis, cis-[[[(carboxymethoxy)carbonyl]cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	523 [M+Na] ⁺
22E		cis, cis, single enantiomer	4-(2-thienylmethyl) cis, cis-[[[(carboxymethoxy)carbonyl]cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	493 [M+Na] ⁺


22F		cis, cis, single enantiomer	4-[(2,4-difluorophenyl)methyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	551.3
22G		cis, cis, single enantiomer	4-[[3-(trifluoromethoxy)phenyl]methyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	599.3
22H		cis, cis, single enantiomer	4-(2-pyridinylmethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	516.3
22i		cis, cis (enantiopure), (S configuration at benzylic carbon atom)	4-[1(S)-(4-fluorophenyl)ethyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	547.3
22J		Single enantiomer, derived from Peak I off SFC separation	4-[[4-(trifluoromethoxy)phenyl]methyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	546.7
22K		Single enantiomer, derived from Peak II off SFC separation	4-[[4-(trifluoromethoxy)phenyl]methyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	546.7

22L		cis, cis, single enantiomer	4-(2,3-dihydro-1H-inden-2-yl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	510.8 [M+Na] ⁺
22M		cis, cis, single enantiomer	4-[(3,4-difluorophenyl)methyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	498.7
22N		cis, cis, single enantiomer	4-[(3,5-difluorophenyl)methyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	498.7
22o		cis, cis, single enantiomer	4-[[4-(trifluoromethyl)phenyl]methyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	530.7

22P		cis, cis, single enantiomer	4-[(4-cyanophenyl)methyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	487.7
22Q		cis, cis (enantiopure), (R-configuration at fluorobenzylic carbon) single enantiomer	4-[1(R)-(4-fluorophenyl)ethyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	516.7 [M+Na] ⁺
22R		cis, cis (enantiopure), (S-configuration at fluorobenzylic carbon) single enantiomer	4-[1(S)-(4-fluorophenyl)ethyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	516.7 [M+Na] ⁺
22S		3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i> , (racemic at 2-tetralene carbon atom)	4-(1,2,3,4-tetrahydro-2(R <i>S</i>)-naphthalenyl) (3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i>)-[(3-carboxy-1-oxopropyl)cyclopropylamino]-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	520.8


22T		cis, cis, single enantiomer	4-[(4-fluorophenyl)methyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	514.8
22U		cis, cis, single enantiomer	4-[1(S)-(4-fluorophenyl)ethyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	551.7 [M+Na] ⁺
22V		cis, cis (enantiopure), S (S configuration at 1-indane carbon atom) single enantiomer	4-(2,3-dihydro-1H-inden-1(S)-yl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	545.3 [M+Na] ⁺
22W		cis, cis (enantiopure), (R configuration at 1-indane carbon atom) single enantiomer	4-(2,3-dihydro-1H-inden-1(R)-yl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	545.2 [M+Na] ⁺
22X		cis, cis, single enantiomer	4-(2,3-dihydro-1H-inden-2-yl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	545.8 [M+Na] ⁺

22Y

cis, cis, single
enantiomer4-[(2,4-difluorophenyl)methyl]
cis, cis-[(3-carboxy-1-
oxopropyl)cyclopropylamino]-
6-chloro-1,2,3,3a,9,9a-
hexahydro-4H-
cyclopenta[b]quinoline-4-
carboxylate555.8
[M+Na]⁺


Example 23: Preparation of Racemic 4-{Cyclopropyl[cis, cis-4-(2,3-dihydro-1H-indol-1-ylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid (23)

Step 1: Methyl 4-{cyclopropyl[cis, cis-4-(2,3-dihydro-1H-indol-1-ylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoate (23A)

**23A**

[00266] Indoline (36.8 mg, 0.309 mmol, 2.5 equiv) was added to a solution of methyl 4-[[[(cis, cis,)-4-(chlorocarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl](cyclopropyl)amino]-4-oxobutanoate (50 mg, 0.123 mmol, 1 equiv, prepared from Example 22 mixture A where the crude reaction mixture was worked up by diluting with ethyl acetate and water, and the organic phase was washed with brine and dried (MgSO₄) followed by removal of solvent) in dichloromethane at 23 °C. The reaction mixture was heated at 60 °C in a sealed tube for 16 h, and then was cooled to 23 °C. The cooled reaction mixture was partitioned between dichloromethane and aqueous potassium bisulfate. The organic layer was washed with water, and concentrated to afford **23A**, which was used in the subsequent step without further purification. [M+H]⁺: 488.2.





Step 2: 4-{Cyclopropyl[*cis*, *cis*-4-(2,3-dihydro-1*H*-indol-1-ylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl]amino}-4-oxobutanoic acid (23)




[00267] **23** was prepared from methyl 4-{cyclopropyl[*cis*, *cis*-4-(2,3-dihydro-1*H*-indol-1-ylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl]amino}-4-oxobutanoate **23A** using a procedure similar to that used in Example 14, Step 3. $[M+H]^+$: 474.2.

[00268] The following examples were prepared from racemic methyl 4-[[*cis*, *cis*-4-(chlorocarbonyl)-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl](cyclopropyl)amino]-4-oxobutanoate using a procedure similar to that used in Example 23, Steps 1 and 2.

#	Structure	Stereo designation	Name	$[M+H]^+$
23B		racemic, <i>cis</i> , <i>cis</i>	4-{cyclopropyl[<i>cis</i> , <i>cis</i> -4-(1 <i>H</i> -imidazol-1-ylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[<i>b</i>]quinolin-9-yl]amino}-4-oxobutanoic acid	423.2
23C		racemic, <i>cis</i> , <i>cis</i>	4-[[<i>cis</i> , <i>cis</i> -4-(benzylcarbamoyl)-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[<i>b</i>]quinolin-9-yl](cyclopropyl)amino}-4-oxobutanoic acid	462.2
23D		racemic, <i>cis</i> , <i>cis</i>	4-(cyclopropyl{ <i>cis</i> , <i>cis</i> -4-[methyl(phenyl)carbamoyl]-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[<i>b</i>]quinolin-9-yl}amino)-4-oxobutanoic acid	462.2


23E		racemic, cis, cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[(3-methoxyphenyl)amino]carbonyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	478.3
23F		racemic, cis, cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[(2-methoxyphenyl)amino]carbonyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	478.3
23G		racemic, cis, cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[(phenylamino)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	448.2
23H		racemic, cis, cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[(4-methoxyphenyl)amino]carbonyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	478.3

23i

racemic, cis,
cis4-[cyclopropyl[*cis,cis*-
2,3,3a,4,9,9a-hexahydro-4-[[[2-
(trifluoromethoxy)phenyl]amin
o]carbonyl]-1H-
cyclopenta[b]quinolin-9-
yl]amino]-4-oxobutanoic acid




532.3

Example 24: Preparation of Racemic 4-[Cyclopropyl[*cis,cis*-2,3,3a,4,9,9a-hexahydro-4-(phenylsulfonyl)-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid (24)




[00269] Methyl 4-(cyclopropyl(2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoate **14A** (30 mg, 0.088 mmol) and benzenesulfonyl chloride (23 mg, 0.13 mmol) were mixed in pyridine (0.3 mL). The reaction mixture was heated at 70 °C overnight and cooled to room temperature. 1 N HCl (aq.) was added. The aqueous layer was separated and extracted with DCM. The organic extracts were combined, washed with brine, dried (MgSO₄), filtered and concentrated. The residue was purified by preparative TLC (eluted with 50% ethyl acetate- hexane) to afford sulfonamide methyl 4-(cyclopropyl(4-(phenylsulfonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoate **24A** (20 mg, 0.042 mmol) which was hydrolyzed to compound **24** with a similar procedure as Example 7, step 2. $[M+H]^+ = 469.3$.

[00270] The compounds in the following table were prepared in a similar fashion to Example 24.

#	Structure	Stereo designation	Name	[M+H] ₊
24B		racemic, cis, cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[(4-phenoxyphenyl)sulfonyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	561.3
24C		racemic, cis, cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[(4-methoxyphenyl)sulfonyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	499.3
24D		racemic, cis, cis	4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[[4-(trifluoromethoxy)phenyl]sulfonyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	553.3


Example 25: Preparation of Racemic 4-[(*cis*, *cis*-3-[(Benzyloxy)carbonyl]-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)amino]-4-oxobutanoic acid (25)

Step 1: Benzyl 4-oxo-2-(2-oxoethyl)-3,4-dihydroquinoline-1(2*H*)-carboxylate (25A)



[00271] Osmium tetroxide (5% in water, 2.0 mL, 0.33 mmol, 0.025 equiv) was added to a biphasic mixture of benzyl 2-allyl-4-oxo-3,4-dihydroquinoline-1(2*H*)-carboxylate (**1A**) (4.20 g, 13.1 mmol, 1 equiv), sodium periodate (11.2 g, 52.3 mmol, 4.00 equiv) and 2,6-lutidine (3.04 mL, 26.1 mmol, 2.0 equiv) in water (33 mL) and dioxane (98 mL) at 23 °C. The reaction mixture was stirred at 23 °C for 3 h, and then it was partitioned between water and dichloromethane. The aqueous layer was further extracted with dichloromethane (1x), and the combined organic layers were dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography (15% ethyl acetate-hexanes, grading to 70% ethyl acetate-hexanes) to afford **25A**. $[M+H]^+$: 324.1

Step 2: Benzyl 2-(2-hydroxyethyl)-4-oxo-3,4-dihydroquinoline-1(2*H*)-carboxylate (25B)




[00272] Sodium borohydride (1.27 g, 33.5 mmol, 3.0 equiv) was added to a solution of **25A** (3.61 g, 11.2 mmol, 1 equiv) in methanol (112 mL) at 0 °C. After stirring at 0 °C for 25 min, the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated.

[00273] The residue was dissolved in 1,2-dichloroethane (50 mL), and manganese dioxide (4.41 g, 50.7 mmol, 5 equiv) was added. The reaction mixture was heated to 65 °C for 2.5 h, and then the heating bath was removed. The cooled reaction mixture was filtered through Celite®,


and the filtrate was concentrated to afford **25B**, which was used in subsequent steps without further purification. $[M+H]^+$: 326.2.

Step 3: Benzyl cis-8-oxo-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate (25C)




[00274] **25C** was prepared from benzyl 2-(2-hydroxyethyl)-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate (**25B**) using procedure ssimilar to those used in Example 1, Steps 3 and 4. $[M+H]^+$: 308.2.

Step 4: Benzyl cis, cis-8-[cyclopropyl(4-methoxy-4-oxobutanoyl)amino]-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate (25D)




[00275] **25D** was prepared from benzyl cis-8-oxo-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate **25C** using a procedure similar to that used for Example 1, Step 5 and Example 7, Step 1. $[M+H]^+$: 463.2.

Step 5: Racemic 4-[(cis, cis-3-[(Benzyloxy)carbonyl]-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)amino]-4-oxobutanoic acid (25)




[00276] Compound **25** was prepared from benzyl cis, cis-8-[cyclopropyl(4-methoxy-4-oxobutanoyl)amino]-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1*H*)-carboxylate **25D** using a procedure similar to that used for Example 7, Step 2. $[M+H]^+$: 449.2.

Example 26: Preparation of Racemic Methyl 4-{cyclopropyl[(cis, cis-3-{[4-(trifluoromethoxy)phenyl]carbonyl}-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino}-4-oxobutanoate (26)



[00277] Compound **26** was prepared from benzyl cis, cis-8-[cyclopropyl(4-methoxy-4-oxobutanoyl)amino]-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1*H*)-carboxylate (**25D**) using a procedure similar to that used in Example 14, Steps 1 and 2. $[M+H]^+$: 517.2.






Example 27: Preparation of Racemic 4-{Cyclopropyl[*cis*, *cis*-3-{[4-(trifluoromethoxy)phenyl]carbonyl}-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino}-4-oxobutanoic acid (27)






**27**






[00278] Compound **27** was prepared from methyl 4-{cyclopropyl[*cis*, *cis*-3-{[4-(trifluoromethoxy)phenyl]carbonyl}-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino}-4-oxobutanoate **26** using a procedure similar to that used in Example 14, Step 3. $[M+H]^+$: 503.2.

[00279] The compounds in the following table were prepared by a similar synthetic process as illustrated in Examples 25-27, and 14. The enantiomerically pure final products were prepared from enantiomerically pure tetraquinoline amides (prepared from chiral tetrahydroquinolin-9(9aH)-one).


#	Structure	Stereo designation	Name	$[M+H]^+$
27A		<i>cis</i> , <i>cis</i> , single enantiomer	3-(benzylmethoxy) <i>cis</i> , <i>cis</i> -[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-fluoro-2,2a,8,8a-tetrahydrocyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoate	467
27B		<i>cis</i> , <i>cis</i> , single enantiomer	4-[cyclopropyl[<i>cis</i> , <i>cis</i> -6-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid	521

27C		cis, cis, single enantiomer	4-[(cyclopropyl[cis, cis-3-(3,5-difluorobenzoyl)-6-fluoro-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid	473
27D		cis, cis single enantiomer	3-(phenylmethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5-chloro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate	483
27E		cis, cis single enantiomer	4-[(cyclopropyl[cis, cis-3-(3,5-difluorobenzoyl)-6-fluoro-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid	472
27F		cis, cis single enantiomer	4-[(cyclopropyl[cis, cis-6-fluoro-1,2,2a,3,8,8a-hexahydro-3-[3-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid	520
27G		cis, cis, single enantiomer	3-(phenylmethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5-chloro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate	483

27H		cis, cis single enantiomer	4-[[cis, cis-5-chloro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]cyclopropylamino]-4-oxobutanoic acid	537
27i		cis, cis single enantiomer	4-[[cis, cis-5-chloro-1,2,2a,3,8,8a-hexahydro-3-[3-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]cyclopropylamino]-4-oxobutanoic acid	537
27J		cis, cis single enantiomer	4-[[cis, cis-5-chloro-3-(3,5-difluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]cyclopropylamino]-4-oxobutanoic acid	489
27K		cis, cis, single enantiomer	4-[[cis, cis-5-chloro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]cyclopropylamino]-4-oxobutanoic acid	537
27L		cis, cis, single enantiomer	4-[[cis, cis-5-chloro-1,2,2a,3,8,8a-hexahydro-3-[3-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]cyclopropylamino]-4-oxobutanoic acid	537

27M		cis, cis, single enantiomer	4-[[cis, cis-5-chloro-3-(3,5-difluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]cyclopropylamino]-4-oxobutanoic acid	489
27N		cis, cis, single enantiomer	3-(phenylmethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-2,2a,8,8a-tetrahydrocyclobuta[b]quinolin-3(1H)-carboxylate	449
27O		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid	503
27Q		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis-3-(4-fluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid	437
27R		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis-3-(3-fluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid	437

27S




cis, cis,
single
enantiomer

4-[cyclopropyl[*cis,cis*-
1,2,2a,3,8,8a-hexahydro-3-[3-
(trifluoromethoxy)benzoyl]cycl
obuta[b]quinolin-8-yl]amino]-
4-oxobutanoic acid

503


Example 28: Racemic 4-[[*cis, cis*-10-[(Benzyloxy)carbonyl]-1,2,3,4,4a,9,9a,10-octahydroacridin-9-yl](cyclopropyl)amino]-4-oxobutanoic acid (28)

Step 1: Benzyl 2-but-3-en-1-yl-4-oxo-3,4-dihydroquinoline-1(2*H*)-carboxylate (28A)



[00280] 3-Butenylmagnesium bromide (0.5 M in THF, 100 mL, 50.0 mmol, 1.7 equiv) was added to a solution of 4-methoxyquinoline (4.65 g, 29.2 mmol, 1 equiv) in tetrahydrofuran (195 mL) at -78°C . The reaction mixture was stirred at -78°C for 1 h, then benzyl chloroformate (8.34 mL, 58.4 mmol, 2.00 equiv) was added via syringe over 5 min. Stirred for an additional 15 minutes at -78°C , then the cooling bath was removed and the reaction mixture was allowed to warm to 23°C . After 1 h, methanol was added (20 mL). After stirring for 5 min, aqueous hydrochloric acid solution (2 N, 20 mL) was added and the mixture was stirred for 10 min. The mixture was then concentrated by rotary evaporation to remove most of the tetrahydrofuran and methanol, and the residue was partitioned between ethyl acetate and water. The organic phase was washed with brine, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography (5% ethyl acetate-hexanes, grading to 20% ethyl acetate-hexanes) to afford **28A** as a colorless oil. $[\text{M}+\text{H}]^{+}$: 336.2.


Step 2: 4-[(*cis*, *cis*-10-[(Benzyloxy)carbonyl]-1,2,3,4,4a,9,9a,10-octahydroacridin-9-yl)(cyclopropyl)amino]-4-oxobutanoic acid was prepared from benzyl 2-but-3-en-1-yl-4-oxo-3,4-dihydroquinoline-1(2*H*)-carboxylate (**28A**)



[00281] **28** was prepared from benzyl 2-but-3-en-1-yl-4-oxo-3,4-dihydroquinoline-1(2*H*)-carboxylate (**28A**) using a sequence with procedures similar to those used for Example 1, Steps 2–5, and Example 7. $[M+H]^+$: 477.2.

Example 29: Racemic 2-Hydroxyethyl cyclopropyl[*cis*, *cis*-4-(phenylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl]carbamate (**29**)


Step 1: Benzyl *cis*, *cis*-9-[[2-(benzyloxy)ethoxy]carbonyl](cyclopropyl)amino]-1,2,3,3a,9,9a-hexahydro-4*H*-cyclopenta[*b*]quinoline-4-carboxylate (**29A**)



[00282] 2-(Benzyloxy)ethyl chloridocarbonate (0.080 mL, 0.44 mmol, 2.0 equiv) was added to a solution of benzyl *cis*, *cis*-9-(cyclopropylamino)-1,2,3,3a,9,9a-hexahydro-4*H*-cyclopenta[*b*]quinoline-4-carboxylate **1E** (80 mg, 0.22 mmol, 1 equiv) and *N,N*-diisopropylethylamine (0.154 mL, 0.883 mmol, 4.0 equiv) in dioxane (1.5 mL). The reaction mixture was heated at 40 °C for 16 h, and then cooled to 23 °C. The cooled reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-


column chromatography (15% ethyl acetate-hexanes, grading to 65% ethyl acetate-hexanes) to afford **29A**. $[M+H]^+$: 541.2.

Step 2: 2-(Benzyloxy)ethyl cyclopropyl[*cis, cis*-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl]carbamate (29B)




[00283] **29B** was prepared from benzyl *cis, cis*-9-[[2-(benzyloxy)ethoxy]carbonyl](cyclopropyl)amino]-1,2,3,3a,9,9a-hexahydro-4*H*-cyclopenta[*b*]quinoline-4-carboxylate using a procedure similar to that used in Example 14, Step 1. $[M+H]^+$: 407.2.

Step 3: 2-(Benzyloxy)ethyl [cis, cis-4-benzoyl-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl]cyclopropylcarbamate (29C)




[00284] **29C** was prepared from 2-(benzyloxy)ethyl cyclopropyl[*cis, cis*-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl]carbamate **29B** using a procedure similar to that used for Example 14, Step 2. $[M+H]^+$: 511.2.

Step 4: 2-Hydroxyethyl cyclopropyl[*cis*, *cis*-4-(phenylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[*b*]quinolin-9-yl]carbamate (29**)**



[00285] Palladium (10% on carbon, 12.3 mg, 0.012 mmol, 0.10 equiv) was added to a solution of 2-(benzyloxy)ethyl [*cis*, *cis*-4-benzoyl-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[*b*]quinolin-9-yl]cyclopropylcarbamate **29C** (62 mg, 0.12 mmol, 1 equiv) in tetrahydrofuran (2.4 mL). A three-way stopcock connected to a hydrogen balloon and a vacuum line was fitted to the top of the flask, and the flask was subjected to alternating vacuum purging and hydrogen filling cycles (4 x). The reaction mixture was then stirred under hydrogen for 18 h at 23 °C, and then was filtered through cotton. The filtrate was concentrated, and the residue was purified by flash-column chromatography (50% ethyl acetate-hexanes, grading to ethyl acetate) to afford **29**. $[M+H]^+$: 421.2.


Example 30: Preparation of Racemic ({Cyclopropyl[*cis*, *cis*-4-(phenylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[*b*]quinolin-9-yl]carbamoyl}oxy)acetic acid (30**)**



[00286] Jones Reagent (0.200 mL) was added to a solution of 2-hydroxyethyl cyclopropyl[*cis*, *cis*-4-(phenylcarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[*b*]quinolin-9-yl]carbamate **29** (46 mg, 0.11 mmol) in acetone (2.2 mL) at 23 °C. After stirring for 30 min, an additional portion of Jones Reagent (0.200 mL) was added, and the reaction mixture was stirred at 23 °C for a further 20 min. The reaction mixture was then partitioned between ethyl acetate

and aqueous hydrogen chloride solution (1 N). The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was then dissolved in DMSO (2 mL), and purified by reverse-phase HPLC (40% acetonitrile-water, grading to 80% acetonitrile-water, with 0.1% trifluoroacetic acid in both the acetonitrile and water) to afford **30**. $[M+H]^+$: 435.2.


Example 31: Preparation of ({Cyclopropyl[*cis*, *cis*-4-{4-(trifluoromethoxy)phenyl}carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]carbamoyl}oxy)acetic acid (**31**)

**31**

[00287] Compound **31** was prepared from 2-(benzyloxy)ethyl cyclopropyl[*cis*,*cis*-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[b]quinolin-9-yl]carbamate **29B**, using procedures similar to those used in Example 29, Steps 3–4, and Example 30. $[M+H]^+$: 519.1.


Example 32: Preparation of Enantiopure 4-(Phenylmethyl) *cis*, *cis*-[[(1*S*)-carboxyethoxy]carbonyl]cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4*H*-cyclopenta[b]quinoline-4-carboxylate (**32**)

Step 1: Enantiopure *cis*, *cis*-Benzyl 9-(chlorocarbonyl(cyclopropyl)amino)-3,3a,9,9a-tetrahydro-1*H*-cyclopenta[b]quinoline-4(2*H*)-carboxylate (**32A**)




[00288] Triphosgene (1.2 g, 4.14 mmol) was added to a solution of enantiopure *cis, cis*-benzyl 9-(cyclopropylamino)-3,3a,9,9a-tetrahydro-1H-cyclopenta[b]quinoline-4(2H)-carboxylate (1.0 g, 2.76 mmol) and DIPEA (720 μ L, 4.14 mmol) in THF (20 mL). After stirring at rt for 2 h, EtOAc (20 mL) and H₂O (20 mL) were added. The aqueous layer was extracted once more with EtOAc (15 mL). The combined organic was washed with brine (10 mL), dried over MgSO₄ and concentrated. The residue **32A** was used directly in the next step.

Step 2: Enantiopure(*cis, cis*,-Benzyl 9-(cyclopropyl(((S)-1-methoxy-1-oxopropan-2-ylloxy)carbonyl)amino)-3,3a,9,9a-tetrahydro-1H-cyclopenta[b]quinoline-4(2H)-carboxylate (32B)



[00289] A solution of enantiopure *cis, cis*-benzyl 9-(chlorocarbonyl(cyclopropyl)amino)-3,3a,9,9a-tetrahydro-1H-cyclopenta[b]quinoline-4(2H)-carboxylate **32A** (25 μ L, 0.240 mmol) in 1,4-dioxane (2 mL) was stirred at rt, and NaH (16 mg, 0.4 mmol) was added. After stirring at rt for 30 mins, (S)-methyl 2-hydroxypropanoate (85 mg, 0.2 mmol) in 1,4-dioxane (1 mL) was added, and the resultant mixture was kept stirring at rt for 2 hours. EtOAc (10 mL) was added, followed by the icy-H₂O (5 mL), and the organic was dried over MgSO₄ and concentrated. The residue was purified via silica gel column chromatography (EtOAc/Hexane = 1:3), to obtain **32B** as a yellow foam, 36 mg; [M+H]⁺ = 493.




Step 3: Enantiopure (cis, cis,)-Benzyl 9-(cyclopropyl(((S)-1-methoxy-1-oxopropan-2-yloxy)carbonyl)amino)-3,3a,9,9a-tetrahydro-1H-cyclopenta[b]quinoline-4(2H)-carboxylate (32)



[00290] **32B** was converted to the desired enantiopure acid **32** by hydrolysis with NaOH (1 N), $[M+Na]^+ = 500.7$. 1H NMR (500 MHz, $CDCl_3$) δ ppm: 7.42 (m, 6H); 7.25 (m, 1H); 7.24 (m, 1H); 7.17 (m, 1H); 7.04 (m, 1H); 5.32 (d, $J = 13$ Hz, 1H); 5.22 (d, $J = 13$ Hz, 1H); 5.11 (q, $J = 7$ Hz, 1H); 3.01 (m, 1H); 2.71 (m, 1H); 2.15 (m, 1H); 1.94 (m, 1H); 1.59 (m, 3H); 1.45 (m, 2H); 1.32 (m, 1H); 1.22~1.14 (m, 2H); 1.11~0.80 (m, 4H).






[00291] The compounds in the following table were prepared by a similar synthetic process as described above in Example 32. The enantiomerically pure final products were prepared from enantiomerically pure tetraquinoline amides (prepared from chiral tetrahydroquinolin-9(9aH)-one).





#	Structure	Stereo designation	Name	$[M+H]^+$
32C		cis, cis (enantiopure), R single enantiomer	4-(phenylmethyl) cis, cis- [[[(1R)- carboxyethoxy]carbonyl]cyclop ropropylamino]-1,2,3,3a,9,9a- hexahydro-4H- cyclopenta[b]quinoline-4- carboxylate	500.6 $[M+Na]^+$
32D		cis, cis single enantiomer	4-(phenylmethyl) cis, cis- [[[(carboxymethoxy)carbonyl]cy clopropylamino]-1,2,3,3a,9,9a- hexahydro-4H- cyclopenta[b]quinoline-4- carboxylate	464.7

32E		cis, cis, single enantiomer	4-(phenylmethyl) cis, cis-[[[(carboxymethoxy)carbonyl]cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	464.7
32F		3aS,9R,9aR single enantiomer	4-(phenylmethyl) (3aS,9R,9aR)-[[[(carboxymethoxy)carbonyl]cyclopropylamino]-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	505.0 [M+Na] ⁺
32G		cis, cis, single enantiomer	3-(phenylmethyl) cis, cis-[[[(carboxymethoxy)carbonyl]cyclopropylamino]-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate	472.6 [M+Na] ⁺


[00292] The compounds in the following table were prepared by similar synthetic processes as those described in Examples 32 and 14. The enantiomerically pure final products were prepared from enantiomerically pure tetraquinoline amides (prepared from chiral tetrahydroquinolin-9(9aH)-one).

#	Structure	Stereo designation	Name	[M+H] ⁺
32H		cis, cis, single enantiomer	[[[cyclopropyl][cis,cis-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]carbonyl]oxy]acetic acid	505.1
32i		cis, cis, single enantiomer r	[[[cyclopropyl][cis, cis-3-(4-fluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino]carbonyl]oxy]acetic acid	439.2
32J		cis, cis single enantiomer	[[[cyclopropyl][cis, cis-3-(3-fluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino]carbonyl]oxy]acetic acid	439.2
32K		cis, cis, single enantiomer	[[[cyclopropyl][cis, cis-3-(3,4-difluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino]carbonyl]oxy]acetic acid	457.3
32L		racemic, cis, cis	[[[cyclopropyl][cis,cis-2,3,3a,4,9,9a-hexahydro-4-[3-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]oxy]acetic acid	519.3

32M		cis, cis, single enantiomer	[[[cyclopropyl[cis, cis-4-(4-fluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]oxy]acetic acid	452.7
32N		cis, cis, single enantiomer	[[[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]oxy]acetic acid	524.6 [M+Na] ⁺
32o		cis, cis, single enantiomer	[[[cyclopropyl[cis, cis-4-(4-ethylbenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]oxy]acetic acid	462.7
32P		cis, cis, single enantiomer	[[[cyclopropyl[cis, cis-4-(3,4-difluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]oxy]acetic acid	470.7
32Q		cis, cis, single enantiomer	[[[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-(2-naphthalenylcarbonyl)-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]oxy]acetic acid	484.7


32R		cis, cis, single enantiomer	[[[cyclopropyl][cis, cis-4-(3,5-difluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]oxy]acetic acid	470.6
32S		cis, cis, single enantiomer	[[[cyclopropyl][cis, cis-4-(3-fluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]oxy]acetic acid	453.7
32T		3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i> , single enantiomer	[[[cyclopropyl][(3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i>)-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]oxy]acetic acid	536.6
32U		cis, cis, single enantiomer	deuterated-[[[cyclopropyl][cis, cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl-(d)]amino]carbonyl]oxy]acetic acid	520

Example 33: Preparation of Enantiopure 4-(Phenylmethyl) cis, cis-[[[(2S)-carboxy-1-azetidiny]carbonyl]cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (33)



[00293] To a solution of the enantiopure amine **1E** (0.05 g, 0.138 mmol) in anhydrous dichloromethane (5 mL) was added phosgene (0.1 mL, 1 M solution) and triethylamine (0.04 mL). The reaction mixture was stirred for two hours and evaporated to dryness. The residue was redissolved in dichloromethane (5 mL) and treated with the amino acid (S)-azetidine-2-carboxylic acid (28 mg) and triethylamine (0.074 mL) and stirred over night. The reaction mixture was acidified with 1 N HCl, extracted with ethyl acetate, and purified by reversed phase HPLC to give compound **33** (0.055 g, 82%). $[M+H]^+ = 490.3$.

Example 34: Preparation of Enantiopure 4-(phenylmethyl) (3aS,9R,9aR) -[[[(3-carboxy-1-azetidiny]carbonyl]cyclopropylamino]-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (34)




[00294] The enantiopure amine **34A** was prepared from compound **17C** (after chiral HPLC, the stereochemistry was confirmed by conversion to **17D**) using a similar procedure as Example 22 to introduce the Cbz group and Example 1, step 5. The solution of amine **34A** (38 mg, 0.1 mmol) and DIPEA (40 μ L, 0.2 mmol) in CH_2Cl_2 (1 mL) was cooled in an ice – H_2O bath, $(COCl)_2$ in toluene (20% solution) (86 μ L, 0.15 mmol) was added. The mixture was kept stirring at $0^\circ C$ for 2 hrs, then rt for 15 mins, the mixture was concentrated, the residue was taken

up in THF (2 mL), azetidine-3-carboxylic acid (30 mg, 0.3 mmol) and NaH (24 mg, 0.6 mmol) were added, respectively. The resultant mixture was kept stirring at rt overnight. EtOAc (10 mL) was added to the mixture, followed by the H₂O (5 mL). The organic layer was washed with H₂O (2 mL), and the combined aqueous layer was acidified with 2 N HCl to pH ~ 2-3, extracted with Et₂O (2 x 5 mL). The combined ether layer was dried over MgSO₄ and concentrated. The residue was purified via reverse phase HPLC, to obtain 4-(phenylmethyl) (3a*S*,9*R*,9a*R*)-[[[(3-carboxy-1-azetidyl)carbonyl]cyclopropylamino]-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[*b*]quinoline-4-carboxylate **34** as a white solid, 25 mg; [M+H]⁺ 508.1. ¹H NMR (500 MHz, CDCl₃) δ ppm: 7.36 (m, 5H); 6.86 (m, 1H); 6.69 (m, 1H); 5.26 (d, *J*= 13 Hz, 1H); 5.17 (d, *J*= 13Hz, 1H); 5.02 (m, 1H); 4.86 (m, 1H); 4.26 (m, 4H); 3.41 (m, 1H); 2.97 (m, 1H); 2.52 (m, 1H); 2.10 (m, 1H); 1.93 (m, 1H); 1.55 (m, 1H); 1.42 (m, 2H); 1.20 ~0.97 (m, 4H); 0.79 (m, 1H).


Example 35: Preparation of N-[[Cyclopropyl[*cis,cis*-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[*b*]quinolin-9-yl]amino]carbonyl]-N-methylglycine (35)

Step 1




[00295] Triphosgene (1.8 g, 6.1 mmol) was added to a mixture of amine **1E** (2.0 g, 5.5 mmol), and triethylamine (0.92 mL, 6.6 mmol) in dry DCM (18 mL) at 0 °C. The reaction mixture was stirred at room temperature under nitrogen for 15 minutes, and concentrated to dryness. NaH (0.27 g, 10.6 mmol) was added to a mixture of sarcosine methyl ester hydrochloride (1.54 g, 11.0 mmol) in THF (18 mL) at 0°C under nitrogen. The resulting mixture was stirred at 0 °C for 2 hours, and at room temperature overnight. Water and EtOAc were added. The aqueous layer was separated and extracted with EtOAc. The organic extracts were combined, washed with brine, dried (MgSO₄), filtered and concentrated. The residue was purified by silica gel column chromatography (eluted with 10% ethyl acetate-hexane, to 40% ethyl acetate in hexane) to afford pure product urea ester **35A** (2.57 g, 5.23 mmol).

Step 2



[00296] 10% Pd on carbon (2.0 g) was added to the solution of urea ester **35A** (2.57 g, 5.22 mmol) in EtOH (17 mL). The reaction mixture was stirred under a balloon of hydrogen at room temperature for 1 h. The reaction mixture was filtered through a pad of Celite®, and the filtrate was concentrated. The residue was purified by silica gel column chromatography (eluted with 10% ethyl acetate in hexane) to afford pure urea amine **35B** (0.43 g, 1.2 mmol).


Step 3



[00297] 4-(Trifluoromethoxy)benzoyl chloride (50 mg, 0.22 mmol) was added to a solution of urea amine **35B** (40 mg, 0.11 mmol) and triethylamine (34 mg, 0.34 mmol) in DCM (2 mL). The reaction mixture was stirred at room temperature for 1 h. Water was added. The aqueous layer was separated and extracted with DCM. The organic extracts were combined, washed with brine, dried (MgSO₄), filtered and concentrated. The residue was purified by preparative thin layer chromatography (eluted with 50% ethyl acetate-hexane) to afford the urea amide **35C** (30 mg, 0.055 mmol).

Step 4




N-[[Cyclopropyl[*cis,cis*-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[*b*]quinolin-9-yl]amino]carbonyl]-N-methylglycine (35)






[00298] Lithium hydroxide monohydrate (18.2 mg, 0.43 mmol) was added to a solution of urea amide (30 mg, 0.055 mmol) in THF (0.5 mL) and H₂O (0.5 mL). The reaction mixture was stirred at room temperature over night. 1 N HCl (aq.) was added to the reaction mixture. The aqueous layer was separated and extracted with EtOAc. The organic extracts were combined, washed with brine, dried (MgSO₄), filtered and concentrated to give acid **35** (20 mg, 0.038 mmol). $[M+H]^+ = 532.3$.

[00299] The compounds in the following table were prepared following protocols similar to those described in Example 35.


#	Structure	Stereo designation	Name	$[M+H]^+$
35D		racemic, <i>cis</i> , <i>cis</i>	N-[[[<i>cis,cis</i> -4-benzoyl-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[<i>b</i>]quinolin-9-yl]cyclopropylamino]carbonyl]-N-methylglycine	448.2
35E		racemic, <i>cis</i> , <i>cis</i> S at acid side chain	N-[[cyclopropyl[<i>cis,cis</i> -2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[<i>b</i>]quinolin-9-yl]amino]carbonyl]-l-alanine	532.3

35F		racemic, cis, cis R at acid side chain	N-[[cyclopropyl[cis,cis- 2,3,3a,4,9,9a-hexahydro-4-[4- (trifluoromethoxy)benzoyl]-1H- cyclopenta[b]quinolin-9- yl]amino]carbonyl]-D-alanine	532.3
35G		racemic, cis, cis	N-[[cyclopropyl[cis,cis- 2,3,3a,4,9,9a-hexahydro-4-[4- (trifluoromethoxy)benzoyl]-1H- cyclopenta[b]quinolin-9- yl]amino]carbonyl]-beta- alanine	532.3
35H		cis, cis, single enantiomer HPLC peak 1	N-[[cyclopropyl[cis, cis- 2,3,3a,4,9,9a-hexahydro-4-[4- (trifluoromethoxy)benzoyl]-1H- cyclopenta[b]quinolin-9- yl]amino]carbonyl]-N- methylglycine	532.3

35i		cis, cis, single enantiomer HPLC peak 2	N-[[cyclopropyl[2,3,3a,4,9,9a-hexahydro-4-(3-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]-N-methylglycine	532.3
35J		cis, cis,, single enantiomer	N-[[cyclopropyl[2,3,3a,4,9,9a-hexahydro-4-(2-thienylcarbonyl)-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]-N-methylglycine	454.2
35K		cis, cis racemic	N-[[cyclopropyl[2,3,3a,4,9,9a-hexahydro-4-(4-(trifluoromethoxy)benzoyl)-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]glycine	518.3


Example 36: Preparation of Racemic 4-[[cis-4-(5-Benzyl-1,3,4-oxadiazol-2-yl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl](cyclopropyl)amino]-4-oxobutanoic acid (36)

Step 1



[00300] Triphosgene (589 mg, 1.99 mmol, 0.40 equiv) was added to a solution of methyl 4-[[cis-4-(cyclopropylamino)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]-4-oxobutanoate **14A** (1.7 g, 5.0 mmol, 1 equiv) and *N,N*-diisopropylethylamine (1.04 mL, 5.96 mmol, 1.2 equiv) in dichloromethane (25 mL) at 23 °C. The reaction mixture was stirred at 23 °C for 15 min, and then was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to afford methyl 4-[[cis-4-(chlorocarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl](cyclopropyl)amino]-4-oxobutanoate, which was used in subsequent steps without further purification. $[M+H]^+$: 405.1.



Step 2




[00301] 2-Phenylacetohydrazide (26.5 mg, 0.177 mmol, 1.1 equiv) was added to a solution of methyl 4-[[cis-4-(chlorocarbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl](cyclopropyl)amino]-4-oxobutanoate **36D** (65 mg, 0.16 mmol, 1 equiv) and *N,N*-diisopropylethylamine (0.033 mL, 0.19 mmol, 1.2 equiv) in tetrahydrofuran (0.80 mL), and the reaction mixture was warmed to 60 °C. After stirring for 2 h at 60 °C, the

reaction mixture was cooled to 23 °C, and 3,3,3-triethyl-1-(methoxycarbonyl)diazathian-3-ium-1-ide 2,2-dioxide (Burgess reagent, 77 mg, 0.32 mmol, 2.0 equiv) was added. The reaction vessel was sealed, and heated in a microwave at 120 °C for 15 min. The reaction mixture was then cooled to 23 °C, and aqueous sodium hydroxide solution (1 N, 8 equiv) was added. The reaction mixture was then heated in a microwave at 110 °C for 30 min. After cooling to 23 °C, dimethyl sulfoxide (1 mL) was added, and the mixture was purified by reverse-phase HPLC (10% acetonitrile-water, grading to 90% acetonitrile-water, with 0.1% trifluoroacetic acid in both the acetonitrile and water) to afford **36** as a white solid. $[M+H]^+$: 487.3.

[00302] The following examples were prepared from methyl 4-[[cis, cis-4-(chlorocarbonyl)-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl](cyclopropyl)amino]-4-oxobutanoate using procedures similar to Example 36, Step 2, and the appropriate hydrazides:


#	Structure	Stereo designation	Name	$[M+H]^+$
36A		racemic, cis, cis	racemic 4-{cyclopropyl[cis, cis-4-(5-phenyl-1,3,4-oxadiazol-2-yl)-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[<i>b</i>]quinolin-9-yl]amino}-4-oxobutanoic acid	473.2
36B		racemic, cis, cis	racemic 4-{cyclopropyl[cis, cis-4-[5-(4-fluorophenyl)-1,3,4-oxadiazol-2-yl]-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[<i>b</i>]quinolin-9-yl]amino}-4-oxobutanoic acid	491.2

36C

racemic, cis,
cisracemic 4-
{cyclopropyl}[cis, cis-4-
{5-[4-
(trifluoromethoxy)phen
yl]-1,3,4-oxadiazol-2-
yl}-2,3,3a,4,9,9a-
hexahydro-1H-
cyclopenta[b]quinolin-
9-yl]amino}-4-
oxobutanoic acid

557.2

Example 37: Preparation of Racemic ({Cyclopropyl[cis, cis-4-(5-phenyl-1,3,4-oxadiazol-2-yl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]carbamoyl}oxy)acetic acid (37)




37

[00303] Compound 37 was prepared from 2-(benzyloxy)ethyl cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]carbamate **29B**, using a sequence of procedures similar to Example 36, Step 1, Example 36, Step 2 (without the hydrolysis step), Example 29, Step 4, and Example 30. $[M+H]^+$: 475.2.


Example 38: Preparation of Racemic [[[Cyclopropyl[*cis,cis*-2,3,3a,4,9,9a-hexahydro-4-[5-[3-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]-1H-cyclopenta[*b*]quinolin-9-yl]amino]carbonyl]oxy]acetic acid (38**)**

Step 1



[00304] Triphosgene (41 mg, 0.32 mmol) was added to a mixture of amine **38A** (0.23 g, 0.67 mmol, prepared from **1E** following a similar procedure as in Example 32, steps 1 and 2, and Example 14, step 1) and *i*-Pr₂NEt (0.14 mL, 0.80 mmol) in DCM (4 mL). The resulting mixture was stirred at room temperature for 1.5 h, and partitioned in EtOAc and water. The organic layer was separated, washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was taken up with THF (2 mL), and treated with Hünig's base (0.14 mL, 0.80 mmol) and anhydrous hydrazine (0.05 mL, 1.59 mmol). The resulting mixture was stirred at room temperature overnight. The volatiles were removed. The residue was taken up with DCM (4 mL), and treated with Et₃N (0.14 mL, 1.0 mmol), DMAP (30 mg, 0.21 mmol), followed by 3-(trifluoromethoxy)benzoyl chloride (185 mg, 0.82 mmol). The resulting mixture was stirred at room temperature overnight. DCM was added and washed with 1 N HCl. The aqueous layer was separated and extracted with DCM. The organic extracts were combined, washed with brine, dried (MgSO₄), and concentrated. The residue was purified by a silica gel chromatography (eluted with EtOAc-hexanes, 1:1 to 2:1) to give the desired product hydrazine amide **38B**.


Step 2:



[00305] Starting material hydrazine amide **38B** (50 mg) was treated with POCl₃ (1.5 mL) and heated at 120 °C for 2 h. The reaction mixture was cooled to room temperature and poured into DCM and washed with 1 N NaOH. The aqueous layer was extracted with DCM. The organic extracts were combined, washed with brine, and dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified by preparative thin-layer-chromatography (eluted with 1: 30 7 N NH₃/MeOH-DCM), to give desired product oxadiazole ester **38C** (27 mg).

Step 3




[[[Cyclopropyl][cis,cis-2,3,3a,4,9,9a-hexahydro-4-[5-[3-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-yl]-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]oxy]acetic acid (38)



[00306] Starting material oxadiazole ester **38C** (29 mg) in THF (0.5 mL) was treated with 2 N LiOH (0.5 mL). The resulting mixture was stirred at room temperature for 3 h. The reaction mixture was treated with 1 N HCl (aq.) until pH reached 6, and was extracted with DCM. The organic extracts were combined, washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo* to give desired product **38**, [M+H]⁺ = 559.3.

[00307] The compounds in the following table were prepared following a similar protocol as described in Example 38.


#	Structure	Stereo designation	Name	[M+H] ⁺
38D		racemic, cis, cis	[[[cyclopropyl][cis,cis-2,3,3a,4,9,9a-hexahydro-4-[5-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,4-oxadiazol-2-yl]-1H-cyclopenta[b]quinoline-9-yl]amino]carbonyl]oxy]acetic acid	573.2

38E		racemic, cis, cis	[[[cyclopropyl][cis,cis-4-[5-[(4-fluorophenyl)methyl]-1,3,4-oxadiazol-2-yl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinoline-9-yl]amino]carbonyl]oxy]acetic acid	507.2
38F		single enantiomer, cis, cis peak 1 from chiral HPLC	[[[cyclopropyl][cis,cis-2,3,3a,4,9,9a-hexahydro-4-[5-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,4-oxadiazol-2-yl]-1H-cyclopenta[b]quinoline-9-yl]amino]carbonyl]oxy]acetic acid	573
38G		single enantiomer, cis, cis peak 2 from chiral HPLC	[[[cyclopropyl][cis,cis-2,3,3a,4,9,9a-hexahydro-4-[5-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,4-oxadiazol-2-yl]-1H-cyclopenta[b]quinoline-9-yl]amino]carbonyl]oxy]acetic acid	573

Example 39: Preparation of Racemic 2-[(cis, cis-4-[(Benzyloxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)(ethyl)amino]-1,3-thiazole-4-carboxylic acid (39)

Step 1

Benzyl cis, cis-9-[[4-(ethoxycarbonyl)-1,3-thiazol-2-yl]amino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (39A)




[00308] Benzyl cis, cis-9-amino-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (2, 104 mg, 0.323 mmol, 1 equiv), Tris(dibenzylideneacetone)dipalladium (44 mg,

0.048 mmol, 0.15 equiv), dicyclohexylphosphino-2'-(*N,N*-dimethylamino)biphenyl (57 mg, 0.15 mmol, 0.45 equiv), and ethyl 2-bromo-1,3-thiazole-4-carboxylate (152 mg, 0.645 mmol, 2.0 equiv) were combined in a microwave tube. Dioxane (3.2 mL) was added to the microwave tube, and nitrogen gas was bubbled through the reaction mixture for 5 min. Lithium bis(trimethylsilyl)amide in tetrahydrofuran (1.0 M, 0.484 mL, 0.484 mmol, 1.5 equiv) was then added, and the reaction mixture was heated to 110 °C. After stirring at 110 °C for 25 min, the heating bath was removed and the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography (5% ethyl acetate-hexanes, grading to 65% ethyl acetate-hexanes) to afford **39A** $[M+H]^+$: 478.1.

Step 2


Benzyl cis, cis-9-[[4-(ethoxycarbonyl)-1,3-thiazol-2-yl](ethyl)amino]-1,2,3,3a,9,9a-hexahydro-4*H*-cyclopenta[*b*]quinoline-4-carboxylate (39B)



[00309] Lithium bis(trimethylsilyl)amide in tetrahydrofuran (1.0 M, 0.095 mL, 0.095 mmol, 1.0 equiv) was added to a solution of **39A** (38 mg, 0.080 mmol, 1 equiv) in tetrahydrofuran (0.80 mL) at 0 °C. The reaction mixture was stirred at 0 °C for 10 min, and then iodoethane (0.026 mL, 0.32 mmol, 4.0 equiv) was added. The cooling bath was removed, and the reaction mixture was stirred at 23 °C. After stirring at 23 °C for 3 h, the temperature was increased to 40 °C, and the reaction mixture was stirred for 16 h. After cooling to 23 °C, the reaction mixture was partitioned between ethyl acetate and water. The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography (10% ethyl acetate-hexanes, grading to 40% ethyl acetate-hexanes) to afford **39B**. $[M+H]^+$: 506.2.


Step 3

2-[{cis, cis-4-[(benzyloxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}(ethyl)amino]-1,3-thiazole-4-carboxylic acid (39)




[00310] Compound **39** was prepared from benzyl cis, cis-9-[[4-(ethoxycarbonyl)-1,3-thiazol-2-yl](ethyl)amino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate **39B** using a procedure similar to that used in Example 14, Step 3. $[M+H]^+$: 478.1.

Example 40: Preparation of Racemic 2-[Ethyl{cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl}amino]-4-oxazolecarboxylic acid (40)


Step 1

[00311] Amine **40A** (100 mg, 0.26 mmol, prepared from **1D** following a similar procedure as in Example 14, step 1 and 2, and Example 2), ethyl 2-chlorooxazole-4-carboxylate (120 mg, 0.68 mmol) and *i*Pr₂NEt were dissolved in dioxane (8 mL) and heated in a sealed tube at 130°C overnight. The resulting mixture was cooled to room temperature, diluted with EtOAc and washed with 1 N HCl. The aqueous layer was separated and extracted with EtOAc. The organic extracts were combined and washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified with preparative thin-layer-chromatography (eluted with 1: 30 7 N NH₃/MeOH:DCM), to give the desired product amino oxazole **40B** (71 mg).

Step 2

[00312] Starting material amino oxazole **40B** (40 mg, 0.078 mmol) was dissolved in DMF (1 mL), treated with NaH (20 mg, 10 mmol). The mixture was stirred at room temperature for 1 h, and EtI (0.06 mL, 0.75 mmol) was added. The resulting mixture was stirred at room temperature overnight, and diluted with EtOAc and washed with water. The aqueous layer was separated and extracted with EtOAc. The organic extracts were combined and washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified with preparative thin-layer-chromatography (eluted with 1: 4 EtOAc-hexanes), to give the desired product ethyl amino oxazole **40C** (28 mg).


Step 3: 2-[Ethyl[*cis,cis*-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[*b*]quinolin-9-yl]amino]-4-oxazolecarboxylic acid (40**)**



[00313] Starting material ethyl amino oxazole **40C** (28 mg) in THF (0.5 mL) was treated with 2 N LiOH (0.5 mL). The resulting mixture was stirred at room temperature for 3 h. The reaction mixture was treated with 1 N HCl (aq.) until pH reached 6, and was extracted with DCM. The organic extracts were combined, washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo* to give the desired product **40**, [M+H]⁺ = 516.


Example 41: Preparation of Racemic 5-[Cyclopropyl[*cis,cis*-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[*b*]quinolin-9-yl]amino]-1,3,4-oxadiazole-2-acetic acid (41)

Step 1




[00314] Triphosgene (148 mg, 0.50 mmol) was added to a mixture of starting amine **41A** (200 mg, 0.48 mmol, prepared from **1D** following a similar procedure as in Example 14, step 1 and 2, and Example 6, step 4) and *i*Pr₂NEt (0.1 mL, 0.57 mmol) in DCM (4 mL). The resulting mixture was stirred at room temperature overnight. *i*Pr₂NEt (0.1 mL, 0.57 mmol) was added followed by anhydrous hydrazine (0.1 mL, 3.2 mmol). The resulting mixture was stirred at room temperature for 2 h and concentrated *in vacuo*. The residue was purified with silica gel chromatography (eluted with 1: 50 7 N NH₃/MeOH-DCM), to give N-cyclopropyl-N-[*cis,cis*-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[*b*]quinolin-9-yl]hydrazine carboxamide **41B**.

Step 2




[00315] Starting material hydrazine **41B** (170 mg, 0.36 mmol) and *i*Pr₂NEt (0.1 mL, 0.57 mmol) were dissolved in DCM (4 mL) and cooled to -4°C. To the mixture, ethyl malonyl chloride (136 mg, 0.90 mmol) was added. The resulting mixture was stirred at room temperature overnight. DCM and 0.1 N HCl were added. The aqueous layer was separated and extracted with DCM. The organic extracts were combined and washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified with preparative thin-layer-chromatography (eluted with 1: 50 7 N NH₃/MeOH-DCM), to give desired product hydrazine amide **41C** (200 mg).

Step 3**5-[Cyclopropyl[*cis,cis*-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[*b*]quinolin-9-yl]amino]-1,3,4-oxadiazole-2-acetic acid (41)**

[00316] The starting material hydrazine amide **41C** (214 mg, 0.36 mmol) was treated with POCl₃ (2 mL), and heated at 120°C for 2 h. The reaction mixture was cooled to room temperature and poured into 4 N NaOH. The aqueous layer was separated and extracted with DCM. The organic extracts were combined and washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo*. The residue was purified with preparative thin-layer-chromatography (eluted with 1: 50 7 N NH₃/MeOH-DCM), to give desired product **41D** (36 mg). The oxadiazole ester **41D** (31 mg) in THF (0.5 mL) was treated with 2 N LiOH (0.5 mL). The resulting mixture was stirred at room temperature for 3 h and then treated with 1N HCl (aq.) until the pH turned 6. The aqueous layer separated and extrated with DCM. The organic extracts were combined, washed with brine, dried (MgSO₄), filtered and concentrated *in vacuo* to give desired product **41**, [M+H]⁺ = 543.3.

Example 42: Preparation of Racemic N-Cyclopropyl-N-[*cis,cis*-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[*b*]quinolin-9-yl]-2H-tetrazole-5-propanamide (42)


Step 1

[00317] To a solution of the amine **41A** (0.050 g, 0.119 mmol) in anhydrous dioxane (5 mL) was added 3-bromopropionylchloride (0.81 mg, 0.48 mmol) and Hunigs base (0.084 mL,

0.48 mmol) at 0 °C. The mixture was stirred at room temperature for two hours. Removal of solvent and chromatographic purification using ethyl acetate/hexane gave the bromoamide **42A** as a white solid (0.04 g, 71%)


Step 2

3-Cyano-N-cyclopropyl-N-[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]propanamide (42B)



[00318] A mixture of bromo amide **42A** and potassium cyanide in DMF was stirred at room temperature and heated to 65 °C overnight. The reaction mixture was taken into a separation funnel, washed with water, brine and dried over anhydrous sodium sulfate. Filtration and removal of the solvent gave the crude cyanide (**42B**), which was used in the next step without purification (0.032 mg, 76%).


Step 3: N-Cyclopropyl-N-[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]-2H-tetrazole-5-propanamide (42)



[00319] To a solution of the nitrile (**42B**) (0.08 g, 0.16 mmol) and trimethylsilylazide (0.32 mmol) in toluene (5 mL) was added dibutyltin oxide (0.016 mmol), and the mixture was heated for two days until the nitrile was consumed. The reaction mixture was concentrated and the residue was dissolved in methanol and concentrated. The residue was partitioned between ethyl acetate and 10% sodium bicarbonate solution. The organic phase was extracted with an additional 10% sodium bicarbonate solution. The combined aqueous phase was acidified to pH 2 with 10% HCl and then extracted with ethyl acetate. The tetrazole product **42** was purified by reverse phase HPLC. (0.040 g, 45%), $[M+H]^+ = 541.3$.


Example 43: Preparation of Enantiopure 4-(Phenylmethyl) deuterated-cis,cis-9-[(3-carboxypropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate-(9D) (43)

Step 1



[00320] Titanium (IV) ethoxide (4.84 mL, 23.3 mmol, 2.50 equiv) was added to a solution of enantiopure benzyl cis, cis-9-oxo-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate **1D'** (3.00 g, 9.34 mmol, 1 equiv, enantiomer of **1D** after chiral HPLC) and cyclopropylamine (1.83 mL, 23.3 mmol, 2.50 equiv) in tetrahydrofuran. The reaction vessel was sealed and heated to 60 °C. After stirring for 16 h, the reaction mixture was cooled to 23 °C and poured over saturated aqueous sodium chloride solution (50 mL). The biphasic mixture was stirred for 5 min, then filtered through Celite® with the aid of ethyl acetate. The filtrate was partitioned between ethyl acetate and brine, and the organic phase was then dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was dissolved in methanol (30 mL) and tetrahydrofuran (60 mL), and the solution was cooled to 0 °C. Sodium borodeuteride (855 mg, 22.6 mmol, 2.50 equiv) was added to the cooled solution. After stirring for 15 min at 0 °C, the cooling bath was removed, and the reaction mixture was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to afford the desired product **43A**. $[\text{M}+\text{H}]^+$: 364.3.


Step 2: Enantiopure 4-(Phenylmethyl) deuterated-cis,cis-9-[(3-carboxypropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate-(9D) (43)




[00321] Enantiopure amine **43A** (100 mg) and aldehyde (200 mg) in DCE were treated with $\text{NaBH}(\text{OAc})_3$ (500 mg) at room temperature overnight. The reaction mixture was then diluted with EtOAc (50 mL), washed with aq. NaHCO_3 (30 mL) and brine (30 mL). The organic layer was dried with Na_2SO_4 , concentrated by rotovap. The residue was dissolved in MeOH/THF (3/3 mL) and treated with 1 N aq. NaOH (3 mL) and the reaction mixture was stirred at room temperature for 3 hours. The crude product was directly purified by reverse phase HPLC to give the product **43** (100 mg, 85%) as white foam, $[\text{M}+\text{H}]^+ = 450$. ^1H NMR (500 MHz, CD_3OD) δ ppm: 7.52-7.30 (m, 9H), 5.28 (d, $J = 12.0$ Hz, 1H), 5.23 (d, $J = 12.5$ Hz, 1H), 5.06 (m, 1H), 3.69-3.59 (m, 3H), 3.33 (m, 1H), 3.17 (m, 1H), 2.46 (dd, $J = 6.5, 7.0$ Hz, 2H), 2.34 (m, 1H), 2.26 (m, 1H), 2.12 (m, 1H), 1.76 (m, 1H), 1.54-1.42 (m, 2H), 1.35 (m, 1H), 1.25-1.10 (m, 4H), 0.99 (m, 1H).

[00322] The compounds in following table were synthesized by as similar route as that described in Example 43, wherein the reducing agent in Step 1 was NaBH_4 , instead of NaBD_4 .

#	Structure	Stereo designation	Name	$[\text{M}+\text{H}]^+$
43B		cis, cis, single enantiomer	4-((cis, cis-3-(benzyloxycarbonyl)-5-fluoro-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)amino)butanoic acid	453



Example 44: Preparation of Racemic 4-[Cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]butanoic acid (44)




[00323] Amine **41A** (100 mg, racemic) and aldehyde (200 mg) in DCE were treated with NaBH(OAc)₃ (500 mg) at room temperature overnight. The reaction mixture was then diluted with EtOAc (50 mL), washed with aq. NaHCO₃ (30 mL) and brine (30 mL). The organic layer was dried with Na₂SO₄, and then concentrated on a rotary evaporator. The residue was dissolved in MeOH/THF (3/3 mL) and treated with 1 N aq. NaOH (3 mL) and the reaction mixture was stirred at room temperature for 3 hours. The crude was directly purified by reverse phase HPLC to give the product **44** (100 mg, 85%) as a white foam, [M+H]⁺ = 503. ¹H NMR (500 MHz, CD₃OD) δ ppm: 7.56 (d, *J* = 8.5 Hz, 2H), 7.51 (d, *J* = 8.0 Hz, 1H), 7.29 (dd, *J* = 7.5, 7.5 Hz), 7.23 (d, *J* = 7.5 Hz, 2H), 7.16 (d, *J* = 7.5 Hz, 1H), 7.12 (dd, *J* = 7.0, 7.5 Hz, 1H), 5.26 (br, 1H), 5.09 (s, 1H), 3.83-3.64 (m, 3H), 3.32 (m, 1H), 3.19 (m, 1H), 2.59 (ddd, *J* = 5.5, 6.0, 18 Hz, 1H), 2.48-2.24 (m, 3H), 1.80 (m, 1H), 1.49-1.38 (m, 3H), 1.32-1.27 (m, 2H), 1.22-1.10 (m, 3H), 0.99 (m, 1H).

[00324] The compounds in following table were synthesized by a similar route as described in Example 44.

#	Structure	Stereo designation	Name	[M+H] ⁺
44B		racemic, cis, cis	4-[[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]butanoic acid	463
44C		(racemic) cis, cis at 3a,9,9a, (racemic) trans at cyclopropyl,	trans-2-[[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]methyl]cyclopropanecarboxylic acid	515
44D		cis, cis, single enantiomer	4-(cyclopropyl(cis, cis-5-fluoro-3-(4-(trifluoromethoxy)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)butanoic acid	507
44E		racemic, cis, cis	4-[[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl](phenylmethyl)amino]butanoic acid	553
44F		racemic, cis, cis	4-[[cyclopropylmethyl][cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]butanoic acid	517

Example 45: Preparation of Racemic 4-[[cis,cis-2,3,3a,4,9,9a-Hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid (45)




[00325] Methyl 4-chloro-4-oxobutanoate (0.2 mL, 2.2 equiv) was added to a solution of amine **40A** (200 mg, 1 equiv) and *N,N*-diisopropylethylamine (0.2 mL, 3.00 equiv) in DCM (8 mL) at 23 °C (used a 23 °C water bath to control the exotherm that was observed during the addition). The reaction mixture was stirred for 1 h, and then it was partitioned between ethyl acetate and aqueous hydrochloric acid solution (1 N). The organic layer was washed sequentially with aqueous sodium hydroxide solution (1N) and saturated aqueous sodium chloride solution, and the washed organic layer was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography (20% ethyl acetate-hexanes, grading to ethyl acetate) to afford the methyl ester of the desired product.

[00326] Aqueous sodium hydroxide solution (1 N, 3 mL) was added to a solution of the ester (80 mg,) in THF/MeOH (3/3 mL). The reaction was stirred at room temperature overnight. The mixture was purified by reverse phase HPLC to give the desired acid **45**, $[M+H]^+ = 477$.


Example 46: Preparation of Enantiopure 4-[Cyclopropyl[*cis*, *cis*-4-[2-[(4-fluorophenyl)amino]-2-oxoethyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[*b*]quinolin-9-yl]amino]-4-oxobutanoic acid (46)

Step 1




[00327] Cs_2CO_3 (110 mg, 0.337 mmol) was added to a solution of enantiopure amine **14A''** (60 mg, 0.168 mmol, prepared in the same manner as compound **14A'** with an ethyl ester.) in DMF (2 mL), and the mixture was stirred at rt for 30 mins. Benzyl 2-bromoacetate (170 μL , 0.84 mmol) was added. The resultant mixture was placed in a Biotage microwave reactor: T = 120°C . t = 1 h, Absorption = High. EtOAc (10 mL) was added to the cooled mixture, followed by H_2O (10 mL). The organic layer was washed with brine (10 mL), dried over MgSO_4 and concentrated. The residue was purified via silica gel column chromatography (EtOAc/Hexane = 1:2), to obtain enantiopure benzyl ester **46A** as a brown syrup, 32 mg; $[\text{M}+\text{H}]^+ = 505$.

Step 2




[00328] 10% Pd on C (6 mg) was added to a solution of benzyl ester (26 mg, 0.05 mmol) in a mixed solvent of EtOH (3 mL) - EtOAc (1 mL). The resultant mixture was degassed and filled with H_2 (balloon, 3 times), the mixture was kept under H_2 , stirring at rt for 2 h. The catalyst was filtered off and washed with EtOH. The filtrate was concentrated to obtain a clear syrup as the acid, 17 mg; $[\text{M}+\text{H}]^+ = 415$.

Step 3

**46B****46C**

[00329] The above obtained enantiopure acid **46B** (17 mg, 0.041 mmol), 4-fluoroaniline (7 μ L, 0.082 mmol), HOBT (11 mg, 0.082 mmol), EDC (16 mg, 0.082 mmol) and DIPEA (22 μ L, 0.123 mmol) were mixed in CH_2Cl_2 (1 mL), and the resultant mixture was kept stirring at rt overnight. The mixture was concentrated, and the residue was purified via silica gel column chromatography (EtOAc/Hexane = 1:1) to obtain amide **46C** as a clear syrup, 17 mg; $[\text{M}+\text{H}]^+ = 508$.

Step 4


**46C****46**

[00330] The above obtained amide was converted to the desired enantiopure acid **46** using a similar procedure to that described in Example 14, $[\text{M}+\text{H}]^+ = 479.7$. ^1H NMR (500 MHz, CDCl_3) δ ppm: 7.54 (m, 2H); 7.10 (m, 1H); 7.01 (m, 2H); 6.75 (m, 1H); 6.52 (m, 1H); 3.93 (s, 2H); 3.76 (m, 2H); 3.05 (m, 1H); 2.75 ~ 2.63 (m, 5H); 1.86 (m, 6H); 1.12 ~ 0.90 (m, 4H).

Example 47: Preparation of Racemic 4-[Acetyl[*cis,cis*-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[*b*]quinolin-9-yl]amino]butanoic acid (47)


Step 1: *Cis,cis*-2,3,3a,4,9,9a-hexahydro-*n*-(4-hydroxybutyl)-4-[4-

(trifluoromethoxy)benzoyl]-1H-cyclopenta[*b*]quinolin-9-amine (47A)




[00331] *Cis,cis*-2,3,3a,4,9,9a-hexahydro-*n*-(4-hydroxybutyl)-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[*b*]quinolin-9-amine **47A** was obtained from **1D** following the similar procedure as Example 14, step 1, 2 to obtain ketone amide **47A'** which was reacted with 4-hydroxybutyl amine following similar procedure as Example 6, step 4.

Step 2: N-[4-(Acetyloxy)butyl]-N-[*cis,cis*-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[*b*]quinolin-9-yl]acetamide (47B)




[00332] To a solution of the amino alcohol **47A** (0.312 g, 0.696 mmol) in anhydrous dichloromethane (10 mL) was added acetyl chloride (0.19 mL, 2.78 mmol) and Hunigs base (0.61 mL, 3.48 mmol) at 0°C. The mixture was stirred at room temperature for six hours. Removal of solvent and chromatographic purification using ethyl acetate/hexane gave the amide **47B** as the major product as a white solid (0.3 g, 81%) and small amount of **47C**.

Step 3: N-[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]-N-(4-hydroxybutyl)acetamide (47D)







[00333] A solution of the acetate **47B** (0.102 g, 0.19 mmol) in methanol (5 mL) and water (1 mL) was treated with potassium hydroxide (0.76 mmol) and refluxed for one hour. The reaction mixture was concentrated and extracted with ethyl acetate, washed with water, brine and dried over anhydrous sodium sulfate. Filtration and removal of the solvent gave the crude alcohol **47D** which was used for the next step without purification (0.070 g, 75%).

Step 4: 4-[Acetyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]butanoic acid (47)




[00334] To a solution of the alcohol **47C** (0.051 mmol) in carbon tetrachloride/acetonitrile/water (2 mL, 2 mL, 3 mL) was treated with sodium periodate followed by catalytic amount of rutheniumchloride.trihydrate. The reaction mixture was stirred at room temperature for two hours, 1 mL of saturated ammonium chloride solution was added and filtered. The filtrate diluted with ethyl acetate and taken into a separatory funnel, was washed with water, brine and dried over anhydrous sodium sulfate. Removal of the solvent gave the crude acid **47** which was purified by using reverse phase HPLC. (0.015 mg, 60%). $[M+H]^+ = 505.3$.

[00335] The compounds in the following table were prepared in a similar procedure as showed above in Example 47.

#	Structure	Stereo designation	Name	[M+H] ⁺
47D		racemic, cis, cis	4-[benzoyl[<i>cis,cis</i> -2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[<i>b</i>]quinolin-9-yl]amino]butanoic acid	567.3
47E		racemic, cis, cis	4-[[<i>cis,cis</i> -2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[<i>b</i>]quinolin-9-yl][4-(trifluoromethoxy)benzoyl]amino]butanoic acid	651.4
47F		racemic, cis, cis	4-[[<i>cis,cis</i> -2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[<i>b</i>]quinolin-9-yl](4-methylbenzoyl)amino]butanoic acid	581.3
47G		racemic, cis, cis	4-[[<i>cis,cis</i> -2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[<i>b</i>]quinolin-9-yl](2-methyl-1-oxopropyl)amino]butanoic acid	533.3

Example 48: Preparation of Enantiopure Ketone Intermediate Containing a Bridgehead Methyl Group for Compounds 48 and 48C:




[00336] The ketone **25C'** (0.5 g, 1.62 mmol, single enantiomer after resolution of the racemate **25C** via chiral HPLC) was taken up in 5 mL of THF, and cooled to -78 °C. To this mixture, LiHMDS was slowly added and the resulting solution stirred for one hour. Excess methyl iodide was then slowly added at -78 °C, and the ice bath was removed. The reaction mixture was stirred at room temperature for an additional hour. The solution was quenched with aqueous NH₄Cl and extracted with ethyl acetate (20 mL) three times. The combined organic layers were then dried over anhydrous sodium sulfate. The filtrate was concentrated *in vacuo* to afford the product **48A** (0.480 g) in 92% yield.

[00337] The ketone **48A** was converted to a mixture of the enantiopure acids **48** and **48C** using procedures similar to those used for Example 1, Step 5 and Example 43, Steps 2. The acids **48** and **48C** were separated at the last stage.



#	Structure	Stereo designation	Name	[M+H] ⁺
48		cis, cis (cyclobutyl ring and cyclopropyl amine), methyl trans to cyclopropyl amine, single enantiomer	4-(((cis, cis-3-(benzyloxycarbonyl)-8a-methyl-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)amino)butanoic acid	449
48C		Cyclobutyl ring cis fused which is trans to cyclopropyl amine, methyl cis to cyclopropyl amine, single enantiomer	4-(((cis, trans-3-(benzyloxycarbonyl)-8a-methyl-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)amino)butanoic acid	449

Example 49: Preparation of Ketone Intermediate for enantiopure 4-[(2,4-Difluorophenyl)methyl] cis, cis-7-bromo-9-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (49) and enantiopure 4-[[cis, cis-7-bromo-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid (49B):




[00338] To a stirring solution of enantiomerically pure compound **cis-49A'** (800 mg, 4.27 mmol, prepared in a similar sequence in Example 17, steps 1, 2, 3 where the racemic ketone was resolved by chiral HPLC.) in DMF (40 mL) was added NBS (760 mg, 4.27 mmol). The resulting solution was stirred at room temperature overnight. The mixture was diluted with EtOAc. The organic layer was washed with water, brine, dried (MgSO₄), filtered and concentrated *in vacuo* to give desired enantiomerically pure **cis** product **49A** (1.14 g) as a yellow solid.

[00339] Following procedures similar to those described in Examples 22 without hydrolysis (for **49**) or Example 14, step 2 (for **49B**), and Example 6, step 4, and Example 7, enantiopure cis ketone **49A** was converted into compounds **49** and **49B** below.


#	Structure	Stereo designation	Name	[M+H] ⁺
49		cis, cis, single enantiomer	4-[(2,4-difluorophenyl)methyl] cis, cis-7-bromo-9-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	579.3
49B		cis, cis,, single enantiomer	4-[[cis, cis-7-bromo-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	597.3

Example 50: Preparation of Ketone Intermediate for enantiopure 4-[[cis, cis-7-cyano-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid (50)




[00340] Starting material enantiopure cis **49A** (100 mg, 0.376 mmol), Zn(CN)₂ (44 mg, 0.376 mmol), Pd(PPh₃)₄ (43 mg, 0.0037 mmol) were mixed in DMF (1.3 mL) and heated in a microwave oven at 110 °C for 30 min. The reaction mixture was diluted with EtOAc and washed with water. The organic layer was separated and washed with brine, dried (MgSO₄), filtered, and concentrated. The residue was purified with preparative TLC, eluting with EtOAc-hexanes, 1:1, to give desired product enantiopure cis **50A** (10 mg).

[00341] Following procedures similar to those described in Examples 14, step 2, Example 6, step 4, Example 7, ketone **50A** was converted into enantiopure compound **50**. [M+H]⁺: 542.3

#	Structure	Stere designation	Name	[M+H] ⁺
50		cis, cis,, single enantiomer	4-[[cis, cis-7-cyano-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid	542.3


Example 51: Preparation of enantiopure cis Ketone Intermediate for enantiopure

Compound 4-[Cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-7-methyl-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid (51)




[00342] Starting material enantiopure cis **49A** (100 mg, 0.376 mmol), methylboronic acid (45 mg, 0.752 mmol), CsF (171 mg, 1.13 mmol), Pd(dppf)₂Cl₂ (31 mg, 0.0038 mmol) were mixed in DMF (1.3 mL), and heated in a microwave oven at 110°C for 80 min. The reaction mixture was diluted with DCM and filtered through a pad of Celite®. The filtrate concentrated under reduced pressure. The residue was purified with preparative TLC, eluting with EtOAc-hexanes, 1:3, to give desired enantiopure cis product **51A** (30 mg).

[00343] Following procedures similar to those described in Examples 14, step 2, Example 6, step 4, Example 7, ketone **51A** was converted into enantiopure compound **51** below.


#	Structure	Stereo designation	Name	[M+H] ⁺
51		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis-2,3,3a,4,9,9a-hexahydro-7-methyl-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	531.3

Example 52: Preparation of Intermediate (52B) for enantiopure 4-(Cyclopropyl(cis, cis-5,6-difluoro-3-(4-(trifluoromethoxy)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid (52)




[00344] To a stirring mixture of compound **52A** (10 g, 55.2 mmol, Beta Pharma, Inc., Branford, Connecticut) in 200 mL toluene in a sealed reaction vessel Ag_2CO_3 (75 g, 273 mmol) and MeI (3.75 mL, 59.9 mmol) was added. The resulting mixture was heated at 120°C overnight. The mixture was cooled to room temperature and filtered through a pad of Celite®. The filtrate was concentrated, and the residue was loaded on a pad of silica gel, eluting with EtOAc, to give 7.9 g (73%) desired product **52B** as a white solid.

[00345] Following procedures similar to those described in Example 1, Step 1, Example 25, Steps 1-3 (where chiral ketone was obtained via chiral HPLC resolution of the racemic ketone), Example 25, Step 4, Example 26, and Example 25 27, compound **52B** was converted into enantiopure compound **52** below.

#	Structure	Stereo designation	Name	[M+H] ⁺
52		cis, cis, single enantiomer	4-(cyclopropyl(cis, cis-5,6-difluoro-3-(4-(trifluoromethoxy)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	539.8


Example 53: Preparation of Enantiopure 4-(Cyclopropyl((cis, cis,)-4-(4-(trifluoromethoxy)benzoyl)-7-vinyl-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid (53)

Step 1



[00346] Enantiopure **53A** (180 mg, 0.289 mmol), 2,6-di-tert-butyl-4-methylphenol (6.36 mg, 0.029 mmol) and Palladium Tetrakis (16.7 mg, 0.014 mmol), tributyl(vinyl)stannane (110 mg, 0.346 mmol) and lithium chloride (36.7 mg, 0.866 mmol) were mixed in a microwave vial, degassed and refilled with nitrogen (3 times). The vial was placed in an oil bath at 100 °C overnight. The mixture was diluted with ethyl acetate (15 mL) and water (6 mL). The mixture was filtered through Celite®, and the filtrate was separated. The organic layer was washed with brine (1 x 5 mL), dried (MgSO_4), filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel silica gel (Si; 40 g prepacked), eluting with EtOAc/isohehexane = 1:3 to give **53B** (120 mg, 72% yield, $[\text{M}+\text{H}]^+$: 571) as a white foam.

Step 2




[00347] NaOH (1 M aq) (0.5 mL, 0.500 mmol) was added to a stirred mixture of enantiopure **53B** (30 mg, 0.053 mmol) in MeOH (0.5 mL) and THF (0.500 mL), and the mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with diethyl ether (3 mL), and water (2 mL) was added. The aqueous layer was separated, acidified with to pH 2-3, extracted with diethyl ether (3 x 2 mL), the combined organic was dried MgSO_4 , filtered and

concentrated. The residue was purified by preparative HPLC (reverse phase C-18), eluting with acetonitrile/water + 0.1% TFA, to give **53** (15 mg, 0.028 mmol, 52.6 % yield, $[M+H]^+$: 543.1) as a white foam. ^1H NMR (500 MHz, CDCl_3) δ ppm: 7.31 (d, $J = 8.5\text{Hz}$, 2H); 7.06 (d, $J = 8.5\text{ Hz}$, 2H); 6.94 (d, 1H); 6.85 (s, 1H); 6.61 (dd, $J_1 = 11\text{Hz}$, $J_2 = 17\text{Hz}$, 1H); 6.38 (d, $J = 8.5\text{Hz}$, 1H); 5.62 (d, $J = 17\text{ Hz}$, 1H); 5.22 (d, $J = 11\text{ Hz}$, 1H); 5.14 (m, 1H); 3.15 (m, 2H); 3.06 (m, 1H); 2.84 (m, 3H); 2.44 (m, 1H); 2.04 (m, 1H); 1.59 (m, 1H); 1.41 (m, 2H); 1.23 (m, 3H); 1.06 (m, 1H); 0.97 (m, 1H).


Example 54: Preparation of enantiopure 4-(Cyclopropyl((cis, cis)-7-ethyl-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid (54**)**

Step 1



[00348] Palladium on carbon 10% (5.0 mg, 4.70 μmol) was added to a stirred, room temperature mixture of enantiopure **53B** (25 mg, 0.044 mmol) in EtOH (1.500 mL) and EtOAc (0.5 mL). The mixture was stirred under hydrogen (using a balloon filled with hydrogen) at room temperature for overnight. The mixture was filtered, washing with ethanol. The filtrate was concentrated to obtain a white foam **54A** (16 mg, 64% yield, $[M+\text{Na}]^+ = 595$), which was used in the next step directly.


Step 2



[00349] NaOH (1 M aq) (0.028 mL, 0.028 mmol) was added to a stirred mixture of enantiopure **54A** (16 mg, 0.028 mmol) in MeOH (0.3 mL) and THF (0.3 mL) and the mixture was stirred at room temperature for 2 h. The mixture was concentrated, and the residue was purified by preparative HPLC (C-18 reverse phase solid phase), eluting with acetonitrile/water + 0.1% TFA, to give **54** (10 mg, 0.018 mmol, 65.7 % yield, $[M+H]^+ = 544.8$) as a white solid. ^1H NMR (500 MHz, CDCl_3) δ ppm: 7.28 (d, $J = 8\text{ Hz}$, 2H); 7.04 (d, $J = 8\text{ Hz}$, 2H); 6.71 (d, $J = 8\text{ Hz}$, 1H); 6.61 (s, 1H); 6.33 (d, $J = 8\text{ Hz}$, 1H); 5.16 (m, 1H); 3.13 (m, 2H); 3.05 (m, 1H); 2.83 (m, 3H); 2.55 (q, $J = 8\text{ Hz}$, 2H); 2.434 (m, 1H); 2.03 (m, 1H); 2.60 (m, 1H); 1.40 (m, 2H); 1.22 (m, 2H); 1.17 (t, $J = 8\text{ Hz}$, 3H); 1.19~0.93 (m, 3H).


Example 55: Preparation of Enantiopure 4-(Cyclopropyl((cis, cis)-7-(hydroxymethyl)-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid (55**)**

Step 1



[00350] Ozone was bubbled into a stirred, cooled $-78\text{ }^{\circ}\text{C}$ mixture of enantiopure **53B** (235 mg, 0.412 mmol) in DCM (2 mL) and MeOH (1.000 mL). The mixture was stirred at $-78\text{ }^{\circ}\text{C}$ for 15 min. until the mixture turned blue. Oxygen was bubbled in to remove the excess ozone, until the blue color disappeared. Dimethyl sulfide (0.2 mL, 2.70 mmol) was added, and the mixture was kept stirring at room temperature for 1 h. The mixture was diluted with DCM (10 mL), washed with water (5 mL), dried MgSO_4 , filtered and the solvent was evaporated under reduced pressure to obtain a white foam. The residue was purified by column chromatography on silica gel (Si; 40 g prepacked), eluting with EtOAc/isohexane = 1:1 to give **55A** (184 mg, 0.321 mmol, 78 % yield, $[M+H]^+ = 573$) as a white foam.


Step 2



[00351] Sodium borohydride (10.57 mg, 0.279 mmol) was added to a stirred, room temperature mixture of enantiopure **55A** (80 mg, 0.140 mmol) in DCM (1 mL) and MeOH (1 mL), and the mixture was stirred at room temperature overnight.

[00352] An LCMS analysis revealed that starting material along with product was present in the mixture. In addition, the ethyl ester was partially replaced by methyl ester. The mixture was cooled, diluted with dichloromethane (5 mL), washed with aqueous sodium hydrogen carbonate (saturated, 2 x 3 mL), dried (MgSO₄), filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel (Si; 24 g prepacked), eluting with EtOAc/isohexane = 1:1 to 3:1 to give **55B** (34 mg, 0.059 mmol, 42.4 % yield [$M+Na$]⁺ = 597) as a white solid.

Step 3




[00353] NaOH (1 M aq) (0.5 mL, 0.500 mmol) was added to a stirred mixture of enantiopure **55B** (10 mg, 0.017 mmol) in tetrahydrofuran (0.500 mL) and MeOH (0.5 mL), and the mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with water (1 mL), diethyl ether (1 mL) was added, the aqueous layer was separated, acidified with 2 M hydrochloric acid to pH 2~3, extracted with diethyl ether (2 x 2 mL), the combined organic was dried Na₂SO₄, filtered and concentrated to give **55** (8.3 mg, 0.015 mmol, 87 % yield [$M+Na$]⁺ = 568.8) as a white solid. ¹H NMR (500 MHz, CDCl₃) δ ppm: 7.32 (d, *J* = 8 Hz, 2H); 7.06 (d, *J* = 8 Hz, 2H); 6.76 (d, *J* = 8 Hz, 1H); 6.63 (d, *J* = 8 Hz, 1H); 5.16 (m, 1H); 4.60 (d, *J* = 12.5 Hz, 1H);

4.51 (d, $J = 12.5$ Hz, 1H); 3.12 ~ 2.70 (m, 5H); 2.37 (m, 1H); 1.95 (m, 1H); 1.46 (m, 2H); 1.24 ~ 1.07 (m, 5H).


Example 56: Preparation of enantiopure 4-(Cyclopropyl((cis, cis)-7-(fluoromethyl)-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid (56)

Step 1



[00354] DEOXO-FLUOR (bis(2-methoxyethyl)aminosulfur trifluoride) (0.2 mL, 1.085 mmol) was added to a stirred, room temperature mixture of enantiopure **55B** (24 mg, 0.042 mmol) in tetrahydrofuran (1 mL) and the mixture was stirred at 80 °C for 6 h. The mixture was cooled, poured into icy water (1 mL), diluted with ethyl acetate (5 mL), and basified with NaHCO_3 (saturated 3 mL). The organic layer was separated, washed with brine (saturated, 1 x 3 mL), dried (MgSO_4), filtered and the solvent was evaporated under reduced pressure obtained a light brown foam, **56A** (27 mg, 0.047 mmol, $[\text{M}+\text{Na}]^+ = 599$), which was used directly in the hydrolysis step.

Step 2




[00355] NaOH (1M aq) (1 mL, 1.000 mmol) was added to a stirred mixture of enantiopure **56A** (27 mg, 0.047 mmol) in MeOH (1.000 mL) and tetrahydrofuran (1 mL), and the mixture

was stirred at room temperature for 2 h. The reaction mixture was diluted with water (1 mL), and diethyl ether (2 mL) was added. The aqueous layer was separated, acidified to pH 2~3, extracted with diethyl ether (3x 2 mL). The combined organic were dried over MgSO_4 , filtered and concentrated. The reaction mixture was concentrated and the residue was purified by preparative TLC with CH_2Cl_2 /isohexane/MeOH/AcOH (1%), to give **56** (15 mg, 0.027 mmol, 58.4 % yield, $[\text{M}+\text{H}]^+ = 549.1$) as a white solid. ^1H NMR (500 MHz, CDCl_3) δ ppm: 7.30 (d, $J = 8\text{ Hz}$, 2H); 7.06 (d, $J = 8\text{ Hz}$, 2H); 6.87 (m, 2H); 6.45 (d, $J = 8\text{ Hz}$, 1H); 5.33 (dd, $J_1 = 6\text{ Hz}$, $J_2 = 17\text{ Hz}$, 1H); 5.23 (dd, $J_1 = 6\text{ Hz}$, $J_2 = 17\text{ Hz}$, 1H); 5.14 (m, 1H); 3.10 (m, 3H); 2.85 (m, 1H); 2.81 (m, 2H); 2.44 (m, 1H); 2.02 (m, 1H); 1.56 (m, 1H); 1.41 (m, 2H); 1.21 ~1.07 (m, 7H).


Example 57: Preparation of enantiopure 4-(cyclopropyl((cis, cis,)-7-(difluoromethyl)-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid (57)

Step 1



[00356] DEOXO-FLUOR (bis(2-methoxyethyl)aminosulfur trifluoride) (0.077 mL, 0.419 mmol) was added to a stirred, room temperature mixture of enantiopure **55A** (60 mg, 0.105 mmol) in THF (1 mL) and the mixture was stirred at 80 °C overnight. LCMS check revealed that both starting material and product were present in the mixture. More DEOXO-FLUOR (0.077 mL, 0.419 mmol) was added. The reaction mixture was heated at 80 °C overnight. The mixture was cooled, poured into icy water (3 mL), diluted with ethyl acetate (10 mL), basified with saturated NaHCO_3 (5 mL), the organic was separated, washed with brine (1x 5 mL), dried (MgSO_4), filtered and the solvent was evaporated under reduced pressure to obtain a light brown foam. The residue was purified by preparative HPLC (Reverse phase C-18), eluting with acetonitrile/water + 0.1% TFA, to give **57A** (25 mg, 0.032 mmol, 30.1 % yield, $[\text{M}+\text{H}]^+ = 595$) as a yellow gum.






Step 2









[00357] NaOH (1 M aq) (0.042 mL, 0.042 mmol) was added to a stirred mixture of enantiopure **57A** (25 mg, 0.042 mmol) in MeOH (1 mL) and tetrahydrofuran (1.000 mL). The mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with water (1 mL), and diethyl ether (2 mL) was added. The aqueous layer was separated, acidified with hydrochloric acid 2 M to pH 2~3, and extracted with diethyl ether (3 x 2 mL). The combined organic layer was dried (MgSO₄), filtered and concentrated. The residue was purified by preparative TLC, CH₂Cl₂/isohexane/MeOH/AcOH (1%) = 2:1: 0.4. The residue was further purified by preparative HPLC (reverse phase C-18), eluting with acetonitrile/water + 0.1% TFA, to give **57** (8.3 mg, 0.015 mmol, 34.8 % yield, [M+H]⁺ = 567) as a white foam. ¹H NMR (500 MHz, CDCl₃) δ ppm: 7.29 (d, *J* = 8 Hz, 2H); 7.07 (d, *J* = 8 Hz, 2H); 7.04 (d, *J* = 8 Hz, 1H); 6.98 (m, 1H); 6.57 (t, *J* = 11.5 Hz, 1H); 6.51 (d, *J* = 8 Hz, 1H); 5.13 (m, 1H); 3.11 (m, 3H); 2.87 (m, 1H); 2.81 (m, 2H); 2.44 (m, 1H); 2.02 (m, 1H); 1.55 (m, 1H); 1.41 (m, 2H); 1.23 (m, 1H); 1.12 ~0.98 (m, 4H).







The following compounds were prepared following procedures similar to those described in the examples above.







#	Structure	Stereo designation	Name	[M+H] ⁺
58		cis, cis (enantiopure), R-configuration at azetidine, single enantiomer	4-(phenylmethyl) cis, cis-[[[(2(R)-carboxy-1-azetidiny)carbonyl]cyclopentylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	490.3







59		cis, cis (enantiopure), S- configuration at azetidine, single enantiomer	4-(phenylmethyl) cis, cis- [[2(S)-carboxy-1- azetidiny]carbonyl]cyclopr opylamino]-1,2,3,3a,9,9a- hexahydro-4H- cyclopenta[b]quinoline-4- carboxylate	490.3
60		cis, cis, single enantiomer	4-(phenylmethyl) cis, cis- [(3- carboxypropyl)cyclopropyl amino]-1,2,3,3a,9,9a- hexahydro-4H- cyclopenta[b]quinoline-4- carboxylate	449.2
61		cis, cis, single enantiomer	4-[ethyl[cis, cis-4-(4- fluorobenzoyl)- 2,3,3a,4,9,9a-hexahydro- 1H-cyclopenta[b]quinolin- 9-yl]amino]-4-oxobutanoic acid	439.2
62		cis, cis, single enantiomer	4-[[cis, cis-4-(3,4- difluorobenzoyl)- 2,3,3a,4,9,9a-hexahydro- 1H-cyclopenta[b]quinolin- 9-yl]ethylamino]-4- oxobutanoic acid	457.3
63		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis- 2,3,3a,4,9,9a-hexahydro-4- [4- [(trifluoromethyl)thio]benz oyl]-1H- cyclopenta[b]quinolin-9- yl]amino]-4-oxobutanoic acid	533.3







64		cis, cis, single enantiomer	4-[[cis, cis-4-(3,5-difluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]ethylamino]-4-oxobutanoic acid	457.3
65		cis, cis, single enantiomer	4-[ethyl[cis, cis-4-(4-ethylbenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	449.2
66		cis, cis, single enantiomer	4-[ethyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-(3,4,5-trifluorobenzoyl)-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	475.3
67		cis, cis, single enantiomer	4-[ethyl[cis, cis-4-[4-fluoro-3-(trifluoromethyl)benzoyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	507.3
68		cis, cis, single enantiomer	4-[ethyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	489.3
69		(cis, cis,); trans at cyclopropyl (enantiopure); single enantiomer	4-[ethyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[(2-phenyl-1-cyclopropyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	461.3







70		cis, cis, single enantiomer	4-[cyclobutyl[cis, cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]butanoic acid	517.3
71		cis, cis, single enantiomer	4-[(4-fluorophenyl)methyl] cis, cis-[(3-carboxy-1-oxopropyl)ethylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	469.3
72		cis, cis, single enantiomer	4-[(3,4-difluorophenyl)methyl] cis, cis-[(3-carboxy-1-oxopropyl)ethylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	487.3
73		cis, cis, single enantiomer	4-[(3,5-difluorophenyl)methyl] cis, cis-[(3-carboxy-1-oxopropyl)ethylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	487.3
74		cis, cis (enantiopure), racemic at benzylic methyl.	4-(1-phenylethyl) cis, cis-[(3-carboxy-1-oxopropyl)ethylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	465.3
75		cis, cis, single enantiomer	4-[[4-(trifluoromethyl)phenyl]methyl] cis, cis-[(3-carboxy-1-oxopropyl)ethylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	519.3






76		cis, cis, single enantiomer	4-[(3-fluorophenyl)methyl] cis, cis-[(3-carboxy-1-oxopropyl)ethylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	469.3
77		(cis, cis), S configuration at benzylic carbon atom, single enantiomer	4-(2,2,2-trifluoro-1(S)-phenylethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	531.3
78		(cis, cis), R configuration at benzylic carbon atom, single enantiomer	4-(2,2,2-trifluoro-1(R)-phenylethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	531.3
79		cis, cis, single enantiomer	(cis, cis)-4H-cyclopenta[b]quinoline-4-carboxylic acid, 9-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-, 4-(8-quinolinylmethyl) ester	514.3
80		cis, cis, single enantiomer	4-((cis, cis-3-(biphenylcarbonyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(ethyl)amino)-4-oxobutanoic acid	483.2
81		cis, cis, single enantiomer	4-(ethyl(cis, cis-3-(thiophene-2-carbonyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	413.2






82		cis, cis, single enantiomer	4-(ethyl(cis, cis-3-(4-fluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	425.2
83		cis, cis, single enantiomer	4-(ethyl(cis, cis-3-(4-(trifluoromethylthio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	507.2
84		cis, cis, single enantiomer	4-(ethyl(cis, cis-3-(4-ethylbenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	435.2
85		cis, cis, single enantiomer	4-((cis, cis-3-(3,5-difluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(ethyl)amino)-4-oxobutanoic acid	443.2
86		cis, cis, single enantiomer	4-(ethyl(cis, cis-3-(3,4,5-trifluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	461.2
87		cis, cis, single enantiomer	4-(ethyl(cis, cis-3-(4-fluoro-3-(trifluoromethyl)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	493.2

88		cis, cis, single enantiomer	4-(ethyl(cis, cis-3-(4-(trifluoromethyl)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	475.2
89		cis, cis, single enantiomer	4-(ethyl(cis, cis-3-((4-fluorobenzyloxy)carbonyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	455.1
90		cis, cis, single enantiomer	4-((cis, cis-3-((3,4-difluorobenzyloxy)carbonyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(ethyl)amino)-4-oxobutanoic acid	473.1
91		cis, cis, single enantiomer	4-(ethyl(cis, cis-3-((4-(trifluoromethyl)benzyloxy)carbonyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	505.1
92		cis, cis, single enantiomer	4-(ethyl(cis, cis-3-((3-fluorobenzyloxy)carbonyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	455.1
93		cis, cis, single enantiomer	4-(ethyl(cis, cis-3-((4-(methylthio)benzyloxy)carbonyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	483.1






94		cis, cis, single enantiomer	4-((cis, cis-3-((benzofuran-5-ylmethoxy)carbonyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(ethyl)amino)-4-oxobutanoic acid	477.2
95		cis, cis, single enantiomer	4-((cis, cis-3-(benzo[d][1,3]dioxole-5-carbonyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(ethyl)amino)-4-oxobutanoic acid	451.2
96		cis, cis, single enantiomer	4-((cis, cis-3-(1-naphthoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(ethyl)amino)-4-oxobutanoic acid	457.2
97		cis, cis, single enantiomer	4-((cis, cis-3-(2,4-difluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(ethyl)amino)-4-oxobutanoic acid	443.2
98		cis, cis (enantiopure), trans at cyclopropyl ring racemic	4-(ethyl(cis, cis-3-(2-phenylcyclopropanecarbonyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	447.2
99		cis, cis, single enantiomer	4-((cis, cis-3-(benzyloxycarbonyl)-6-phenyl-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)amino)-4-oxobutanoic acid	525.2







100		cis, cis, single enantiomer	3-[[4-(trifluoromethyl)phenyl]methyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-fluoro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate	535
101		cis, cis (enantiopure), single enantiomer	3-(1(S)-phenylethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-fluoro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate	481
102		cis, cis, single enantiomer	3-[(3-fluorophenyl)methyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-fluoro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate	485
103		cis, cis (racemic), racemic at alpha carbon of acid chain	4-(phenylmethyl) cis, cis-[(2(RS)-carboxypropyl)amino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	409
104		cis, cis, racemic; R configuration at beta carbon of acid chain	4-(phenylmethyl) cis, cis-9-[(3-carboxy-2(R)-methyl-1-oxopropyl)ethylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	465
105		all cis, racemic; R configuration at alpha carbon of acid chain	4-(phenylmethyl) cis, cis-9-[(3(R)-carboxy-1-oxobutyl)ethylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	465






106		cis, cis (enantiopure), single enantiomer, R configuration at alpha carbon of acid chain	(R)-4-(((cis, cis)-4- (benzyloxycarbonyl)- 2,3,3a,4,9,9a-hexahydro- 1H-cyclopenta[b]quinolin- 9-yl)(cyclopropyl)amino)- 2-methyl-4-oxobutanoic acid	477
107		cis, cis, single enantiomer	4-((cis, cis-3- (benzyloxycarbonyl)-6- chloro-1,2,2a,3,8,8a- hexahydrocyclobuta[b]quin olin-8- yl)(cyclopropyl)amino)-4- oxobutanoic acid	484
108		cis, cis, single enantiomer	4-((cis, cis-3- (benzyloxycarbonyl)-6- chloro-1,2,2a,3,8,8a- hexahydrocyclobuta[b]quin olin-8- yl)(cyclopropyl)amino)buta noic acid	470
109		cis, cis (enantiopure), single enantiomer	(R)-4-((cis, cis-3- (benzyloxycarbonyl)- 1,2,2a,3,8,8a- hexahydrocyclobuta[b]quin olin-8-yl)(ethyl)amino)-3- methyl-4-oxobutanoic acid	451
110		cis, cis, single enantiomer	3-(phenylmethyl) cis, cis- [(3-carboxy-1- oxopropyl)(2- hydroxyethyl)amino]- 2,2a,8,8a- tetrahydrocyclobuta[b]quin oline-3(1H)-carboxylate	474.9 [M+Na] ⁺






111		cis, cis, single enantiomer	3-(phenylmethyl) deuterated-cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate-(8D)	449.9
112		cis, cis, single enantiomer	4-[[3-fluoro-4-(trifluoromethoxy)phenyl]methyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	565.3
113		cis, cis, single enantiomer	4-(2-pyridinylmethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	464.3
114		cis, cis, single enantiomer	4-(2-thienylmethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	469
115		cis, cis, single enantiomer 1	3-(phenylmethyl) 8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5,6-difluoro-2,2a,8,8a-tetrahydro-cyclobuta[b]quinoline-3(1H)-carboxylate	485.2






116		cis, cis, single enantiomer 2	3-(phenylmethyl) 8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5,6-difluoro-2,2a,8,8a-tetrahydro-cyclobuta[b]quinoline-3(1H)-carboxylate	485.2
117		cis, cis, single enantiomer	4-((cis, cis-3-(benzyloxycarbonyl)-5,6-difluoro-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)amino)butanoic acid	470.8
118		cis, cis, single enantiomer	4-(phenylmethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	515.3
119		cis, cis, single enantiomer	3-(phenylmethyl) cis,cis-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5,6-dichloro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate	519.3
120		cis, cis, single enantiomer	3-(phenylmethyl) cis,cis-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5,6-dichloro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate	519.3






121		cis, cis, single enantiomer	4-[cyclopropyl][cis, cis-5,6-dichloro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid	573.3
122		racemic, cis, cis	4-[(cyclobutylmethyl)[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]butanoic acid	531
123		racemic, cis, cis	4-[(cyclopentylmethyl)[cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]butanoic acid	545
124		cis, cis, single enantiomer	3-(phenylmethyl) deuterated-cis,cis-8-[(3-carboxypropyl)cyclopropyl amino]-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate-(8D)	436
125		3aS,9R,9aR, single enantiomer	4-(phenylmethyl) (3aS,9R,9aR)-9-[(3-carboxypropyl)cyclopropyl amino]-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	467






126		racemic, cis, cis	4-[[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl](2-phenylethyl)amino]butanoic acid	567
127		racemic, cis, cis	4-[[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl](2-oxazolylmethyl)amino]butanoic acid	544
128		racemic, cis, cis	4,4'-[[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]imino]bisbutanoic acid	549
129		racemic, cis, cis	4-[[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]phenylamino]butanoic acid	561
130		cis, cis, single enantiomer	4-[cyclopropyl[cis,cis-4-(4-fluorobenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino]butanoic acid	437
131		cis, cis, single enantiomer	4-(phenylmethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	462.9






132		cis, cis, single enantiomer	4-(phenylmethyl) deuterated-cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate-(9D)	463.9
133		3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i> , single enantiomer, R configuration at azetidine carbon atom	4-(phenylmethyl) (3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i>)-[[[2(<i>R</i>)-carboxy-1-azetidiny]carbonyl]cyclopropylamino]-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	507.9
134		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	534.8
135		cis, cis, single enantiomer	4-[cyclopropyl[cis, cis-6-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxo-butanoic acid	534.8
136		3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i> , single enantiomer	4-[cyclopropyl[(3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i>)-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[3-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid	534.8






137		cis, cis, single enantiomer, R configuration at benzylic carbamate	4-(1(R)-phenylbutyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	526.8 [M+Na] ⁺
138		cis, cis, single enantiomer, S configuration at benzylic carbon of carbamate	4-(1(S)-phenylbutyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	526.8 [M+Na] ⁺
139		cis, cis, single enantiomer, S configuration at benzylic carbamate	4-(1(S)-phenylpropyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	512.8 [M+Na] ⁺
140		cis, cis (enantiopure), racemic at benzylic carbamate	4-[1-[4-(trifluoromethoxy)phenyl]ethyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	582.7 [M+Na] ⁺
141		cis, cis, single enantiomer, R at benzylic carbamate	4-(1(R)-phenylpropyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	512.8 [M+Na] ⁺





142		cis, cis, single enantiomer, racemic at benzylic carbamate	4-(cyclopropylphenylmethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	502.8
143		cis, cis (enantiopure), racemic at benzylic carbamate	4-[1-(4-methoxyphenyl)ethyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	529.2 [M+Na] ⁺
144		cis, cis, single enantiomer, S configuration at benzylic carbamate	4-(1(S)-phenylethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	516.8 [M+Na] ⁺
145		cis, cis, single enantiomer, R configuration at benzylic carbamate	4-(1(R)-phenylethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	516.8 [M+Na] ⁺
146		cis, cis, single enantiomer, S configuration at benzylic carbamate	4-[1(S)-(4-fluorophenyl)ethyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	534.8 [M+Na] ⁺

147		cis, cis, single enantiomer, R configuration at benzylic carbamate	4-[1(R)-(4-fluorophenyl)ethyl] cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	534.7 [M+Na] ⁺
148		cis, cis, single enantiomer	4-(2-pyridinylmethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	481.8
149		cis, cis, single enantiomer	4-(2,3-dihydro-1H-inden-2-yl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	506.8
150		cis, cis, single enantiomer	4-(phenylmethyl) cis, cis-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate	480.8
151		cis, cis, single enantiomer; R at acid side chain	(R)-1-((cis, cis-3-(benzyloxycarbonyl)-5,6-difluoro-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)carbamoyl)azetidine-2-carboxylic acid	533.7 [M+Na] ⁺

152		3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i> single enantiomer	4-(((3a <i>S</i> ,9 <i>R</i> ,9a <i>R</i>)-4-(benzo[d]thiazole-2-carbonyl)-7-fluoro-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[b]quinolin-9-yl)(cyclopropyl)amino)-4-oxobutanoic acid	507.8
153		cis, cis, single enantiomer	4-(cyclopropyl((cis, cis)-7-(4-fluorophenyl)-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid	610.6
154		cis, cis, single enantiomer	4-(((cis, cis)-4-((benzo[d]thiazol-2-ylmethoxy)carbonyl)-6-fluoro-2,3,3a,4,9,9a-hexahydro-1 <i>H</i> -cyclopenta[b]quinolin-9-yl)(cyclopropyl)amino)-4-oxobutanoic acid	537.8
155		cis, cis, single enantiomer, racemic at benzylic carbon of the alcohol	4-((cis, cis-3-((benzyloxy)carbonyl)-6-(1-hydroxyethyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)amino)-4-oxobutanoic acid	515 [M+Na]
156		cis, cis, single enantiomer	4-((cis, cis-3-((benzyloxy)carbonyl)-6-(difluoromethyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)amino)-4-oxobutanoic acid	499


157		single enantiomer, cyclopropylamine trans to cyclobutyl ring, cyclobutyl ring cis fused	4-(cyclopropyl(cis, trans-8a-methyl-3-(4-(trifluoromethoxy)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	517
158		single enantiomer, cyclobutyl ring cis fused, cyclopropylamine cis to cyclobutyl ring	4-(cyclopropyl(cis, cis-8a-methyl-3-(4-(trifluoromethoxy)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	517
159		cis, cis, single enantiomer	4-(cyclopropyl(cis, cis-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	519
160		single enantiomer, cyclopentyl ring cis fused, cyclopropylamine cis to cyclopentyl ring	4-((cis, cis-4-((benzyloxy)carbonyl)-9a-methyl-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)(cyclopropyl)amino)-4-oxobutanoic acid	477
161		single enantiomer, cyclopentyl ring cis fused, cyclopropylamine cis to cyclopentyl ring	4-((cis, cis-4-((benzyloxy)carbonyl)-9a-methyl-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)(cyclopropyl)amino)butanoic acid	463

162		cis, cis, single enantiomer	4-(cyclopropyl(cis, cis-4-(4-cyclopropylbenzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid	473
163		cis, cis, single enantiomer	4-(cyclopropyl(cis, cis-4-(6-(trifluoromethyl)nicotinoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid	502
164		cis, cis, single enantiomer	4-(ethyl(cis, cis-6-fluoro-3-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	525
165		3aS,9R,9aR, single enantiomer	4-(ethyl((3aS,9R,9aR)-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid	539
166		3aS,9R,9aR, single enantiomer	4-(cyclopropyl((3aS,9R,9aR)-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid	551

167		cis, cis, single enantiomer	4-(cyclopropyl(cis, cis-6-fluoro-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid	537
168		cis, cis, single enantiomer	4-(cyclopropyl(cis, cis-7-cyclopropyl-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid	557
169		cis, cis, single enantiomer	4-(cyclopropyl(cis, cis-7-(pyrimidin-5-yl)-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid	595
170		3aS,9R,9aR, Single enantiomer	4-(cyclopropyl((3aS,9R,9aR)-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)butanoic acid	521


Example 171: Preparation of 4-(Cyclopropyl-(3a*S*,9*R*,9a*R*)-7-fluoro-4-(2-hydroxy-4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl)amino)-4-oxobutanoic acid (171)

Step 1



[00358] A mixture of 2-methoxy-4-(trifluoromethoxy)benzoic acid (70.9 mg, 0.300 mmol) in thionyl chloride (2 mL, 27.4 mmol) was heated up 40 °C for 2 h before the mixture was cooled and then concentrated under reduced pressure to remove the excess thionyl chloride. The residue was taken up in dichloromethane (2 mL), the solution was added to a stirred, room temperature mixture of ethyl 4-(cyclopropyl((3a*S*,9*R*,9a*R*)-7-fluoro-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl)amino)-4-oxobutanoate (75 mg, 0.200 mmol), DMAP (4.89 mg, 0.040 mmol) and Hunig's Base (0.105 mL, 0.601 mmol) in dichloromethane (2 mL) and the mixture was stirred at room temperature for overnight before it was diluted with dichloromethane (10 mL), washed with aqueous sodium hydroxide (0.5 M, 2 x 6 mL), dried (MgSO₄), filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel 40 g prepacked column, eluting with EtOAc/isohexane = 50% to give ethyl 4-(cyclopropyl((3a*S*,9*R*,9a*R*)-7-fluoro-4-(2-methoxy-4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl)amino)-4-oxobutanoate **171A** (73 mg, 0.123 mmol, 61.5 % yield) as a white foam.


Step 2



[00359] 1 M BBr₃ (0.089 mL, 0.089 mmol) in dichloromethane was added to a stirred mixture of ethyl 4-(cyclopropyl((3a*S*,9*R*,9a*R*)-7-fluoro-4-(2-methoxy-4-

(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoate (42 mg, 0.071 mmol) in dichloromethane (5 mL) at -78 °C and the mixture was stirred at -78°C for 30 min. then room temperature for 1 h. LCMS showed the reaction was complete. The mixture was concentrated, the residue was taken up in MeOH (1.0 mL) and tetrahydrofuran (1.0 mL), NaOH (1 M aq) (0.284 mL, 0.284 mmol) was added, the mixture was kept stirring at room temperature for 2 h. The reaction mixture was diluted with water (5 mL), diethyl ether (20 mL) was added. The aqueous layer was separated, acidified with 2 M hydrochloric acid to pH ~3, extracted with dichloromethane (2 x 10 mL), the combined organic was dried MgSO₄, filtered and concentrated. The residue was purified by column chromatography on silica gel; 24 g prepacked column, eluting with CH₂Cl₂/MeOH = 6% to 4-(Cyclopropyl-(3a*S*,9*R*,9a*R*)-7-fluoro-4-(2-hydroxy-4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid **171** (35 mg, 0.064 mmol, 90 % yield) as a white solid; [M+H⁺] = 551.2.


Example 172: Preparation of 4-(Cyclopropyl-(3a*S*,9*R*,9a*R*)-7-fluoro-4-(2-methoxy-4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid (172**)**



[00360] NaOH (1 M aq) (0.017 mL, 0.017 mmol) was added to a stirred, room temperature mixture of ethyl 4-(cyclopropyl((3a*S*,9*R*,9a*R*)-7-fluoro-4-(2-methoxy-4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoate (10 mg, 0.017 mmol) in MeOH (1 mL) and tetrahydrofuran (1.0 mL), and the mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with water (2 mL), diethyl ether (2 mL) was added. The aqueous layer was separated, acidified with hydrochloric acid (1 M) to pH ~3, extracted with dichloromethane (2 x 3mL), the combined organic was dried (MgSO₄), filtered and concentrated to give 4-(cyclopropyl(3a*S*,9*R*,9a*R*)-7-fluoro-4-(2-methoxy-4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid **172** (4.5 mg, 7.97 μmol, 47.2 % yield) as a white foam; [M+H⁺] = 565.2


Example 173: Preparation of 4-(Cyclopropyl-(3a*S*,9*R*,9a*R*)-7-fluoro-4-(3-hydroxy-4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl)amino)-4-oxobutanoic acid (173)

Step 1




[00361] NaH (1.647 g, 41.2 mmol) was added to a stirred, 0 °C mixture of methyl vanillate (5 g, 27.4 mmol) in DMF (30 mL) and the mixture was stirred at 0 °C for 30 min. Dibromodifluoromethane (14.96 mL, 165 mmol) in DMF (30 mL) was then added via an additional funnel, the resultant mixture was allowed to warm up to 50°C and kept stirring at 50°C for 16 h. The mixture was cooled, diluted with ethyl acetate (150 mL), washed with water (100 mL), the organic was washed with brine (100 mL), dried (MgSO₄), filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on; 120 g prepacked column, eluting with 10% EtOAc/isohexane to give methyl 4-(bromodifluoromethoxy)-3-methoxybenzoate **173A** (1.5 g, 4.82 mmol, 17.57 % yield) as a colorless liquid.


Step 2



[00362] Antimony (V) Chloride (26.4 mg, 0.088 mmol) was added to a stirred, room temperature mixture of **173A** (550 mg, 1.768 mmol) and antimony trifluoride (221 mg, 1.238 mmol) in a sealed tube, and the mixture was stirred at 170 °C for 4 h. The mixture was cooled, diluted with diethyl ether (50 mL), washed with water (50 mL), dried (MgSO₄), filtered and the solvent was evaporated under reduced pressure. The residue was purified by column chromatography on silica gel; 24 g prepacked column, eluting with EtOAc/isohexane= 10% to give methyl 3-methoxy-4-(trifluoromethoxy)benzoate **173B** (240 mg, 0.959 mmol, 54.3 % yield) as a white solid.

Step 3


[00363] NaOH (1 M aq) (1 mL, 1.000 mmol) was added to a stirred, room temperature mixture of **179B** (120 mg, 0.480 mmol) in tetrahydrofuran (2 mL) MeOH (2.000 mL), and the mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with diethyl ether (10 mL), water (2 mL) was added, the aqueous layer was separated, acidified with hydrochloric acid (2 M) to pH 2~3, extracted with dichloromethane (3 x 6 mL). The combined organic layers were dried (MgSO_4), filtered and concentrated to give 3-methoxy-4-(trifluoromethoxy)benzoic acid **173C** (110mg, 0.466 mmol, 97 % yield) as a white solid.

Steps 4 and 5

[00364] 3-methoxy-4-(trifluoromethoxy)benzoic acid was converted to 4-(cyclopropyl-(3aS,9R,9aR)-7-fluoro-4-(3-hydroxy-4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid **173** as a white solid ($[\text{M}+\text{H}]^+ = 551.2$) by following similar procedure as described in Steps 1 and 2 of Example 171.


Example 172: Preparation of 6-((4-(Cyclopropyl-(3a*S*,9*R*,9a*R*)-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl)amino)-4-oxobutanoyl)oxy)-3,4,5-trihydroxytetrahydro-2*H*-pyran-2-carboxylic acid (174)

Step 1



N-methylmorpholine (0.077 mL, 0.702 mmol) was added to a stirred mixture of 4-((cyclopropyl((3a*S*,9*R*,9a*R*)-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl)amino)-4-oxobutanoic acid (150 mg, 0.281 mmol), HATU (133 mg, 0.351 mmol) and benzyl 3,4,5,6-tetrahydroxytetrahydro-2*H*-pyran-2-carboxylate (100 mg, 0.351 mmol) in acetonitrile (3 mL) and the mixture was stirred at room temperature for 3 h. TLC showed clean reaction (MeOH in DCM 10%). Solvent was removed and the residue was purified by column chromatography on silica gel (24 g prepacked column) eluting with DCM/MeOH gradient up to 20% MeOH to give benzyl 6-((4-(cyclopropyl((3a*S*,9*R*,9a*R*)-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl)amino)-4-oxobutanoyl)oxy)-3,4,5-trihydroxytetrahydro-2*H*-pyran-2-carboxylate **174A** (0.23 g).

Step 2



[00365] Palladium on carbon (80 mg, 0.752 mmol) was added to a stirred mixture of benzyl 6-((4-(cyclopropyl((3a*S*,9*R*,9a*R*)-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl)amino)-4-oxobutanoyl)oxy)-3,4,5-trihydroxytetrahydro-2*H*-pyran-2-carboxylate (0.23 g, 0.29 mmol) and cyclohexadiene (1.5 mL, 0.293 mmol) in isopropanol (7.5 mL) and cyclopentylmethyl ether (7.50 mL) and the mixture

was stirred at 60 °C for 1 h. The mixture was filtered through a Celite® pad and washed with ether/isopropanol (1/1). Solvent was removed to give crude product which was purified using reverse phase HPLC to give 6-((4-(cyclopropyl((3*aS*,9*R*,9*aR*)-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3*a*,4,9,9*a*-hexahydro-1*H*-cyclopenta[*b*]quinolin-9-yl)amino)-4-oxobutanoyl)oxy)-3,4,5-trihydroxytetrahydro-2*H*-pyran-2-carboxylic acid **174** (140 mg), $[M+H]^+ = 710.1$.

BIOLOGICAL ASSAYS

Radioligand Binding Assays

[00366] Certain representative compounds of the invention were tested in Radioligand Binding Assay A and others were tested in Radioligand Binding Assay B.

Radioligand binding assay A.

[00367] Radioligand Binding Assay A was performed at room temperature in 50 mM Tris-HCl pH 7.4, 1 mM EDTA containing 2 mM MnCl₂ and 3.0 nM [³H]PGD₂ (New England Nuclear, Boston, MA) (171 Ci mmol⁻¹), in a final volume of 0.2 mL. Competing ligands were diluted in dimethylsulfoxide (Me₂SO) that was kept constant at 1% (v/v) of the final incubation volume. The reaction was initiated by the addition of 8-20 µg of membrane protein prepared from a human embryonic kidney (HEK)-hCRTH₂ cell line. Total and non-specific binding were determined in the absence and the presence of 10 µM PGD₂, respectively. Under these conditions, specific binding (total minus non-specific) of the radioligand to the receptor reached equilibrium within 50 min and was stable up to 180 min. The reaction was routinely conducted for 60 min at room temperature and terminated by rapid filtration through prewetted (0.3% polyethyleneimine) 96-well printed filtermateTM (Wallac) using a Tomtec® harvester (Hamden, CT). After washing with cold buffer, the filter was dried for 2 minutes in microwave, and Meltilex Scintillator sheet (Wallac) was melted on for 2 min. The radioactivity was measured with Betaplate model 1205 (Wallac). Table A below lists representative compounds of the invention with binding data which were tested in Radioligand Binding Assay A whereby the K_i values are rated "A", "B," "C," or "D." The K_i values are rated "A" for K_i values in the range of 1.0 to 5.0 nM, "B" for K_i values in the range from 5.1-20.0 nM, "C" for K_i values in the range from 20.1-200 nM, and "D" for K_i values in the range from 201-7500 nM. The designation "N.A." indicates that data is unavailable for that entry.

Table A

No.	Ki (nM)
9	B
9A	A
9B	B
11	D
11A	C
11B	C
11C	B
17	B
17G	B
17i	C
17J	D
17K	B
17L	B
17M	C
17R	D
17S	B
17T	C
17U	D
17V	C
17W	B
17X	C
17Y	C
17Z	C
17AA	C
17AB	C
17AC	B
17AD	B
17AE	D
17AF	D
17AG	C
17AH	B
17Ai	B
17AJ	C
17AK	A
17AL	B
17AM	C
17AN	C
17Ao	C
17AP	B
17AQ	C
17AR	B
17AS	C
17AT	B
17AU	B
17AV	B
17AW	B

No.	Ki (nM)
27K	A
27L	A
27M	B
27N	B
27o	A
27Q	B
27R	B
27S	A
32	C
32C	C
32D	C
32E	A
32F	A
32G	A
32H	A
32i	A
32J	A
32K	A
32L	A
32M	A
32N	A
32O	A
32P	B
32Q	A
32R	B
32S	A
32T	A
32U	A
33	D
34	D
35	B
35D	B
35E	C
35F	D
35G	D
35H	B
35i	B
35J	B
35K	B
38	C
38D	B
38E	C
38F	B
38G	D
40	C
41	D

No.	Ki (nM)
17AX	B
17AY	C
17AZ	C
17BA	C
17BB	C
17BC	C
17BD	C
17BE	B
17BF	C
17BG	B
17BH	B
17Bi	B
17BJ	C
17BK	B
17BL	C
17BM	A
17BN	B
17Bo	A
17BP	B
17BQ	B
17BR	B
17BS	B
17BT	A
17BU	A
17BV	B
17BW	B
17BX	D
17BY	A
17BZ	D
17CA	A
17CB	B
17CC	A
17CD	A
17CE	A
17CF	B
17CG	B
17CH	B
17Ci	D
17CJ	D
17CK	A
17CL	B
17CM	B
17CN	B
17Co	B
17CP	B
18CQ	A
17CR	A

No.	Ki (nM)
42	C
43	B
43B	A
43C	C
44	A
44B	D
44C	C
44D	A
44E	B
44F	C
45	C
46	D
47	D
47D	B
47E	N.A.
47F	D
47G	D
48	B
48C	D
49	C
49B	B
50	C
51	B
52	A
53	B
54	C
55	C
56	B
57	B
58	C
59	D
60	C
61	B
62	B
63	B
64	B
65	B
66	B
67	B
68	B
69	A
70	C
71	A
72	B
73	C
74	C
75	B

No.	Ki (nM)
17CS	B
17CT	A
17CU	A
17CV	A
17CW	B
17CX	A
17CY	A
17CZ	B
17DA	C
17DB	C
17DC	C
17DD	C
17DE	B
17DF	D
17DG	D
17DH	B
17Di	C
17DJ	B
17DK	B
17DL	A
17DN	B
17Do	D
18	C
18C	A
18D	B
18E	B
18F	C
18G	B
18H	C
18i #	C
18J	B
18K	B
18L	A
18M	A
18N	C
18o	B
18P	C
18Q	C
18R	B
18S	B
18T	C
19	D
20	C
22	B
22A	D
22D	A
22E	B

No.	Ki (nM)
76	B
77	C
78	B
79	C
80	B
81	A
82	B
83	A
84	B
85	C
86	C
87	B
88	B
89	C
90	C
91	C
92	C
93	C
94	C
95	C
96	B
97	C
98	B
99	D
100	A
101	D
102	D
103	D
104	D
105	D
106	D
107	B
108	B
109	C
110	D
111	B
112	C
113	C
114	C
115	D
116	A
117	A
118	B
119	A
120	D
121	A
122	C

No.	Ki (nM)
22F	B
22G	B
22H	B
22i	A
22J	D
22K	B
22L	B
22M	B
22N	C
22O	C
22P	C
22Q	B
22R	B
22S	B
22T	B
22U	A
22V	A
22W	B
22X	B
22Y	B
23E	C
23F	C
23G	C
23H	C
23i	D
24B	C
24C	C
27A	B
27B	A
27C	B
27D	D
27E	D
27F	D
27G	B
27H	D
27i	D
27J	D

No.	Ki (nM)
123	C
124	B
125	B
126	B
127	C
128	D
129	C
130	B
131	C
132	B
133	B
134	D
135	A
136	B
137	C
138	B
139	B
140	C
141	C
142	C
143	C
144	A
145	B
146	A
147	B
148	B
149	A
150	A
151	B
152	B
153	C
154	B
155	D
156	C
157	C
158	C
159	A
160	D
161	C
162	B
163	C
164	B
165	A
166	B
167	B
168	C
169	D

No.	Ki (nM)
-----	---------

No.	Ki (nM)
170	A
171	B
172	B
173	B
174	D

[00368] Representative compounds of the invention had the Ki values specified in parentheses immediately following the compound number in Radioligand Binding Assay A: **9A** (4.7 nM), **17** (5.1 nM), **17U** (604.9 nM), **17BL** (36.0 nM), **17Co** (10.9 nM), **17Ci** (838.0), **18CQ** (2.4 nM), **17DA** (34.2 nM), **18o** (9.8 nM), **18 P** (28.5 nM), **22A** (1083.5 nM), **27K** (1.5 nM), **38G** (637.5 nM), **44** (2.541 nM), **51** (6.9 nM), **55** (37.7 nM), **60** (21.2 nM), **69** (4.972), **72** (15.7 nM), and **134** (236.4 nM).

Radioligand binding assay B.

[00369] Radioligand Binding Assay B was performed at room temperature in 10 mM HEPES/KOH pH 7.4, 1 mM EDTA containing 10 mM MnCl₂ and 0.7 nM [³H]PGD₂ (NEN, 171 Ci mmol⁻¹), in a final volume of 0.2 mL. Competing ligands were diluted in dimethylsulfoxide (Me₂SO) that was kept constant at 1% (v/v) of the final incubation volume. The reaction was initiated by the addition of 8-20 µg of membrane protein prepared from a HEK-hCRTH2 cell line. Total and non-specific binding were determined in the absence and the presence of 10 µM PGD₂, respectively. Under these conditions, specific binding (total minus non-specific) of the radioligand to the receptor reached equilibrium within 50 min and was stable up to 180 min. The reaction was routinely conducted for 60 min at room temperature and terminated by rapid filtration through prewetted Unifilters GF/C (Packard), using a Tomtec MachIII semi-automated harvester (for HEK-hCRTH₂). The filters were then washed with 4 mL of the same buffer and residual radioligand bound to the filter was determined by liquid scintillation counting following equilibration in 25 µl Ultima Gold F™ (Unifilter) (Packard). Table B below lists representative compounds of the invention with binding data which were tested in Radioligand Binding Assay B whereby the Ki values are rated "A", "B," "C," or "D." The Ki values are rated "A" for Ki values in the range of 1.0 to 5.0 nM, "B" for Ki values in the range from 5.1-20.0 nM, "C" for Ki values in the range from 20.1-200 nM, and "D" for Ki values in the range from 201-7500 nM.

Table B

No.	Ki (nM)
7	A
10	D

No.	Ki (nM)
17P	D
17Q	D

No.	Ki (nM)
12	D
12B	C
12C	B
12D	B
12E	B
13	B
13C	B
13D	B
13E	C
14	B
14C	B
14D	B
14E	B
14F	B
14G	C
14H	C
14i	C
14K	B
14L	C
14N	D
14o	D
14P	D
15	C
16	A
16A	D
16B	B
16C	C
16D	C
16E	A
17H	D
17N	D
17o	D

No.	Ki (nM)
21	C
21A	C
21B	D
21C	C
21D	C
21E	C
21F	C
21G	C
21H	D
21i	C
21J	D
21K	D
21L	C
23	C
23B	C
23C	C
23D	C
24	C
24D	C
25	C
26	C
27	B
28	C
29	D
30	B
31	B
36	C
36A	C
36B	C
36C	D
37	B
39	C

[00370] Representative compounds of the invention had the Ki values specified in parentheses immediately following the compound number in Radioligand Binding Assay B: **7** (3.1 nM), **10** (514.5 nM), **13E** (122.6 nM), **14E** (9.9 nM), **14K** (18.4 nM), **14P** (413.6 nM), **16** (2.7 nM), **16C** (140.3 nM), **21A** (45.7 nM), **21K** (905.4 nM), and **27** (7.7 nM).

i[cAMP] measurements.

[00371] The ability of the compounds to antagonize the formation of cAMP can be assayed using the ELISA-based assay described in this example. HEK-hCRTH₂ cells are grown to 80-90% confluency. On the day of the assay, the cells are washed with phosphate buffered saline (PBS), incubated for 2 min in cell dissociation buffer, harvested by centrifugation at 300 g

for 7 min at room temperature and resuspended at 1.25×10^6 cells mL^{-1} in Hanks' balanced salt solution containing 20 mM HEPES pH 7.4 and 0.75 mM IBMX (HBSS/HEPES/IBMX). The assay is performed in 384-plate format with 0.01 mL HBSS/HEPES/IBMX per well containing 12 500 cells and 70 to 75 nl of the test compound and DK-PGD₂ at various concentrations. Following a 0 to 10 min pre-incubation of the cells with the test compound at 37°C, 0.005 mL of 30 μM Forskolin dilute in HBSS 20 mM HEPES, is added at a final concentration of 10 μM to initiate the reaction. After 10 to 60 min incubation at room temperature or 37 °C, the cAMP content was quantified using the cAMP XS+ HitHunter chemiluminescence assay (GE Healthcare 90-0075). Percent inhibition is calculated using the Forskolin and EC85 DK-PGD₂ controls.

β -Arrestin assay:

[00372] CHO-K1 cells obtained from DiscoverX are stably transfected with human CRTH₂ (propagation medium: F-12, 10% FBS, 300 $\mu\text{g/mL}$ hygB and 800 $\mu\text{g/mL}$ G418). Cells are grown in T175 cm² flask. While in log phase, cells are collected via 0.05% trypsin treatment. Triturated cells are filtered and 40 μL (10K cells) are plated per well in a 384-well white clear bottom plate and incubated O/N. Cell plate is emptied via inversion and blotted dry. Each well is filled with 35 μL of HBSS (with Ca^{++} and Mg^{++}) and incubated for 5 min. Compounds are added in volumes of 1 μL and the plate is gently shaken for 2 min., followed by incubation at 37 °C for 20 min. All compounds and controls are diluted in HBSS assay buffer (with Ca^{++} and Mg^{++}) with a final concentration range of 10^{-5} M to 3×10^{-11} M, 11 point Dose response curves at appropriate half-log increments. Final DMSO % is $\leq 0.3\%$. Agonist Assay: 1 μL /well of compound is added into cell plate and left to incubate at 37 °C for 90 min. Antagonist Assay: 1 μL /well of compounds are added into a cell plate. Incubate 30 minutes at 37 °C. Stimulate cells with 1 μL /well of PGD₂ [100 nM] final. Incubate plate for 60 minutes at 37 °C. Resulting luminescent signal is detected via Discoverx PathHunter Detection Kit per manufacturer's instructions. A total of 12 μL /well is added to each well. The plate is covered and incubated for 60 min. with gentle shaking. Chemiluminescent detection is done by a SpectraMax plate reader.

Eosinophil shape change assay in human whole blood:

[00373] Blood is collected in vacutainers containing EDTA. The antagonist is added to blood and incubated for 10 min at room temperature. DK-PGD₂ (13,14-dihydro-15-keto prostaglandin D₂) are then added to blood for 4 min at 37° C in a running water bath. Blood cells are then fixed in presence of cold 0.25%(v/v) paraformaldehyde prepared in 75%(v/v) DPBS


without Ca^{++} and Mg^{++} for 1 min on ice. 175 μL of fixed blood is transferred into 870 μL of cold 155 mM NH_4Cl lysis solution and incubated at 4 °C for at least 40 min. The solution is then centrifuged at 430 g for 5 min and the supernatant is discarded. Centrifuged cells are resuspended in residual supernatant and sodium azide is added (1% final concentration). Samples are analyzed with a FACs Calibur flow cytometer (Becton Dickinson). Flow cytometry raw data is analyzed with Diva software by isolating the eosinophils from the neutrophils based on their high autofluorescence and determining the percent of total eosinophils with increased forward light scatter. Maximum (100%) and minimum (0%) shape change is determined in the presence of 10 μM DK-PGD₂ and DPBS, respectively. A dose response curve with DK-PGD₂ is performed with every assay to determine the EC₅₀ for each blood donor. Compounds are tested in 11-dose titration curves in the presence of 50 nM DK-PGD₂ to determine an antagonist IC₅₀.

[00374] Compounds of the present invention are selective for the CRTH₂ receptor over the DP receptor. Assays on the DP, as well as other prostanoid, receptors are described in WO2003/06220.

[00375] While the present invention has been described in conjunction with the specific embodiments set forth above, many alternatives, modifications and other variations thereof will be apparent to those of ordinary skill in the art. All such alternatives, modifications and variations are intended to fall within the spirit and scope of the present invention.

WHAT IS CLAIMED IS:


1. A compound of the Formula (I)



or a pharmaceutically acceptable salt or ester thereof, wherein

R^1 is

- (i) H,
- (ii) C_1 - C_4 alkyl,
- (iii) C_2 - C_4 alkenyl,
- (iv) C_3 - C_7 cycloalkyl,
- (v) $-(C_1-C_3 \text{ alkylene})-R^9$ wherein R^9 is C_3 - C_7 cycloalkyl, phenyl or a 5- to 6-membered heteroaryl containing 1 to 2 heteroatoms selected from the group consisting of N, O, and S,
- (vi) phenyl,
- (vii) $-C(O)-R^5$, wherein R^5 is C_1 - C_6 alkyl, C_3 - C_6 cycloalkyl, phenyl,

- (viii) or a group of the formula , wherein v is 1, 2, or 3;


R^2 is

- (i) $-Q-W-V$, wherein

Q is $-C(O)-$, $-C(O)O-$, $-C(O)N(H)-$, $-C(O)N(C_1-C_6 \text{ alkyl})-$, $-CH_2-$, or $-S(O)_2-$;


W is

- (a) C_1 - C_8 alkylene, wherein said alkylene of W is unsubstituted or substituted by 1 to 2 fluoro;
- (b) $-CH=CH-$, or


- (c) a phenylene of the formula ; wherein said phenylene is unsubstituted or substituted by 1 to 2 halo;

V is

- (a) $-\text{CO}_2\text{H}$,
 (b) tetrazolyl, or

- (c) a group of the formula , wherein R^{V1} is selected from the group consisting of $\text{C}_1\text{-C}_6$ alkyl, $\text{C}_3\text{-C}_6$ cycloalkyl, and phenyl;


(ii) $-\text{M-CO}_2\text{H}$, wherein



X^{A} is S or O;

X^{B} is N or C(H);

with the proviso that when R^1 is $-\text{C}(\text{O})-\text{R}^5$, then R^2 is $-\text{CH}_2-\text{W}-\text{V}$;


Y is $-\text{C}(\text{O})-$, $-\text{S}(\text{O})_2-$, or a group of the formula ,

wherein X^{A1} is S or O; and

X^{B1} is N or C(H);

Z is

- (i) absent,
 (ii) $-(\text{C}_1\text{-C}_6)\text{ alkylene}-$,
 (iii) $-\text{O}-$,
 (iv) $-\text{O}-(\text{C}_1\text{-C}_6\text{ alkylene})-$, wherein said $-\text{O}-(\text{C}_1\text{-C}_6\text{ alkylene})-$ of Z is unsubstituted or substituted by 1 to 3 fluoro,
 (v) $-\text{N}(\text{H})-$, or

- (vi) a group of the formula , wherein r is 1, 2, 3, or 4;

E is

- (i) phenyl,
 (ii) naphthyl,
 (iii) tetrahydronaphthyl,
 (iv) indanyl,

(v) 5- to 10-membered mono- or bicyclic heteroaryl containing one to three heteroatoms selected from the group consisting of N, O, and S,

(vi) 5- to 10-membered mono- or bicyclic heterocyclenyl containing one to three heteroatoms selected from the group consisting of N, O, and S,

wherein said phenyl, naphthyl, tetrahydronaphthyl, indanyl, 5- to 10-membered heteroaryl, or 5- to 10-membered heterocyclenyl of E is unsubstituted or substituted by one to three R⁴ moieties, wherein

each R⁴ is selected from the group consisting of C₁-C₆ alkyl, C₁-C₃ alkoxy, -CN, halo, hydroxyl, C₁-C₃ fluoroalkyl, -O-(C₁-C₃ fluoroalkyl), -S-(C₁-C₃ alkyl), -S-(C₁-C₃ fluoroalkyl), C₃-C₇ cycloalkyl, R^{4a}, -O-R^{4a}, or 5- to 6-membered heterocyclenyl containing 1 or 2 heteroatom selected from the group consisting of N, O, and S;

R^{4a} is phenyl or a 5 to 6-membered heteroaryl ring containing one to two heteroatoms selected from the group consisting of N, O, and S;

wherein R^{4a} is unsubstituted or substituted by one to two moieties

independently selected from the group consisting of C₁-C₆ alkyl, C₁-C₃ alkoxy, halo, -CN, C₁-C₃ fluoroalkyl, -O-(C₁-C₃ fluoroalkyl), -S-(C₁-C₃ fluoroalkyl), and -SO₂-(C₁-C₃ alkyl),

or, wherein two R⁴ moieties are substituted on vicinal carbon atoms of E, the two R⁴ moieties together with the carbon atoms to which they are attached form a dioxolane ring;

(vii) C₃-C₇ cycloalkyl, or

(viii) C₁-C₆ alkyl,

n is 0, 1, or 2;

each occurrence of R⁷ is independently halo, C₁-C₃ fluoroalkyl, hydroxy(C₁-C₃ alkyl), -CN, phenyl, or a 5- to 6-membered heteroaryl containing 1 to 2 heteroatoms selected from the group consisting of N, O, and S, wherein said phenyl or heteroaryl of R⁷ is independently unsubstituted or substituted with 1 to 2 halo;

t is 0, 1, 2, or 3;

each occurrence of R⁸ is independently C₁-C₃ alkyl, C₂-C₃ alkenyl, or fluoro;

u is 0, 1, or 2; and

R^{8a} is H or C₁-C₆ alkyl.


2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein R² is -Q-W-V;

Q is -C(O)-, -C(O)O-, -C(O)N(CH₃)- or -CH₂-;

W is C₁-C₄ alkylene; and


V is -CO₂H.

3. The compound of claim 2 or a pharmaceutically acceptable salt thereof, wherein the group -Q-W-V is selected from the group consisting of:




4. The compound of any one of claims 1 to 3 or a pharmaceutically acceptable salt thereof, wherein R¹ is C₁-C₄ alkyl, C₃-C₇ cycloalkyl, -CH₂-(C₃-C₇ cycloalkyl), or phenyl.
5. The compound of claim 4 or a pharmaceutically acceptable salt thereof, wherein R¹ is methyl, ethyl, cyclopropyl, cyclobutyl, -CH₂-cyclopropyl, or phenyl.

6. The compound of any one of claims 1 to 5 or a pharmaceutically acceptable salt thereof,




7. The compound of claim 6 or a pharmaceutically acceptable salt thereof, wherein Y is -C(O)-.

8. The compound of claim 7 or a pharmaceutically acceptable salt thereof, wherein the group -Y-Z is selected from the group consisting of -C(O)-, -C(O)O-CH₂-, -C(O)O-C(H)(CH₃)-,




9. The compound of any one of claims 1 to 8 or a pharmaceutically acceptable salt thereof,



wherein E is phenyl, thienyl, , or , wherein E is unsubstituted or substituted by one to two moieties independently selected from the group consisting of methyl, fluoro, trifluoromethoxy, -O-phenyl, and thiazolyl.

10. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula (IB)





wherein



R^1 is H, C_1 - C_4 alkyl, cyclopropyl, cyclobutyl, $-\text{CH}_2$ -cyclopropyl, $-\text{CH}_2$ -cyclobutyl, or phenyl;

Q is $-\text{C}(\text{O})-$, $-\text{C}(\text{O})\text{O}-$, $-\text{C}(\text{O})\text{N}(\text{CH}_3)-$, or $-\text{CH}_2-$;

m is 1 or 2;




Z is absent, $-(C_1-C_3)$ alkylene-, $-\text{OCH}_2-$, $-\text{OCH}(\text{CH}_3)-$, or a group of the formula  ;

E is phenyl, thienyl,  , or  , wherein E is unsubstituted or substituted by one to two R^4 moieties independently selected from the group consisting of C_1 - C_3 alkyl, fluoro, trifluoromethoxy, $-\text{S}-\text{CF}_3$, -O-phenyl, and thiazolyl;

n is 0 or 1;

each occurrence of R^7 is independently chloro or fluoro; and
 t is 0, 1, or 2.

11. The compound of claim 10 or a pharmaceutically acceptable salt thereof, wherein the compound has the Formula (IC)



wherein

Q is $-C(O)-$, $-C(O)O-$, or $-CH_2-$;

m is 1 or 2;

Z is absent or $-OCH_2-$;

each occurrence of R^4 is independently C_1 - C_3 alkyl, fluoro, trifluoromethoxy, or $-S-CF_3$;


v is 0, 1, or 2;

n is 0 or 1;

each occurrence of R^7 is independently chloro or fluoro; and

t is 0, 1, or 2.

12. The compound of claim 11 or a pharmaceutically acceptable salt thereof, wherein the



13. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

4-[{cis, cis-4-[(Benzyloxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}(cyclopropyl)amino]-4-oxobutanoic acid;

4-[{cis, cis-4-[(benzyloxy)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}(phenyl)amino]-4-oxobutanoic acid;

4-{ethyl [cis, cis-4-{[4-(trifluoromethoxy)phenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid;

4-{cyclopropyl[cis, cis-4-{[4-(trifluoromethoxy)phenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid;

4-[{cis, cis-4-[(benzyloxy)carbonyl]-6-fluoro-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl}(cyclopropyl)amino]-4-oxobutanoic acid;

4-{cyclopropyl[cis, cis-6-fluoro-4-{[4-phenoxyphenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid;

4-{cyclopropyl[cis, cis-3-{[4-(trifluoromethoxy)phenyl]carbonyl}-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino}-4-oxobutanoic acid;

({cyclopropyl[cis, cis-4-{[4-(trifluoromethoxy)phenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]carbonyl}oxy)acetic acid;

3-(phenylmethyl) cis,cis-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5-fluoro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

4-(phenylmethyl) cis, cis-9-[(3-carboxy-1-oxopropyl)cyclopropylamino]-6-chloro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

4-(phenylmethyl) cis, cis-9-[(3-carboxy-1-oxopropyl)cyclopropylamino]-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

4-[cyclopropyl[(cis, cis)-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

4-[[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]methylamino]-4-oxobutanoic acid;

4-[(cyclobutylmethyl)[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-(3-phenoxybenzoyl)-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxo-butanoic acid;

4-(cyclopropyl(cis, cis-4-(thiophene-2-carbonyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid;

[[[[cis,cis-6-chloro-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]carbonyl]oxy]acetic acid;

4-[cyclopropyl[cis,cis-5-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

deuterated-4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9(R)-yl-(d)]amino]-4-oxobutanoic acid;

4-[[[(cis, cis)-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclobutylamino]-4-oxobutanoic acid;

4-[[[(cis, cis)-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[[[(cis, cis)-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[(trans-2-phenylcyclopropyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[cyclobutyl[(cis, cis)-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

4-[[[(cis, cis)-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[(1,2,3,4-tetrahydro-1-naphthalenyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[[[(cis, cis)-6-chloro-4-[(2,3-dihydro-1H-inden-2-yl)carbonyl]-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[[[(cis, cis)-6-chloro-2,3,3a,4,9,9a-hexahydro-4-[(1,2,3,4-tetrahydro-2-naphthalenyl)carbonyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[3-(5-thiazolyl)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

4-[(2,4-difluorophenyl)methyl] (cis, cis)-9-[[[(carboxymethoxy)carbonyl]cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

4-[1-(4-fluorophenyl)ethyl] (cis,cis)-9-[(3-carboxy-1-oxopropyl)cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

4-(1,2,3,4-tetrahydro-2-naphthalenyl) (cis, cis)-9-[(3-carboxy-1-oxopropyl)cyclopropylamino]-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

4-[cyclopropyl[(cis, cis)-6-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

3-(phenylmethyl) (cis,cis)-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5-chloro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

4-[[[(cis,cis)-5-chloro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]cyclopropylamino]-4-oxobutanoic acid;

3-(phenylmethyl) (cis,cis)-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

4-[cyclopropyl[(cis,cis)-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

4-(phenylmethyl) (cis,cis)-9-[[[(carboxymethoxy)carbonyl]cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

4-(phenylmethyl) (cis,cis)-9-[[[(carboxymethoxy)carbonyl]cyclopropylamino]-7-fluoro-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

[[[cyclopropyl[(cis,cis)-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]carbonyl]oxy]acetic acid;

[[[cyclopropyl[(cis,cis)-3-(3,4-difluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino]carbonyl]oxy]acetic acid;

[[[cyclopropyl[(cis,cis)-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]oxy]acetic acid;

4-(phenylmethyl) (cis,cis)-9-[[[(2S)-carboxy-1-azetidiny]carbonyl]cyclopropylamino]-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate;

N-[[cyclopropyl[(cis,cis)-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]carbonyl]-N-methylglycine;

[[[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[5-[[4-(trifluoromethoxy)phenyl]methyl]-1,3,4-oxadiazol-2-yl]-1H-cyclopenta[b]quinoline-9-yl]amino]carbonyl]oxy]acetic acid;

2-[ethyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxazolecarboxylic acid;

3-(phenylmethyl) cis,cis-8-[(3-carboxypropyl)cyclopropylamino]-5-fluoro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]butanoic acid;

4-[cyclopropyl[cis,cis-5-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]butanoic acid;

4-[cyclopropyl[(cis,cis)-2,3,3a,4,9,9a-hexahydro-4-[4-[(trifluoromethyl)thio]benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

4-(ethyl((cis,cis)-3-(4-(trifluoromethylthio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid;

4-(ethyl((cis,cis)-3-(4-ethylbenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid;

3-(phenylmethyl) 8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5,6-difluoro-2,2a,8,8a-tetrahydro-cyclobuta[b]quinoline-3(1H)-carboxylate;

4-[cyclopropyl[(cis,cis)-5,6-dichloro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

4-(cyclopropyl((cis,cis)-5,6-difluoro-3-(4-(trifluoromethoxy)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid;

4-[cyclopropyl[(cis,cis)-6-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxo-butanoic acid;

(R)-1-(((cis,cis)-3-(benzyloxycarbonyl)-5,6-difluoro-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)carbamoyl)azetidine-2-carboxylic acid;

4-(cyclopropyl(cis, cis-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid ;

4-(ethyl(cis, cis-6-fluoro-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid ;

4-(ethyl(cis, cis-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ;

4-(cyclopropyl(cis, cis-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ; and

4-(cyclopropyl(cis, cis-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)butanoic acid

14. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

4-{cyclopropyl[cis, cis-4-{[4-(trifluoromethoxy)phenyl]carbonyl}-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl]amino}-4-oxobutanoic acid;

4-[cyclopropyl[cis,cis-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid;

4-[[cis,cis-6-chloro-7-fluoro-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]cyclopropylamino]-4-oxobutanoic acid;

4-[cyclopropyl[cis,cis-5-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

4-[cyclopropyl[cis,cis-6-fluoro-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

3-(phenylmethyl) (cis,cis)-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-5-chloro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

3-(phenylmethyl) (cis,cis)-8-[(3-carboxy-1-oxopropyl)cyclopropylamino]-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

4-[cyclopropyl[cis,cis-1,2,2a,3,8,8a-hexahydro-3-[4-(trifluoromethoxy)benzoyl]cyclobuta[b]quinolin-8-yl]amino]-4-oxobutanoic acid;

[[[cyclopropyl[cis,cis-3-(3,4-difluorobenzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl]amino]carbonyl]oxy]acetic acid;

3-(phenylmethyl) cis,cis-8-[(3-carboxypropyl)cyclopropylamino]-5-fluoro-2,2a,8,8a-tetrahydrocyclobuta[b]quinoline-3(1H)-carboxylate;

4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-(trifluoromethoxy)benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]butanoic acid;

4-[cyclopropyl[cis,cis-2,3,3a,4,9,9a-hexahydro-4-[4-[(trifluoromethyl)thio]benzoyl]-1H-cyclopenta[b]quinolin-9-yl]amino]-4-oxobutanoic acid; and

(R)-1-((cis,cis-3-(benzyloxycarbonyl)-5,6-difluoro-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)(cyclopropyl)carbamoyl)azetidine-2-carboxylic acid;

4-(cyclopropyl(cis, cis-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid ;

4-(ethyl(cis, cis-6-fluoro-3-(4-((trifluoromethyl)thio)benzoyl)-1,2,2a,3,8,8a-hexahydrocyclobuta[b]quinolin-8-yl)amino)-4-oxobutanoic acid ;

4-(ethyl(cis, cis-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ;

4-(cyclopropyl(cis, cis-7-fluoro-4-(4-((trifluoromethyl)thio)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)-4-oxobutanoic acid ; and

4-(cyclopropyl(cis, cis-7-fluoro-4-(4-(trifluoromethoxy)benzoyl)-2,3,3a,4,9,9a-hexahydro-1H-cyclopenta[b]quinolin-9-yl)amino)butanoic acid;

15. A pharmaceutical formulation comprising a therapeutically effective amount of the compound of any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

16. A method for treating a disease or condition associated with uncontrolled or inappropriate stimulation of CRTH₂ function comprising administering to a patient in need of such treatment a

therapeutically amount of a compound of any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof.

17. The method according to claim 16, wherein the disease or condition is asthma, allergic rhinitis, or COPD.

18. A method for treating a disease or condition associated with uncontrolled or inappropriate stimulation of CRTH₂ function comprising administering to a patient in need of such treatment a therapeutically amount of a compound of any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof and an additional therapeutic agent.

19. Use of a compound of any one of claims 1 to 14 or a pharmaceutically acceptable salt thereof in the treatment of a disease or condition associated with uncontrolled or inappropriate stimulation of CRTH₂ function.